Biological Evaluation Of The Vaccine Candidate Tf-Ps A1 And A One-Pot Multicomponent Coupling/cyclization For Natural Product Herbicide (±)-Thaxtomin A by Bourgault, Jean Paul
Wayne State University
Wayne State University Dissertations
1-1-2015
Biological Evaluation Of The Vaccine Candidate
Tf-Ps A1 And A One-Pot Multicomponent
Coupling/cyclization For Natural Product
Herbicide (±)-Thaxtomin A
Jean Paul Bourgault
Wayne State University,
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Chemistry Commons
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Bourgault, Jean Paul, "Biological Evaluation Of The Vaccine Candidate Tf-Ps A1 And A One-Pot Multicomponent Coupling/
cyclization For Natural Product Herbicide (±)-Thaxtomin A" (2015). Wayne State University Dissertations. 1391.
https://digitalcommons.wayne.edu/oa_dissertations/1391
BIOLOGICAL EVALUATION OF THE VACCINE CANDIDATE TF-PS A1 AND A ONE-
POT MULTICOMPONENT COUPLING/CYCLIZATION FOR NATURAL PRODUCT 
HERBICIDE (±)-THAXTOMIN A 
By 
JEAN PAUL BOURGAULT 
DISSERTATION 
Submitted to the Graduate School  
of Wayne State University,  
Detroit, Michigan  
in partial fulfillment of the requirements  
for the degree of  
DOCTOR OF PHILOSOPHY 
      2015 
      MAJOR: CHEMISTRY 
      Approved By: 
      _____________________________________ 
Advisor     Date 
       _____________________________________ 
      _____________________________________ 
      _____________________________________ 
      _____________________________________ 
 
 
 
 
  
 
 
 
 
 
 
 
 
© COPYRIGHT BY 
JEAN PAUL BOURGAULT 
2015 
All Rights Reserved 
 
 ii 
 
DEDICATION 
This document is dedicated to my parents and siblings  
whose patient advice, encouragement, and guidance  
have kept me in sight of the path throughout my life.   
They have aided me more then they will ever know. 
 
 
  
 iii 
 
ACKNOWLEDGMENTS 
I would like to thank my advisor 
for teaching me the extreme importance of detail 
and all of my lab mates for their 
friendship and useful insights during my time in graduate school. 
  
 iv 
 
TABLE OF CONTENTS 
Dedication………………………………………………………………………………………………...ii 
Acknowledgments………………………………………………………………………………………iii 
List of Tables……………………………………………………………..……………………….…….vi 
List of Figures……………………………………………………………………..…..…..….….….vii-ix 
List of Schemes………………………………………………………………………………….………x 
Abbreviations…………………………………………………………………………………..……xi-xiii 
Chapter 1 - Synthesis of the Tumor Associative α-Aminooxy Derivative of the TF Antigen and 
Its Conjugation to a Polysaccharide Immune Stimulant……………………………………….…1-19 
 
A. Introduction 
A1.  Aminooxy Derivative of the TF Antigen and Oxime Conjugation……...……………………....1 
B.  Results and Discussion 
B1.  Synthesis of TF-PS A1……………………………………………………………….……..……...4 
C.  Experimental……………………………………………………………………………………..…10 
Chapter 2 - Biological Evaluation of the Vaccine Candidate TF-PS A1………………......….20-66 
A. Introduction 
A1.  Biological Relevance of the TF Antigen……………………………………….……….…….…20 
A2.  Inhibitors of TF/Galectin-3 Interactions……………………………………………..……….….25 
A3.  The TF Antigen and Cancer Immunotherapy………………………………………….…….…28 
A4. The Zwitterionic Polysaccharide A1’s (PS A1) T-cell Dependent Immune Response 
……………………………………………………………………………….…………………………....35 
 
A5.  PS A1 Conformation and Function......................................................................................43 
B.  Results and Discussion  
B1.  ELISA…………………………………………………………………………………………….…46 
B2.  Cytotoxicity, FACS, and SCID mice…………………………..…………………….…………..51 
C.  Experimental........................................................................................................................63 
 v 
 
Chapter 3 - A One-Pot Multicomponent Coupling/Cyclization for Natural Herbicide (±)-
Thaxtomin A………………………………………………………………………………………..67-100 
 
A. Introduction 
A1.  Thaxtomin A source and biological activity……………………………………………………..67 
A2.  TA biosynthesis……………………………………………………………………………………70 
A3.  Diketopiperazines and the Ugi reaction…………………………………………………………73 
A4.  Previous TA synthetic work………………………………………………………………………75 
A5.  Keto-amide cyclization for the preparation of TA………………………………………………77 
B.  Results and Discussion 
B1.  Synthesis of (±)-thaxtomin A……………………………………………………………….…….79 
B2.  CH-pi interactions………………………………………………………………………...………..83 
B3.  Isoskeletal TA derivatives………………………...……………………………………...……....90 
C.  Experimental……………………………………………………………………………..…………92 
Appendices  
Appendix A  1H and 13C NMR for Chapter 1……………………………………………………....101 
Appendix B 1H and 13C NMR Spectra for Chapter 3…………………………………………......140 
Appendix C Crystal structure data for (±)-syn-1 and (±)-anti-1…………………..….................177 
References…………………………………………………………………………………...……….187 
Abstract……………………………………………………………………………………………..…203 
Autobiographical Statement……………………………………………………………………….205 
  
 vi 
 
LIST OF TABLES 
Chapter 1  
Table 1  Percent loading comparison…………………..…………………………………………….10 
Chapter 3 
Table 1  Preparation of electronically modified TA derivatives………………….…….….…….….91 
  
 vii 
 
LIST OF FIGURES 
Chapter 1 
Fig. 1  (left) The TF antigen is found alpha linked to Ser/Thr on cancer mucins such as MUC1, 
(right)α-TF-ONH2 (2)……………………………………………………………………………………..1 
 
Fig. 2  (left) Previous synthesis of the α-aminooxy TF antigen, (right) α-TF-ONH2 conjugation to 
a cyclic peptide scaffold through oxime bond formation……………………………………..……….2 
 
Chapter 2 
Fig. 1  (left) TF antigen is found α-linked to Ser/Thr on cancer mucins such as MUC1, (right) 
gastric cancer patients survivability, high responders (anti TF antibody) top line vs. low 
responders bottom line………………………………………………………………………………....21 
 
Fig. 2  Aberrant glycosylation of O-glycans………………………………………………………….22 
Fig. 3  Quinn model for TF/galecin-3 mediated metastasis………………………………….……..23 
Fig. 4  Rhodes MUC1 polarization model for TF/galectin-3 mediated metastasis……………….24 
Fig. 5  Galectin-3 inhibitors, (left) thiodigalactoside bis-benzamido example, (right) triazol 
thiodigalactosides……………………………………………………………………………………….27 
 
Fig. 6  Trivalent TF-KLH glycoconjugate……………………………………………………………..30 
Fig 7  RAFT glycoconjugate design, circles = TACAs………………………………………….…..31 
Fig. 8  TF gold nanoparticle constructs…………………………………………………………..…..32 
Fig 9  (left) PAMAM glycodendrimers, (right) TF mimic dendrimer based on a branched 
tripeptide lysine core……………………………………………………………………………………33 
 
Fig. 10  (left) Tetrasaccharide repeating unit of PS A1, chemical modification of the amine or 
carboxylate results in loss of biological activity, (right) hexasaccharide repeating unit of PS 
B…………………………………………………………………………………………………………..37 
 
Fig. 11  Polyuronic acid from Salmonella typhi, removal of the N-acetyl creates zwitterionic 
character and biological properties similar to PS A1……………………………………………..…38 
 
Fig. 12  B-cell/T-cell interaction required for production of IgG antibodies and immunological 
memory…………………………………………………………………………………………………..39 
 
Fig.13  Confocal microscopy of APC and T-cells incubated without (A) and with PS A1 (B), red 
correlates to MHC II, green correlates to T-cell receptors, yellow represent overlap of these 
regions…………………………………………………………………………………………………....41 
 
 viii 
 
Fig. 14  (A) Native PS A1 (red) is seen inside and on the surface of APC, also PS A1 is located 
in the same regions as MHC II (green), (B, C) Charge modified PS A1 is only seen inside APC 
and not on the cell surface…………………………………………………………………………..…42 
 
Fig. 15  (A) PS A2 stick model of four repeating units, (B) Electrostatic model of PS A2 with 
positive charges in red and negative in blue, arrows showing grooves with the presence of 
charges on all edges………………………………………………………………………………....…44 
 
Fig. 16  (left) myoglobin CD spectra, (center) CD spectra of native PS A1 (black) and oxidatively 
cleaved PS A1 exposed to O3 for 15-90 minutes creating fragments ranging from 30-1 kDa, 
(right) Inhibition of peptide binding by various MW PS A1 fragments……………………………..46 
 
Fig. 17  TF-PS A1 sera vs. TF-BSA……………………………………………………………..…..48 
Fig. 18  TF-PS A1 sera vs. Tn-BSA……………………………………………………………..…..48 
Fig. 19, TF-PS A1 sera vs. TF-BSA………………………………………………………………….49 
Fig. 20  (left) Protein G purification of whole sera, (right) antibody titers of IgG purified sera vs. 
TF-BSA…………………………………………………………………………………………………...49 
 
Fig. 21  Previous Tn-PS A1 data...............................................................................................50 
Fig. 22  % binding of murine bone marrow derived APCs to polyacrylamide-carbohydrate 
coated ELISA plates, α-GalNAc (Tn) displays twice the binding of core 1 (TF)……………..…..51 
 
Fig. 23  ADCC mechanism, this pathway is mediated only by IgG antibodies………………..…53 
Fig. 24  (left) multisubunit C1q complex, (right) C1q recognizing bound antibody on target cell 
surface beginning CMC…………………………………………………………………………...……53 
 
Fig. 25  Cytotoxicity counts SK-BR-3………………………………………………………………55 
Fig. 26  Cytotoxicity SK-BR-3………………………………………………………………………..55 
Fig. 27  Cytotoxicity counts MDA-231…………………………………………………………...…56 
Fig. 28  Cytotoxicity counts MCF-7…………………………………………………………………56 
Fig. 29  Cytotoxicity MCF-7……………………………………………………………..………..….57 
Fig. 30  FACS of TF-PS A1 sera (blue), PS A1 sera (red), secondary antibody alone (green) 
and cells alone (gray)……………………………………………………………….…………………..58 
 
Fig. 31  Cytotoxicity counts MCF-7…………………………………………………………………58 
Fig. 32 Cytotoxicity MCF-7…………………………………………………………………..……….59 
Fig. 33  Passive immunotherapy of MCF-7 induced tumors…………………………………...61 
Fig. 34  Passive immunotherapy of individual mice………………………………………....….61 
 ix 
 
Fig. 35  Individual tumor volumes………………………………………………………..……..….62 
Chapter 3 
Fig. 1  (left) 2,5-diketopiperazine Thaxtomin A, (TA) (center, right) TA causes plant cell necrosis 
seen as raised or pitted lesions……………………………………………………...……………..…68 
 
Fig. 2  (left) Possible model for TA phytotoxic activity, (right) morphological response of TA and 
S. scabies on radish seedlings, (A) broth from culture of S. Scabies, (B) culture supernatant, TA 
at (C) 0, (D) 100, (E) 50, (F) 25, (G) 10 µM concentrations………………………………….……..69 
 
Fig. 3  Proposed biosynthetic pathway for the formation of TA………………………………...….72 
Fig. 4  Examples of previously prepared TA derivatives……………………………………….…..75 
Fig. 5  Keto-amide cyclization from key Ugi precursor 2……………………………………………77 
Fig. 6  Ugi based disconnection of acyclic precursor 3………………..……………………………79 
Fig. 7  ORTEPs of (±)-thaxtomin A/syn-1 and (±)-anti-1 with hydrogen atoms omitted……..….82 
Fig. 8  Proton shielding of syn-1 vs. anti-1………………………………………...…………………84 
Fig. 9  (left, center) ORTEP diagrams of syn-1 highlighting CH-pi interactions with a CH-phenol 
bond distance of 2.60 Å very similar to previous examples reported by Grossel,1 (right) anti-1 
ORTEP showing no interaction with C21 methyl, bond distances of 4.0 and 4.5 Å to the phenyl 
plane are too far for CH-pi bonding and no shielding is observed in 1H NMR……………………85 
 
Fig. 10  Change in C-H chemical shift in ppm of nonaromatic DKP vs. aromatic DKP……...….85 
Fig. 11  Hinged dibenzodiazocine for the study of intramolecular CH-pi interactions, folded on 
left, extended on right, Y = NO2 or CN ratio 75:25, Y = H, CH3, or OCH3 ratio 60:40, tert-butyl 
ester in the place of the aryl ester provides a ratio of 80:20, folded:extended…………..……….89 
 
Fig. 12  Syn:anti ratios of substituted Diels-Alder imides………………………….……………….90 
  
 x 
 
LIST OF SCHEMES 
Chapter 1 
Scheme 1  Gabriel synthesis of primary amines using Ing-Manske NH2NH2 based 
deprotection……………………………………………………………………………………………….3 
 
Scheme 2  Preparation of aminooxy sugar precursors…………………………………………..…..3 
Scheme 3  Synthesis of thioglycoside (6)………………………………………………………..……5 
Scheme 4  Initial attempt at preparing NHS acceptor 10………….………………………………...6 
Scheme 5  Preparation of α-NHS acceptor 10 from chloroacetyl thioglycoside 11α or 11β..........7 
Scheme 6  Preparation of α-aminooxy TF (2)…………………...………………………………...….8 
Scheme 7  Synthesis of TF-PS A1 conjugate (16)…………...………………………………….....10 
Chapter 2 
Scheme 1  Amadori rearrangement for the preparation of Lac-L-Leu………………………...…..26 
Scheme 2  [4 + 2] cycloaddition for the preparation of a TF-glycopeptide mimic…………...…..27 
Chapter 3 
Scheme 1  Mechanism of the Ugi reaction…………………………………………………………..73 
Scheme 2  Ugi reaction and DKP synthesis………………………………………………………....74 
Scheme 3  First synthesis of TA………………………………………………………………………76 
Scheme 4  Intramolecular aza-Michael addition of Ugi adducts…………………………..………77 
Scheme 5  (top) Use of keto acids in three component Ugi reactions generating lactams, 
(bottom) Three bifunctional components in the Ugi reaction for the preparation of a polycyclic 
scaffold…………………………………………………………………………………………………...78 
 
Scheme 6  Preparation of 3-indolylacetaldehyde (4) and methyl isocyanide (5)…………….….79 
Scheme 7  Synthesis of TA derivative 8……………………………………………………..……....80 
Scheme 8  Preparation of CHO (9) and acid (10)………………………………………....………..81 
Scheme 9  Stepwise and one pot procedures for the preparation of TA, (a) 5 equiv. KOH, 70 oC, 
MW, 30 min, all yields based on combined DKPs with the exception of the one pot preparation 
…………………………………………………………………………………………………………….82 
  
 xi 
 
ABBREVIATIONS 
2,4-D-2,4-Dichlorophenoxyacetic acid 
Ac-acetyl 
AD50-abscess dose 50% of the population 
ADCC-antibody dependent cellular cytotoxicity  
APC-antigen presenting cell 
Boc- tert-butyloxycarbonyl 
BSA-bovine serum albumin 
Bz-benzoyl 
C1q-the first subcomponent of the C1 complex for the classical pathway of complement 
activation 
CD- circular dichroism 
CD4+-mature T helper cells expressing the surface protein CD4 
Cha-cyclohexylalanine  
ClAc-chloroacetyl 
CMC-complement mediated cytotoxicity 
CP-capsular polysaccharide  
DCM-dichoromethane 
DKP-diketopiperazine  
DIBALH-diisobutylaluminium hydride  
EA-ethyl acetate 
EDC-1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
ELISA-enzyme linked immunosorbent assay 
FACS- fluorescent activated cell sorting  
Fc-fraction crystallizable  
 xii 
 
Gal-galactose 
GalNAc-N-acetylgalactosamine 
Glc-glucose 
Hex-hexanes 
HSA-human serum albumin 
HLA-DR-MHC class II cell surface receptor 
IAA-indole acetic acid  
IBX-2-Iodoxybenzoic acid 
IL- interleukin 
IP-intraperitoneal injection 
KLH-keyhole limpet hemocyanin 
Lac-lactose 
MGL2- macrophage galactose N-acetyl-galactosamine specific lectin 2 
MHC II- major histocompatibility complex class II 
MUC-mucin protein or peptide 
NIS- N-iodosuccinimide 
NHS-N-hydroxysuccinimide  
NK-natural killer 
NOS-Nitric oxide synthase 
ORTEP-Oak Ridge Thermal Ellipsoid Plot Program 
p-TSA-para-toluene sulfonic acid  
PAMAM-polyamidoamine 
PBS-phosphate buffered saline  
PEG-polyethylene glycol 
PhtO-N-hydroxyphthalimide 
PNPP-para-nitrophenylphosphate 
 xiii 
 
PS A1-polysaccharide A1 
py-pyridine  
RAFT-cyclodecapeptide 
SC- subcutaneous 
SCID-severe combined immunodeficiency 
STn-Sialyl Tn antigen  
Sulfo-SMCC-sulfosuccinimidyl-4-N-maleimidomethyl cyclohexane-1-carboxylate 
TA-thaxtomin A 
TACA-tumor associated carbohydrate antigen 
TBDPS-tert-butyldiphenylsilyl 
TBS- Tris-buffered saline 
TF or T- Thomsen Friedenreich antigen 
TfOH-trifluoromethanesulfonic acid  
THF-tetrahydrofuran 
TLC-thin layer chromatography’ 
Tn-Thomsen nouveau antigen 
Tris-tris(hydroxymethyl)aminomethane 
TsCl-tosyl chloride 
TMSOTf-trimethylsilyl trifluoromethanesulfonate 
TOCSY-total correlation spectroscopy 
WO-without 
ZPS-zwitterionic polysaccharide  
1 
 
 
 
CHAPTER 1 - Synthesis of the Tumor Associative α-
AminooxyDerivative of the TF Antigen and Its Conjugation to a 
Polysaccharide Immune Stimulant 
A.  Introduction 
A1.  Aminooxy Derivative of the TF Antigen and Oxime Conjugation 
 The Thomsen Friedenreich (TF or T) disaccharide α linked to Ser/Thr (1) has attracted 
considerable attention from the scientific community due to its presence on mucin proteins, 
which are over expressed on the surface of numerous carcinoma cells.2  The occurrence of TF 
is believed to play a direct role in adhesion and metastasis through interaction with the Gal 
binding lectin galectin-3.3  Verification of the biological relevance for TF being correlated to 
cancer has encouraged our group to investigate the preparation of an aminooxy derivative of 
the TF antigen (2, Fig. 1) for subsequent conjugation to the immunogenic zwitterionic 
polysaccharide PS A1 (15, Scheme 7).4  This capsular polysaccharide is isolated from the 
commensal anaerobic bacteria Bacteroides fragilis which has challenged the belief that 
carbohydrates can only elicit T-cell independent immune responses.  PS A1 consists of a 
tetrasaccharide repeating unit, has a MW of approximately 130 kDa, and contains a right 
handed helical structure with two repeating units per turn.  The T-cell dependent activity of this 
polysaccharide has been shown to arise from the zwitterionic nature of the polymer.  Previous 
work has revealed that when this alternating charge character is chemically neutralized the T-
cell dependent response is as well.8d 
 
Fig. 1  (left) The TF antigen is found alpha linked to Ser/Thr on cancer mucins such as MUC1, 
(right) α-TF-ONH2 (2). 
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 The nucleophilic disaccharide (2) can be conjugated to various biologically relevant 
carbonyl constructs through physiological stable oxime bond formation.  An important yet facile 
component for this conjugation strategy involves the use of anomeric aminooxy sugars.  To the 
best of our knowledge the α-aminooxy TF antigen (2) has been synthesized previously by only 
one other group (Fig. 2).5  The preparation relied on peracetylated-D-galactal chemistry 
incorporating a trichloroacetimidate sugar donor to install the β-Gal-(1,3)-GalN3 linkage and a 
glycosyl fluoride for the preparation of the N-hydroxyphthalimide (PhtO) glycoside.  The 
resulting α-TF-ONH2 was then conjugated, via oxime formation in a clustered motif, to a cyclic 
peptide for use in biological studies (Fig. 2).6  TF linked to Ser/Thr has also been prepared by 
various methods as a building block for solid phase peptide synthesis.2a,7 
 
Fig. 2  (left) Previous synthesis of the α-aminooxy TF antigen, (right) α-TF-ONH2 conjugation to 
a cyclic peptide scaffold through oxime bond formation.5  This figure was inspired by Renaudet, 
O.; Dumy, P. Tetrahedron Lett. 2004, 45, 65-68. 
 One of the most efficient methods for synthesizing the aminooxy moiety takes advantage 
of the classical Gabriel synthesis8 (Scheme 1), which provides a route to primary amines by 
using a succinimidyl or phthaloyl group to mask the amine until deprotection is desired, thereby 
avoiding over alkylated products.  The deprotection can be mediated by either acid or base 
hydrolysis, however a much more common method is the Ing-Manske9 procedure which utilizes 
hydrazine hydrate.  Roy and coworkers expanded on this methodology by reacting glycosyl 
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chlorides under phase transfer conditions in the presence of N-hydroxysuccinimide (NHS) to 
provide N-hydroxysuccinimidoglycosides,10 while N-hydroxyphthalimidoglycosides have been 
prepared by Dumy using glycosyl fluorides (Scheme 2).11  In addition, the NHS moiety has been 
introduced under Koenigs–Knorr conditions12 and also directly from hemiacetals through 
Mitsunobu reactions.13  An alternative approach involves the use of N-hydroxypentenamide as 
an effective way of protecting the aminooxy functionality, which can then be removed on 
treatment with aqueous I2 (Scheme 2).14  In addition, the versatility of the NHS/PhtO glycosides 
can be extended to an alternative reaction pathway whereby the NHS ring can be opened with 
NaOMe to afford a glycosyl carboxylic acid upon saponification.10,15   
 
Scheme 1  Gabriel synthesis of primary amines using Ing-Manske NH2NH2 based deprotection. 
 
Scheme 2  Preparation of aminooxy sugar precursors. 
 These facile and yet highly functional aminooxy sugar syntheses have led to several 
groups reporting the preparation of glyco-oxime peptide/protein conjugates,6,12,16 including our 
group which has previously conjugated the aminooxy Thomsen-nouveau (Tn) antigen to the 
zwitterionic polysaccharide PS A1.4  The aforementioned conjugations were achieved through 
formation of an oxime bond by condensation of an aminooxy sugar on various carbonyl species.  
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The oxime strategy provides mild coupling conditions and also has the added advantage of 
being less susceptible to physiological hydrolysis then either alkyl hydrazones or acyl 
hydrazones as demonstrated by Raines and coworkers.17  In addition, this strategy has been 
utilized with an aminooxy peptide/protein for conjugation with an aliphatic aldehyde or reducing 
sugar18 as well as for the ligation of two extended protein fragments.19  With a similar coupling 
strategy in mind, combined with a need to overcome current limitations with successive 
transformations carrying the NHS moiety in carbohydrate chemistry, the synthesis of the 
aminooxy TF antigen (2) is described herein. 
B.  Results and Discussion 
B1.  Synthesis of TF-PS A1 
 Alternatively to the previous synthesis of α-TF-ONH25, D-galactosamine.HCl (3) was 
chosen as a suitable starting material (Scheme 3).  First, 3 was treated with imidazole-1-sulfonyl 
azide hydrochloride, followed by acetic anhydride to provide the peracetylated azide 4.20  The 
phenyl thioglycoside 5 was then prepared through treatment of 4 with BF3OEt2 and PhSH.   The 
acetyl groups of 5 were removed using Zemplén conditions, followed by the instillation of the 
benzylidene acetal to provide thioglycoside acceptor 6, which yielded an α/β ratio of 1.7:1 that 
was readily separable by silica gel column chromatography.  Inspired by previous uses of alkoxy 
protection5,7c at the anomeric position during the required glycosylation, an acceptor was 
envisioned that would carry a preinstalled α-NHS group for the duration of the synthetic 
strategy.  The implementation of this strategy would thereby serve two purposes: 1) to define 
the stability of an anomeric NHS group for continued evolvement of efficient synthetic strategies, 
including those that would require glycosylation procedures and 2) garner access to various TF 
derivatives without having to install the aminooxy moiety in the late stage of synthesis.  While 
there are numerous reports of reductions,5,10-12 and also a single example of TBS protection13 
being conducted in the presence of NHS glycosides.  To the best of our knowledge, a 
5 
 
 
 
glycosylation involving a NHS protecting group has only been reported once before by Bertozzi 
and co-workers12 in the preparation of the aminooxy STn antigen.  Our approach would also be 
efficient for negating the requirement of anomeric protecting group manipulations as previously 
reported.5  In order for the Bertozzi approach to be realized, a suitable protecting group was 
required, whose removal would occur under mild conditions, leaving the α-NHS moiety intact at 
the anomeric position. 
 
 
Scheme 3  Synthesis of thioglycoside (6). 
 In our initial attempts at examining this chemistry, along the lines of the aforementioned 
work by Bertozzi,12 we elected to pursue TBDPS as the silyl ether for 3-OH protection.  To this 
end, compound 7 was prepared in 79% yield by treatment of 6α with excess TBDPSCl and 
imidazole in DMF (Scheme 4).  The protected donor 7 was then activated with NIS/TfOH in the 
presence of 1.1 equiv. of NHS.  Unfortunately, under these conditions the succinimidyl anion, 
the by-product from the NIS activation, out competed NHS for the donor.  This unexpected 
reaction pathway gave a 2:1 α/β mixture of compound 8 that was isolated in a 73% yield.  It 
must be noted that we were able to isolate α-NHS glycoside 9, albeit in a ratio of 1:6 
NHS/succinimidyl glycoside (calculated as an average of two reactions 100 mg (1:5) and 500 
mg (1:7), mass with respect to donor).  In an attempt to avoid the unwanted C-N bond 
formation, the subsequent reaction was conducted with excess (4 equiv.) NHS.  These 
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conditions proved sufficient for the formation of the α-NHS product 9 in 75% yield and in a ratio 
of 5:1 NHS/succinimidyl glycoside.  It had previously been shown that 4,6-benzylidene 
thiogalactoside donors, when activated with NIS/TMSOTf, had a preponderance for 
α selectivity21 and in regards to the NHS glycoside formation it was gratifying to note that this 
convention indeed held true (α/β - 8:1). 
 
Scheme 4  Initial attempt at preparing NHS acceptor 10. 
 With protected NHS acceptor 9 in hand, we turned our attention to the removal of the 
TBDPS group.  Compound 9 was treated with TBAF in THF at r.t., which completely converted 
9 into 10 as observed by thin layer chromatography (TLC).  The newly formed molecule proved 
to be the desired NHS acceptor 10, however we were only able to isolate 10 in <40% yield.  The 
low yield was attributed to opening of the NHS ring by hydroxide, forming the glycosyl carboxylic 
acid as directly observed by Andersson and Roy.10,15  The presence of a hydroxyl nucleophile is 
believed to arise from the strong basicity of TBAF and the fact that moisture entered our 
reaction vessel.  It is important to note that this alternate reaction pathway can be avoided 
simply by adjusting the pH of the commercial TBAF before addition.12,22  This strategy could 
indeed provide a viable pathway to 10 but reported deprotections utilizing this method in the 
presence of NHS continually suffered from low yields.12  Due to the fact that excess silyl chloride 
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and the following laborious separation using pure toluene as the eluent were required to prepare 
7, we abstained from continuing with this strategy.23 
 Mindful of various other strategies and in a similar manner to a reported synthesis of TF-
O-Ser/Thr7a, the chloroacetyl group (ClAc) was examined as an alternative to TBDPS for both 
relative ease of installation and removal.  Starting from 6α or 6β, the chloroester 11 was 
prepared in 84% yield by treating the respective 3-OH secondary alcohol with chloroacetyl 
chloride (ClAcCl)/py (Scheme 5).24  The masked thioglycoside 11α or 11β was then subjected to 
conditions as previously described so as to install the important NHS moiety.  Gratifyingly, this 
reaction produced a similar result providing the α-NHS glycoside as the major product.25  
Determining the α/β ratio for this reaction, however, was complicated by the formation of the 
aforementioned succinimidyl by-product, however our yield is based solely on isolated α-NHS.  
The NHS group proved to be extremely base liable with decomposition occurring under both 
NEt3/MeOH24 and saturated NaHCO3 5:1 MeOH/H2O26 conditions.  The successful deprotection 
was achieved through the use of the non-basic nucleophile thiourea in 5:1 EtOH:py27 at room 
temperature giving rise to the deprotected NHS acceptor 10 in 65% yield over two steps. 
 
 
Scheme 5  Preparation of α-NHS acceptor 10 from chloroacetyl thioglycoside 11α or 11β. 
 With access to appreciable quantities of our desired α-NHS acceptor 10, we attempted 
the glycosylation using trichloroacetimidate donor 1228 (Scheme 6).  Several recent reports 
noted this reaction as being hampered by competing orthoester formation when a 
trichloroacetimidate donor was utilized for similar reactions.7d,29  However, as previously 
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mentioned, we were first drawn to this approach by the success of alkoxy protected anomeric 
acceptors under Schmidt conditions.5,7c  Indeed the major product of this pivotal glycosylation 
was the required β-1,3 linkage found in the TF antigen, which provided the disaccharide 13 in 
56% isolated yield.  The characteristic anomeric doublet observed at 4.80 ppm with a JH1-H2 of 
8.00 Hz confirmed that the desired β linkage was formed.  COSY and HMQC further supported 
the fact that this doublet was one of the two anomeric protons found in the disaccharide. 
 
Scheme 6  Preparation of α-aminooxy TF (2). 
 With the protected disaccharide in hand, the next steps focused on the removal of the 
benzylidene acetal protecting group and the reduction of the azide.  First, activated zinc dust in 
3:2:1 THF:AcOH:Ac2O was used to reveal the N-acetyl7c,30 moiety at the 2-position of 
disaccharide 13.  The crude reaction mixture obtained from the azide reduction was then treated 
with 80% aqueous acetic acid at 80 oC to remove the benzylidene acetal and provide diol 14 in 
56% yield over two steps.29  At this stage in the synthesis there was no overlap of signals in the 
13C NMR and therefore all of the carbonyls were precisely accounted for.31  This spectrum 
further confirmed that the β-1,3 linkage had been made and that the compound was not the 
unwanted orthoester. 
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 In the final deprotection step, hydrazine hydrate was utilized to remove the remaining 
acetyls as well as to displace the succinimidyl protecting group to reveal the α-aminooxy TF 
antigen 2.  As earlier reports noted5,10 the two byproducts from this reaction, acetohydrazide and 
tetrahydropyriddazine-3,6-dione, complicated the purification of the respective aminooxy sugar.  
After several attempts at crystallizing the crude reaction mixture from methanol, we elected to 
turn our attention towards size exclusion chromatography.  This decision was based on the fact 
that the MWs of the acetohydrazide and tetrahydropyridazine-3,6-dione are 74.1 g/mol and 
114.0 g/mol respectively creating a significant difference in size with 2 (MW 398.4 g/mol).  This 
disparity in MW provided excellent separation on a Bio-gel P-2 column using water as the 
eluent, giving rise to pure 2 with NMR data matching the previously reported values5 in 64% 
yield from protected disaccharide 14. 
 Following the preparation of 2, the key one pot oxidation and conjugation between PS 
A1 and the α-aminooxy TF was conducted (Scheme 7).  This was accomplished by cleaving the 
vicinal diols of galactofuranose residues present on PS A1 with NaIO4, creating strategically 
placed aldehydes along the tetrasaccharide repeating unit.4a,32 After 90 minutes of PS A1 (15) 
exposure to NaIO4, KCl was introduced to precipitate any remaining periodate as KIO4.33  
Finally, 2 was added to oxidized PS A1 and the reaction mixture was allowed to stir overnight in 
the dark at r.t. to provide the TF-PS A1 oxime conjugate with a percent loading of 14% (w/w), 
similar to TF-glycopeptide loading of previous BSA constructs and our TF-BSA conjugate, Table 
1.  The 1H NMR spectrum of 16 showed a distinct oxime doublet centered at 8.00 ppm.  In 
addition a new singlet could be observed at 2.29 ppm (N-acetyl of TF) and 1D TOCSY of 
anomeric protons at 4.61 ppm and 5.46 ppm displayed spin systems comparable to the TF-
ONH2 (2) proton spectra. 
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Scheme 7  Synthesis of TF-PS A1 conjugate (16). 
Table 1  Percent loading comparison  
Construct TF-glycopeptide % loading w/w TACA % loading w/w 
TF-MUC1-BSA2e 13% 2.0% 
3’-fluoro-TF-MUC1-BSA34 15% 2.4% 
4’-fluoro-TF-MUC1-BSA35 20% 3.3% 
TF-BSA (maleimide linked) - 15% 
 
 In summary, the synthetic preparation of the α-aminooxy TF antigen and its conjugation 
to PS A1 has been described.  The synthesis of 2 is highlighted by successful α selective 
glycosylation and deprotection in the presence of the succinimidyl protecting group.  New 
evidence has been presented that the succinimidyl group can be carried through a number of 
transformations provided that basic conditions are avoided.10,12,15  This study further establishes 
the utility of NHS glycosides in the synthesis of aminooxy sugars, thereby making conjugations 
of nucleophilic sugars to appropriate carbonyls possible through physiologically stable oxime 
formation.17  The biological evaluation of the TF-PS A1 construct as a vaccine candidate in 
C57/BL6 mice will be discussed in chapter 2. 
C.  Experimental, reproduced from, Bourgault, J. P.; Trabbic, K. R.; Shi, M.; Andreana, P. R. 
“Synthesis of the tumor associative α-aminooxy disaccharide of the TF antigen and its 
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conjugation to a polysaccharide immune stimulant” Organic & Biomolecular Chemistry 2014, 12, 
1699-1702. 
General:  All reagents and solvents were purchased from commercial sources and used without 
further purification.  Compounds were purified using flash chromatography with Whatman 
Purasil 60 Å 230-400 mesh silica gel, with the exception of 2 which was purified with Biorad P2 
gel.  Thin layer chromatography was conducted with Dynamic Absorbents Inc. silica gel TLC 
250 µm w/h F-254, catalog no. 84111.  Proton and carbon NMR spectra were recorded using 
Mercury 400, Varian 400, Varian 500 and Bruker Avance III 600 spectrometers.  The residual 
CHCl3 was referenced to 7.26 ppm and 77 ppm in proton and carbon spectra respectively. The 
residual HDO was referenced to 4.79 ppm with spectra taken in D2O. Mass spectral data were 
taken on a Waters ESI-MS, model LCT premier XE.  PS A1 was isolated and purified as in De 
Silva, R. A.; Wang, Q.; Chidley, T.; Appulage, D. K.; Andreana, P. R., J. Am. Chem. Soc. 2009, 
131, 9622-9623. 
Phenyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-1-thiol-D-galactopyranoside (5).  3.22 g (8.62 mmol) 
of compound 4 was co-evaporated 3 times with toluene and dried under high vacuum for 2 
hours.  The dried compound was then dissolved in 48 mL of anhydrous DCM and then cooled to 
0 oC.  Next 1.32 mL (12.9 mmol) of thiophenol and 5.32 mL (43.1 mmol) of BF3OEt2 were added 
and the reaction was allowed to stir overnight while warming to room temperature.  This was 
followed by dilution of the mixture with 50 mL DCM and then pouring this diluted reaction 
mixture into 240 mL of water.  The organic layer was then separated, washed with sat NaHCO3, 
dried over MgSO4, and concentrated to an oil.  The crude product was then purified on silica gel 
with 2:7 EA/Hex to provide 5 (2.75 g, 75% yield) as a syrup.  Data for 5.  1H NMR (400 MHz, 
CDCl3): δ 7.60 (m, 1HAr), 7.49 (m, 2HAr), 7.32 (m, 5HAr), 5.68 (d, J = 5.6 Hz, 1H, H1α), 5.46 (d, J 
= 3.2 Hz, 1H, H4α), 5.33 (d, J = 2.4 Hz, 1H, H4β), 5.16 (dd, J1 = 3.2 Hz, J2 = 11.2 Hz, 1H, H3α), 
4.85 (dd, J1 = 3.2 Hz, J2 = 10.4 Hz, 1H, H3β), 4.74 (t, J = 6.4 Hz, 1H, H5α), 4.51, (d, J = 10.0 Hz, 
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1H, H1β), 4.30 ( dd, J1 = 5.6 Hz, J2 = 11.2 Hz, 1H, H2α), 4.06 - 4.18 (m, 4H, H6,6’α, H6,6’β), 3.87 (t, J 
= 6.6 Hz, 1H, H5β), 3.63 (t, J = 10.0 Hz, 1H, H2β), 2.14 (s, 3H Acα), 2.07 (s, 3H Acβ), 2.05 (s, 3H 
Acα), 2.02 (s, 3H Acβ), 2.01 (s, 3H Acβ), 1.96 (s, 3H Acα); 13C NMR (100 MHz, CDCl3): δ 170.3, 
170.2, 169.84, 169.80, 169.6, 169.5, 133.5, 132.5, 132.4, 129.0, 128.9, 128.5, 127.9, 86.8, 86.3, 
74.3, 72.9, 70.0, 67.42, 67.35, 66.4, 61.6, 61.5, 59.2, 58.0, 20.6, 20.5; ESI HRMS: [M+Na]+ 
calcd for C18H21N3NaO7S 446.0998, found 466.0995. 
Phenyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio-D-galactopyranoside (6).  Sodium metal 
(0.023 g) was washed with hexanes and allowed to air dry briefly.  The sodium was then 
dissolved in 10 mL of anhydrous MeOH to prepare a 0.1 M NaOMe solution.  Next, 2.75 g (6.49 
mmol) of 5 was dissolved in a separate round bottom with 8 mL of anhydrous MeOH.  A 0.1 M 
NaOMe (6.5 mL) solution was added dropwise to the solution of 5.  When the reaction was 
judged to be completed by TLC 1:2 EA/Hex, Dowex 50W x 8-100 ion exchange resin was 
added portion wise until the pH reached 7.  The resin was then filtered off and the solution was 
concentrated to a thick oil.  Next, the crude triol was co-evaporated 3 times with toluene and 
dried under high vacuum for 1 hour.  The dried sugar was then dissolved in 68 mL of anhydrous 
acetonitrile.  After the triol was completely dissolved, 0.125 g (0.649 mmol) of p-TSA was 
added, when the reaction was judged to be complete by TLC (1:1 EA/Hex), 2.1 mL of NEt3 was 
added and the reaction mixture was concentrated.  The crude oil was then purified on silica gel 
with EA/Hex 1:4 - 1:1 to provide 6α and 6β (2.38 g, 95%, combined yield) as syrups, α/β 1.7:1.  
Data for 6α and 6β.  6α, 1H NMR (400 MHz, CDCl3):  δ 7.48 – 7.52 (m, 4HAr) 7.39 – 7.41 (m, 
3HAr) 7.26-7.33 (m, 3HAr), 5.76 (d, J = 5.6 Hz, 1H, H1), 5.61 (s, 1H, HCHPh), 4.33 (d, J = 2.4 Hz, 
1H, H4), 4.24 (m, 2H, H6, H5), 4.20 (dd, J1 = 5.6 Hz, J2 = 10.4 Hz 1H, H2), 4.12 (m, 1H, H6’), 4.02 
(dt, J = 3.6 Hz, J2 = 10.4 Hz, 1H, H3), 2.58 (m, 1H, HOH); 13C NMR (100 MHz, CDCl3): δ 137.1, 
133.4, 130.8, 129.1, 128.9, 128.1, 127.1, 126.0, 100.9, 87.0, 74.8, 69.1, 68.8, 63.4, 60.8; 1H 
NMR (400 MHz, CDCl3): 6β, δ 7.45 (d, J = 7.2 Hz, 1H, HAr), 7.29-7.43 (m, 8HAr), 5.52 (s, 1H, 
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HCHPh), 4.40 (m, 2H, H1, H6), 4.15 (d, J = 3.2 Hz, 1H, H4), 4.01 (d, J = 12.0 Hz, 1H, H6’), 3.62 (dt, 
J1 = 3.6 Hz, J2 = 9.3 Hz, 1H, H3), 3.54 (t, J = 9.8 Hz, 1H, H2), 3.48 (s, 1H, H5), 2.62 (d, J = 9.6 
Hz, 1H, HOH); 13C NMR (100 MHz, CDCl3): δ 137.3, 134.1, 130.3, 129.4, 128.9, 128.4, 128.2, 
126.4, 101.3, 85.0, 74.3, 73.0, 69.8, 69.1, 62.0; ESI HRMS: [M + H]+ calcd for C19H20N3O4S 
386.1175, found 386.1174. 
Phenyl 2-azido-4,6-O-benzylidene-3-O-t-butyldiphenyl silyl-2-deoxy-1-thio-α-D-
galactopyranoside (7).  1.01 g (2.62 mmol) 6α and 0.392 g (5.76 mmol) imidazole were 
dissolved in a minimal amount of DMF at room temperature, then 0.74 mL (2.88 mmol) 
TBDPSCl was added slowly.  After 4 hours an additional 0.27 mL (1.05 mmol) of TBDPSCl was 
added to the reaction mixture.  At the 5 hour point an additional 0.34 mL (1.32 mmol) of the silyl 
chloride was added.  The reaction was allowed to stir 3 more hours then was quenched with 50 
mL of water.  The reaction mixture was extracted 3 times with 50 mL ethyl acetate. The 
combined organic layers were washed with sat. NaHCO3, dried over MgSO4, filtered and 
concentrated.  The resulting residue was then purified on silica gel utilizing pure toluene as the 
eluent to provide 7 (1.29 g, 79%) as a colorless oil.  Data for 7.  1H NMR (400 MHz, CDCl3): δ 
7.81 (d, J = 5.6 Hz, 4HAr), 7.40 – 7.56 (m, 11HAr), 7.20 – 7.35 (m, 5HAr), 5.80 (d, J = 4.8 Hz, 1H, 
H1), 5.06 (s, 1H, HCHPh), 4.52 (dd, J1 = 4.8 Hz, J2 = 10.8 Hz, 1H, H2), 4.13 (dd, J1 = 3.6 Hz, J2 = 
10.4 Hz, 1H, H3), 4.05 (d, J = 12.0 Hz, 1H, H6), 3.83 (s, 1H, H5), 3.72 (d, J = 12.8 Hz, 1H, H6’), 
3.43 (d, J = 3.2 Hz, 1H, H4), 1.13 (s, 9Ht-butyl); 13C NMR (100 MHz, CDCl3): δ 137.6, 135.8, 134.2, 
133.9, 132.5, 130.9, 130.1, 130.0, 129.0, 128.9, 128.1, 128.0, 127.6, 127.1, 126.0, 100.4, 87.6, 
74.9, 71.4, 69.1, 63.6, 61.7, 26.8, 19.3; ESI HRMS: [M + Na]+ calcd for C35H37N3NaO4SSi 
646.2172, found 646.2173. 
Succinimidyl 1-amino-2-azido-4,6-O-benzylidene-3-O-t-butyldiphenylsilyl-2-deoxy-α-D-
galactopyranoside (8).  0.100 g (0.160 mmol) 7, 0.020 g (0.176 mmol) of NHS, and 2.91 mL 
DCM were stirred with 300 mg of flame dried 4 Å molecular sieves for 1 hour.  Then 0.072 g 
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(0.320 mmol) NIS was added and the reaction mixture was cooled to -40 oC.  Next 0.006 mL 
(0.0642 mmol) of TfOH was added and the mixture was allowed to stir for 30 minutes.  The 
reaction was stopped by the addition of 3 mL of sat NaHCO3 and then diluted with 3 mL of 
DCM.  The mixture was then filtered through a pad of celite and washed with 50 mL of 10% 
Na2S2O3, water, and brine.  The resulting organic layer was dried over MgSO4, filtered and 
concentrated to provide an oil which was purified on silica gel using EA/Hex 1:3 to provide 8 
(0.072 g, 73% yield, α/β 2:1) as a syrup.  Data for 8α.  1H NMR (400 MHz, CDCl3): δ 7.74 – 7.78 
(m, 4HAr), 7.30 – 7.53 (m, 9HAr), 7.30 (t, J = 7.2 Hz, 2HAr), 6.18 (d, J = 7.2 Hz, 1H, H1), 5.02 (s, 
1H, HCHPh), 4.88 (dd, J1 = 3.6 Hz, J2 = 10.0 Hz, 1H, H3), 4.47 (dd, J1 = 7.2 Hz, J2 = 10.4 Hz, 1H, 
H2), 4.00 (dd, = 1.6 Hz, J2 = 12.4 Hz, 1H, H6), 3.81 (s, 1H, H5) 3.59 (m, 1H, H6’), 3.51 (d, J = 3.2 
Hz, 1H, H4), 2.72 (s, 4Hsuc), 1.11 (s, 9Ht-butyl); 13C NMR (100 MHz, CDCl3): δ 177.4, 137.7, 135.8, 
134.3, 133.1, 129.9, 129.8, 128.8, 128.1, 127.8, 127.6, 126.0, 118.9, 100.3, 76.6, 74.7, 71.2, 
69.3, 68.6, 60.5, 28.1, 26.9, 19.3; ESI HRMS: [M + Na]+ calcd for C33H36N4NaO6Si 635.2302, 
found 635.2314. 
Succinimidyl 2-azido-4,6-O-benzylidene-3-O-t-butyldiphenylsilyl-2-deoxy-α-D-galactopyranoside 
(9). 0.100 g (0.160 mmol) of compound 7 and 0.074 g (0.641 mmol) of N-hydroxysuccinimide 
(NHS) were dissolved in a minimal amount of anhydrous acetonitrile then 5 mL of anhydrous 
toluene was added and the solution was evaporated to dryness.  This was repeated 3 times and 
the mixture was left under high vacuum overnight.  To the dried reagents were added 300 mg of 
flame dried 4 Å molecular sieves and 2.9 mL of anhydrous DCM.  This mixture was then 
allowed to stir at room temperature for 1 hr.  Next 0.040 g (0.176 mmol) of NIS was added and 
the reaction mixture was cooled to -40 oC.  Subsequently 0.003 mL (0.0321 mmol) of TfOH was 
added.  After 3 hrs. thioglycoside still remained in the reaction mixture, therefore an additional 
0.040 g (0.176 mmol) NIS was added followed by 0.003 mL (0.0321 mmol) TfOH.  The reaction 
was stopped after 4.5 hours by the addition of 3 mL of sat NaHCO3 and then the reaction was 
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diluted with 3 mL of DCM.  The biphasic mixture was then filtered through a pad of celite and 
washed with 50 mL of 10% Na2S2O3, water, and brine.  The resulting organic layer was dried 
over MgSO4, filtered, and concentrated to an oil which was purified on silica gel using EA/Hex 
1:3 to provide 9 (0.075 g, 75%) as a syrup.  Data for 9.  1H NMR (400 MHz, CDCl3): δ 7.77 (d, J 
= 7.6 Hz, 4HAr), 7.34 – 7.50 (m, 9HAr), 7.30 (t, J = 8.4 Hz, 2HAr), 5.54 (d, J = 3.6 Hz, 1H, H1), 
5.00 (s, 1H, HCHPh), 4.37 (dd, J1 = 3.6 Hz, J2 = 11.2 Hz, 1H, H3), 4.23 (s, 1H, H5), 4.18 (dd, J1 = 
4.0 Hz, J2 = 10.4 Hz, 1H, H2), 3.98 (d, J = 12.4 Hz, 1H, H6), 3.65 (d, J = 12.8 Hz, 1H, H6’), 3.47 
(d, J = 3.2 Hz, 1H, H4), 2.67 (s, 4H, HNHS), 1.10 (s, 9H, Ht-butyl); 13C NMR (100 MHz, CDCl3): δ 
170.8, 137.6, 135.8, 135.7, 134.1, 132.4, 130.0, 129.9, 128.8, 128.1, 127.9, 127.6, 125.9, 103.1, 
100.2, 74.6, 69.4, 68.7, 64.7, 60.0, 26.8, 25.3, 19.2; ESI HRMS: [M + Na]+ calcd for 
C33H36N4NaO7Si 651.2251, found 651.2247. 
Phenyl 2-azido-4,6-O-benzylidene-3-O-chloroacetyl-2-deoxy-1-thiol-α-D-galactopyranoside 
(11α). 2.23 g (5.79 mmol) of 6α was dissolved in 30 mL of anhydrous DCM and 1 mL of pyridine 
and cooled to 0 oC.  Next 0.553 mL (0.695 mmol) of chloroacetyl chloride was added dropwise 
and the reaction was allowed to warm to r.t. over 2 hours.  Subsequently 30 mL of water was 
added to the reaction mixture and the organic layer was then separated and washed with 3M 
HCl, sat NaHCO3, and brine, dried over MgSO4, filtered and concentrated.  This residue was 
purified with EA/Hex 1:5 to provide 11α (2.25 g, 84% yield) as a white solid.  Data for 11α.  1H 
NMR (400 MHz, CDCl3): δ 7.48-7.51 (m, 4HAr), 7.37-7.41 (m, 3HAr), 7.28-7.34 (m, 3HAr), 5.82 
(d, J = 5.2 Hz, 1H, H1), 5.56 (s, 1H, CHPh), 5.18 (dd, J1 = 3.6 Hz, J2 = 11.2 Hz, 1H, H3), 4.60 (dd, 
J1 = 5.2 Hz, J2 = 10.8 Hz, 1H, H2), 4.57 (m, 1H, H4), 4.27 (s, 1H, H5), 4.23 (dd, J1 = 1.2 Hz, J2 = 
12.8 Hz, 1H, H6), 4.17 (s, 2HCH2Cl), 4.10 (dd, J1 = 1.6 Hz, J2 = 12.8 Hz, 1H, H6’); 13C NMR (100 
MHz, CDCl3): δ 166.7, 137.2, 133.0, 131.3, 129.1, 129.2, 128.2, 127.7, 126.1, 100.8, 87.1, 73.2, 
72.7, 69.0, 63.3, 57.8, 40.6; ESI HRMS: [M + Na]+ calcd for C21H20ClN3NaO5S 484.0710, found 
484.0710. 
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Succinimidyl 2-azido-4,6-O-benzylidene-2-deoxy-α-D-galactopyranoside (10).  1.06 g (2.30 
mmol) of compound 11α or 11β and 1.06 g (9.20 mmol) of N-hydroxysuccinimide (NHS) was 
dissolved in a minimal amount of anhydrous acetonitrile.  10 mL of anhydrous toluene was 
added and the solution was evaporated to dryness.  This was repeated 3 times and the mixture 
was left under high vacuum overnight.  To the dried reagents were added 3 g of flame dried 4 Å 
molecular sieves and 28 mL of anhydrous DCM.  This mixture was then allowed to stir at room 
temperature for 1 hr.  Next 1.04 g (4.60 mmol) of NIS was added and the reaction mixture was 
cooled to -40 oC.  Subsequently 19 drops of TMSOTf was added.  After 3 hours the reaction 
was stopped by the addition of 30 mL of sat NaHCO3.  The biphasic mixture was then filtered 
through a pad of celite and washed with 30 mL of 10% Na2S2O3, water, and brine.  The resulting 
organic layer was dried over MgSO4, filtered, and concentrated to an oil.  Next the crude oil was 
dissolved in 90 mL of 5:1 EtOH:py then 0.574 g (7.55 mmol) thiourea was added and this 
mixture was allowed to stir for 1 hour at r.t.  The reaction mixture was concentrated and co-
evaporated with toluene 2 times.  The residue was extracted 3 times with DCM.  The combined 
organic layers were washed with sat. NaHCO3 and water, dried over MgSO4, filtered and 
concentrated.  The crude product was purified on silica gel with EA:Hex 3:2 to provide 10 (0.642 
g, 65% over 2 steps) as a white solid.  Data for 10.  1H NMR (500 MHz, CDCl3): δ 7.48 – 7. 50 
(m, 2HAr), 7.37 – 7.40 (m, 3HAr), 5.58 (s, 1HCHPh), 5.54 (d, J = 3.5 Hz, 1H, H1), 4.66 (s, 1H, H5), 
4.37 (d, J = 3.5 Hz, 1H, H4), 4.26 (dt, J1 = 3.5 Hz, J2 = 10.5 Hz 1H, H3), 4.20 (dd, J1 = 1.5 Hz, J2 
= 13.0 Hz 1H, H6), 4.08 (dd, J1 = 1.5 Hz, J2 = 13.0 Hz 1H, H6’), 3.85 (dd, J1 = 3.5 Hz, J2 = 11.0 
Hz 1H, H2) 2.73 (s, 4HNHS), 2.67 (d, J = 10.0 Hz, 1H HOH); 13C NMR (125 MHz, CDCl3): δ 170.8, 
137.2, 129.4, 128.3, 126.1, 103.0, 101.2, 75.0, 68.9, 67.2, 64.8, 59.7, 25.4; ESI HRMS: [M + 
Na]+ calcd for C17H18N4NaO7 413.1073, found 413.1073. 
Succinimidyl [2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-(1,3)-2-azido-4,6-O-benzylidene-2-
deoxy-α-D-galactopyranoside (13).  0.109 g (0.279 mmol) of acceptor 10 and 0.391 g (0.794 
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mmol) of trichloroacetimidate donor 12 were co-evaporated with anhydrous toluene 3 times and 
then left overnight under high vacuum.  These dried starting materials were then transferred by 
cannula with 2.25 mL of anhydrous DCM onto 220 mg of flame dried AW-300 molecular sieves 
and stirred at r.t. for 30 minutes.  Next the reaction mixture was cooled to 0 oC and 1 drop of 
TMSOTf was added. The reaction was monitored by TLC (2:1 EA/Hex).  The reaction was 
stopped after 1 hour by the addition of 3 mL of sat NaHCO3.  This mixture was filtered through a 
pad of celite, the organic layer was separated and washed with water and brine, dried over 
MgSO4, filtered and concentrated.  The crude product was purified with silica gel 
chromatography using 2:1 EA:Hex to provide 13 (0.113 g, 56%) as a white solid.  Data for 13.  
1H NMR (400 MHz, CDCl3): δ 7.50 - 7.53 (m, 2HAr), 7.34 – 7.40 (m, 3HAr), 5.57 (m, 2H, HCHPh, 
H1GalN3), 5.41 (d, J = 3.2 Hz, 1H, H4Gal), 5.30 (dd, J1 = 8.0 Hz, J2 = 10.4 Hz, 1H, H2Gal), 5.03 (dd, 
J1 = 3.2 Hz, J2 = 10.4 Hz, 1H, H3Gal), 4.79 (d, J = 8.0 Hz, 1H, H1Gal), 4.58 (s, 1H, H5GalN3), 4.47 (d, 
J = 2.4 Hz, 1H, H4GalN3), 4.10 – 4.22 (m, 5H, H3GalN3, H6/6’Gal, H6GalN3, H2GalN3), 4.07 (d, J = 12.8 Hz, 
1H, H6’GalN3), 3.94 (t, J = 6.4 Hz, 1H, H5Gal), 2.76 (s, 4HNHS), 2.17 (s, 3HAc), 2.06 (s, 6HAc), 1.98 (s, 
3HAc); 13C NMR (100 MHz, CDCl3): δ 170.8, 170.2, 170.0, 169.3, 137.4, 128.9, 128.1, 126.0, 
102.9, 102.3, 100.5, 75.3, 75.1, 71.0, 68.7, 68.5, 67.0, 65.2, 61.5, 57.9, 25.4, 20.7, 20.5; ESI 
HRMS: [M + Na]+ calcd for C31H36N4NaO16 found 743.2024, 743.2018. 
Succinimidyl [2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-(1,3)-2-N-acetyl-2-deoxy-α-D-
galactopyranoside (14).  0.110 g of 13 (0.153 mmol) was dissolved in 2.54 mL of 3:2:1 
THF/AcOH/Ac2O.  This mixture then was cooled to 0 oC and 0.211 g of activated zinc dust was 
added.  The reaction was allowed to stir for 3.5 hours.   An additional 0.050 g of zinc was added 
and the reaction was allowed to reach r.t.  At 4.5 hours of reaction time, the reaction was diluted 
with DCM and this mixture was filtered through a pad of celite.  The organic solution was then 
separated and washed with water and sat NaHCO3, dried over MgSO4, filtered, and 
concentrated.  The crude residue obtained was then dissolved in 10 mL of 80% acetic acid and 
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heated at 80 oC for 1.5 hours.  The mixture was concentrated and co-evaporated with toluene 3 
times.  The crude product was purified on silica gel using 15:1 DCM/MeOH to provide diol 14 
(0.060 g, 61% over 2 steps) as a white solid.  Data for 14.  MP 150-152 oC; [α]D +94 (c 1.91, 
MeOH); 1H NMR (400 MHz, CDCl3): δ 6.39 (d, J = 8.8 Hz, 1HNHAc), 5.36 (d, J = 3.2 Hz, 1H, 
H4Gal), 5.21 (d, J = 4.0 Hz, 1H, H1GalNAc), 5.18 (m, 1H, H2Gal, overlapping with H1GalNAc), 5.02 (dd, 
J1 = 3.6 Hz, J2 = 10.4 Hz 1H, H3Gal), 4.71 (m, 1H, H2GalNAc, overlapping with H1Gal), 4.70 (d, J = 7.6 
Hz, 1H, H1Gal), 4.56 (t, J = 4.4 Hz, 1H, H5GalNAc), 4.24 (s, 1H, H4GalNAc), 4.17 (dd, J1 = 7.2 Hz, J2 = 
11.2 Hz, 1H, H6’Gal), 4.09 (dd, J1 = 6.4 Hz, J2 = 13.6 Hz, 1H, H6’Gal), 3.91 (m, 3H, H5Gal, H3GalNAc, 
H6GalNAc), 3.81 (dd, = 4.0 Hz, J2 = 11.2 Hz, 1H, H6’Gal), 2.74 (s, 4HNHS), 2.15 (s, 3HAc), 2.05 – 2.06 
(m, 9HAc), 1.97 (s, 3HAc); 13C NMR (100 MHz, CDCl3): δ 171.4, 170.6, 170.5, 170.2, 170.15, 
169.5, 105.2, 101.6, 76.9, 71.7, 70.9, 70.5, 69.6, 68.5, 66.9, 62.9, 61.4, 47.1, 25.5, 23.2, 20.6, 
20.5; ESI HRMS: [M+H]+ calcd for C26H37N2O17 649.2092 found 649.2103. 
Aminooxy [β-D-galactopyranosyl]-(1,3)-2-N-acetyl-2-deoxy-α-D-galactopyranoside (2).   0.060 g 
(0.0925 mmol) of 14 was dissolved in 3 mL of 95% ethanol and 0.090 mL (1.85 mmol) of 
hydrazine hydrate was added. The reaction was allowed to stir for 8 hours and then 
concentrated to dryness.  This residue was dissolved in a minimal amount of water and purified 
using P-2 biogel with water as the eluent (column 1.5 cm x 22.5 cm, collecting ~0.5 mL 
fractions), to provide 2 (0.024 g, 64%) as a white solid.  Data for 2.  MP 186-187 oC; [α]D +100 (c 
0.67, H2O); 1H NMR (600 MHz, D2O): δ 5.00 (d, J = 4.1 Hz, 1H, H1GalNAc), 4.50 (d, J = 7.8 Hz, 
1H, H1Gal), 4.44 (dd, J1 = 4.1 Hz, J2 = 11.3 Hz, 1H, H2GalNAc), 4.29 (d, J = 2.7 Hz, 1H, H4GalNAc), 
4.07 (dd, J1 = 4.7 Hz, J2 = 7.6 Hz, 1H, H5GalNAc), 4.02 (dd, J1 = 3.1 Hz, J2 = 11.3 Hz, 1H, H3GalNAc), 
3.95 (d, J = 3.4 Hz, 1H, H4Gal), 3.78 – 3.87 (m, 4H, H6,6’GalNAc, H6,6’Gal), 3.70 (dd, J1 = 4.5 Hz, J2 = 
7.8 Hz, 1H, H5Gal), 3.65 (dd, J1 = 3.4 Hz, J2 = 10.0 Hz, 1H, H3Gal), 3.56 (dd, J1 = 7.8 Hz, J2 = 10.0 
Hz, 1H, H2Gal), 2.07 (s, 3HAc); 13C NMR (150 MHz, D2O): δ 174.7, 104.7, 100.8, 77.0, 75.0, 72.6, 
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70.8, 70.6, 68.7, 68.6, 61.1, 61.0, 47.9, 22.0; ESI HRMS: [M+Na]+ calcd for C14H26N2NaO11 
421.1434 found 421.1423. 
TF-PS A1 (16).  0.001g (9.1 x 10-9 mol) of PS A1(15) was dissolved in 0.5 mL of 0.1 M NaOAc 
pH 5 buffer in a 1 dram amber vial.  To this solution 55 µL of 0.01 M NaIO4 (5.5 x 10-7 mol, 0.5 
equiv. assuming PS A1 has an average MW of 110,000 g/mol and 120 repeating units/mol) was 
added and the reaction was allowed to stir for 90 min in the dark at r.t.  Subsequently 2 mg of 
KCl was added and the mixture was allowed to stir for an additional 30 min.  Finally 0.0007 g 
(1.8 x 10-6 mol, 3.2 equiv.) of α-TF was added and the reaction was left 18 hours in the dark.  
Next the reaction mixture was dialyzed against distilled water for 48 hours and lyophilized.  This 
material was then further purified with DEAE sepharose (GE life sciences), using 50 mM 
Tris.HCl (pH 7.3) as the eluent.  Fractions were then collected in 1 mL intervals, analyzed by 1H 
NMR, pooled, dialyzed, and lyophilized to provide the TF-PS A1 construct.  Percent loading was 
calculated by the following formula (% loading = MW TF-ONH2/ MW TF-PS A1 hexasaccharide 
conjugate x mol fraction) mol fraction obtained from NMR integration of the respective NHAc 
methyl protons of PS A1 and the TF antigen.  398.37 / 1164.13 x 0.40 x 100 = 14% w/w.  
  
20 
 
 
 
CHAPTER 2 - Biological Evaluation of the Vaccine Candidate TF-PS 
A1 
A. Introduction 
A1.  Biological Relevance of the TF Antigen 
 The Thomsen Friedenreich (TF or T) antigen [β-D-Gal-(1,3)-α-D-GalNAc-O-Ser/Thr], 
(Fig. 1, 1), is an important cancer antigen/biomarker found in high density on human breast, 
colon, stomach, bladder, prostate, and liver tumor cells.2f  TF was discovered by the combined 
efforts of Thomsen and Friedenreich.36  Their initial observation occurred during an attempt to 
determine the ABO blood type of bacterial contaminated red blood cells.  The bacteria 
neuraminidases present exposed the disaccharide and the resulting desialylated TF caused 
agglutination on addition of all human sera.  Two significant facts were determined from the 
discovery namely: (1) that antibodies against the TF antigen are present in normal human sera 
and (2) humans are intolerant to this antigen and hence application thereof in vaccine design 
and development could prove promising.2f  The latter point is supported by a 80 month study 
done on gastric cancer patients in which higher naturally occurring anti TF antibody titers 
coincided with a 30% increase in survivability when compared to responders below the median 
titer value (Fig. 1, right).37   
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Fig. 1  (left) TF antigen is found α-linked to Ser/Thr on cancer mucins such as MUC1, (right) 
gastric cancer patients survivability, high responders (anti TF antibody) top line vs. low 
responders bottom line.37  This figure was inspired by Kurtenkov, O.; Klaamas, K.; Mensdorff-
Pouilly, S.; Miljukhina, L.; Shljapnikova, L.; Chužmarov, V. Acta Oncologica 2007, 46, 316-323. 
 TF is naturally present on the large transmembrane (>250,000 kDa) mucin proteins such 
as MUC1 but is found in a masked form modified by sialylation, N-acetylglucosamine or fucose 
creating a host of O-glycans on healthy tissues.3c,38  These proteins contain many serine, 
threonine and proline residues in the extracellular domain and are heavily O-glycosylated on the 
hydroxyl amino acids beginning complex glycan formation.  Mucin proteins are normally 
expressed on the apical sides of secretory cells found in the intestine, respiratory, urinary and 
reproductive tracks.3c  However in epithelial cancers, cancers which begin on tissues lining the 
outside of organs, mucin proteins are over expressed on the entire cell surface.  Furthermore, 
the glycosylation patterns of these proteins become truncated revealing the TF antigen along 
with other O-linked tumor associated carbohydrate antigens (TACA), including the Sialyl Tn 
(STn) and Tn antigens (Fig. 2).  The presence of TF on cancer cells could occur through 
increased T(F) synthase activity or through decreased subsequent modification.39  Alternatively, 
increased cellular concentrations of UDP-Gal and TF precursor, the Tn antigen, (α-D-GalNAc-
Ser/Thr) could play a role.2f  An increase in the variable number tandem repeats present in the 
extracellular region of MUC1 has also been shown to amplify the expression of TF.40  At this 
point it is important to state that the aberrant glycosylation of mucin proteins is not the cause of 
cancer but rather a consequence of cancer.  Although this altered cell surface glycosylation 
does not lie at the root origin of disease, it provides an encouraging target to exploit in cancer 
immunotherapies.   
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 Intriguingly, the presence of TF on MUC1 has been linked to cancer cell adhesion and 
metastasis to the vasculature through interaction with the β-Gal binding lectin, galectin-3.3,41  
Support for this conclusion has been demonstrated through passive immunotransfer murine  
Fig. 2  Aberrant glycosylation of O-glycans.38  This figure was inspired by Ju, T.; Otto, V. I.; 
Cummings, R. D. Angew. Chem. Int. Ed. 2011, 50, 1770-1791. 
experiments3b, immunoprecipitation/immunoblotting,3c competitive ELISA3a, fluorescence 
microscopy,3a,3c and cell adhesion experiments under flow conditions.41c,42 The interesting 
conclusions of these studies provide strong evidence that breast, colon and prostate cancer 
cells adhere to endothelium (cells that line the inner wall of blood vessels) in a TF/galectin-3 
dependent manner and this interaction is believed to initiate the early stages of metastasis.  
Two separate models have emerged in an attempt to explain the TF/galectin-3 involvement in 
  
TF 
Tn 
STn 
Disialyl-
TF 
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metastasis, Fig. 3 and Fig. 4.3a,3c  The Quinn model suggests release of TF containing 
glycoproteins and cells from the primary tumor that “prime” the endothelial vasculature which is 
thought to elicit the expression of galectin-3 on the surface of these cells.  In this model it is 
believed that initial cell binding occurs through TF/galectin-3 interactions allowing for irreversible 
protein-protein binding to take place resulting in tumor formation.  This model is supported by 
confocal microscopy experiments where endothelial cells were treated with HSA or TF-HSA 
along with a fluorescent anti-galectin-3 antibody.  The cells treated with TF-HSA displayed 
increased staining for galectin-3 surface exposure suggesting that TF-glycoproteins can indeed 
modulate surface expression of this protein.   
 
 
 
 
 
Fig. 3  Quinn model for TF/galecin-3 mediated metastasis.3a  This figure was inspired by 
Glinsky, V. V.; Glinsky, G. V.; Rittenhouse-Olson, K.; Huflejt, M. E.; Glinskii, O. V.; Deutscher, S. 
L.; Quinn, T. P. Cancer Res. 2001, 61, 4851-4857. 
 
 
 
Fig. 4  Rhodes MUC1 polarization model for TF/galectin-3 mediated metastasis.3c  This figure 
was inspired by Yu, L.-G.; Andrews, N.; Zhao, Q.; McKean, D.; Williams, J. F.; Connor, L. J.; 
24 
 
 
 
Gerasimenko, O. V.; Hilkens, J.; Hirabayashi, J.; Kasai, K.; Rhodes, J. M. J. Biol. Chem. 2007, 
282, 773-781. 
 The Rhodes model suggests a dual role for MUC1 as an anti-adhesion/adhesion 
molecule, initially allowing cancer cells to break away from primary tumors due to its large size, 
therefore being capable of disrupting close cell-cell contacts.  Following this shedding, TF 
expressing MUC1 is thought to act as a ligand for circulating galectin-3 causing a polarization 
effect of the glycoprotein on the cancer cell surface revealing smaller cell adhesion molecules 
needed for binding to the endothelium.  The polarization effect is thought to be the result of 
galectin-3’s ability to form pentamers after successful ligand binding through N-terminal domain 
contacts, resulting in cross linking of MUC1-galectin-3 complexes.41a  Experimental evidence for 
this process involved treating MUC1 transfected human breast cells with galectin-3 followed by 
staining with anti-MUC1 fluorescein antibody and monitoring under fluorescent microscopy.3c  
This work showed a loss of uniform distribution of MUC1 in 65% of treated cells as well as 
adhesion of these breast cells to a monolayer of endothelium cells opposite of MUC1 
polarization.  A similar mechanism is thought to increase the survivability of cancer cells which 
have broken free from primary tumors by allowing circulating cells to aggregate, avoiding 
anoikis.41b  Anoikis is a form of apoptosis induced when a loss of cell-cell interactions occur; it is 
also called suspension induced apoptosis.41b,43  In addition, the Rhodes model is supported by 
findings that serum levels of galectin-3 in cancer patients are five times greater than those of 
healthy blood donors.44  Furthermore, those patients that had metastatic cancer showed 
increased galectin-3 sera concentrations when compared with patients that possessed localized 
tumors.  While both the Quinn and Rhodes models have compelling evidence to support them, it 
may be that each mechanism is acting in unison to aid in the initial stages of the metastatic 
cascade.  Regardless of the exact mechanism of TF/galectin-3 interactions, this abundant 
amount of work supports the goal of generating a cytotoxic or inhibitory response against TF 
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bearing cancer cells to provide protection against distant tumor invasion and limit growth of 
primary tumors. 
A2.  Inhibitors of TF/Galectin-3 Interactions  
 In an effort to block the aforementioned TF/galectin-3 mediated metastasis, several 
groups have studied TF antigen mimics as well as galectin-3 inhibitors.3a,45  Recent inhibitory 
approaches involve the use of glycofreeze proteins isolated from northern cod species which 
contain large amounts of the TF antigen.45a  The presence of TF on this protein is thought to 
provide protection from freezing in frigid waters.  This cod glycoprotein possesses pm affinity for 
galcectin-3, has inhibited tumor cell-endothelial interactions in vitro and has shown the ability to 
stop metastasis of prostate cancer cells in mice.  Another inhibitory strategy exploited plant 
pectins isolated from citrus fruits which were hydrolyzed under basic conditions (pH 10.0, 50-60 
oC).45h  The chemically modified pectin was dissolved in drinking water and then given orally to 
nude mice where it reduced angiogenesis, growth, and metastasis of human breast cancer 
cells.  The authors attributed this activity to the disruption of carbohydrate/galectin-3 contacts 
which may include the TF antigen.  A more recent report studied a ginseng pectin which bound 
the carbohydrate domain of galectin-3 in nM concentrations.45b  The activity of this polymer was 
accredited to significant amounts of short β-1,4 galactan side chains which are thought to act in 
unison to bind galectin-3.  The structure of this material suggests a similar mechanism of action 
as with the chemically modified citrus pectin mentioned above.  The above examples rely on 
natural proteins or peptides expressing the TF antigen or β linked Gal residues which 
presumably block effective TF/galectin-3 binding, however, synthetic inhibitors have also been 
studied.   
 One such synthetic strategy uses lactulose-L-leucine (Lac-L-Leu, Scheme 1) prepared by 
the Amadori rearrangement.46  Lac-L-Leu (1 mM concentration in vitro) reduced the adhesion of  
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Scheme 1  Amadori rearrangement for the preparation of Lac-L-Leu. 
breast cancer cells to a monolayer of endothelium cells by 70% as well as significantly reducing 
galectin-3 binding to TF-HSA in an ELISA format.3a  In addition, when this mimetic was 
administered daily (20 µM, 0.20 mL) to SCID mice challenged with human prostate cancer cells 
the tumor spread was reduced by three fold when compared to control animals.45c  Furthermore, 
the co-administration of Lac-L-Leu with Taxol amplified apoptotic effects of this drug resulting in 
a fivefold increase of metastasis free animals (70%) compared to controls (14%).45d  An 
alternate plan of attack involves masking TF with a small synthetic peptide dubbed P-303a,45i 
(HGRFILPWWYAFSPS).  This peptide sequence was discovered through the study of a 
bacteriophage display library.47  P-30 showed promise in vitro by disrupting breast cancer cells 
homotopic aggregation and reducing their heterotopic adhesion.  Another small molecule 
inhibitor study began with the observation that β-methyl N-acetyllactosamine acts as a mM 
inhibitor of galectin-3.  This insight eventually evolved into C2-symmetrical thiodigalactoside bis-
benzamido derivatives with nM activity (Fig. 5, left).45e  The presence of the phenyl amide 
substitutions is thought to increase active site affinity by interacting with two arginine residues 
on either side of the carbohydrate recognition domain through cation-pi contacts.48  This group 
has prepared a significant amount of similar derivatives49 including triazol thiodigalactosides 
(Fig. 5, right) which proved to have similar inhibition properties as well as galetin-3 selectivity 
over several other human galectins.50 
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Fig. 5  Galectin-3 inhibitors, (left) thiodigalactoside bis-benzamido example, 
(right) triazol thiodigalactosides. 
 A final synthetic example involves the cycloaddition of a di-tert-butylsilylene protected 
galactal with a heterodiene generated in situ from phthalimidosulfenyl derivatives (Scheme 2).51  
Gal was then added to this cycloadduct to provide a TF mimic that could effectively compete for 
the binding site of a plant lectin with known affinity for galactosides including the TF antigen.51a  
While the authors were pleased with the inhibitory activity, this derivative was also prepared with 
application to TACA based cancer vaccines in mind, however, as of yet this compound has not 
been investigated in vivo but the Tn analogue has been studied yielding promising results.52 
 
Scheme 2  [4 + 2] cycloaddition for the preparation of a TF-glycopeptide mimic. 
The significant amount of data obtained through the usage of various natural and 
synthetic molecules to interfere with TF/galectin-3 promoted cancer development is truly 
remarkable.  The combination of these techniques with more traditional therapies may indeed 
provide increased protection against metastasis and the progression of cancer increasing 
patient survivability.  Another enticing plan to exploit the expression of TF on numerous cancers 
involves the preparation of TACA based cancer vaccines in an effort to stimulate the body’s own 
immune system to fight against the carcinoma.  If a significant antibody response can be 
generated against this TACA, metastasis should be reduced and cytotoxic effects could occur 
against not only circulating cancer cells but the primary tumor as well.  Furthermore, due to TF’s 
pancarcinomic expression and role in metastasis a vaccine against this antigen is capable of 
helping a tremendous amount of cancer patients.2f 
A3.  The TF Antigen and Cancer Immunotherapy  
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 Accordingly, many researchers have shown interest in the TF disaccharide through the 
preparation of synthetic vaccines.2a,2d,2e,2g,5,34-35,53  However, carbohydrates by themselves are 
poorly immunogenic only generating low affinity pentameric IgM antibodies through cross linking 
B-cell receptors in the absence of a strong memory immune response.54  Noteworthy exceptions 
are zwitterionic polysaccharides which are capable of inducing T-cell dependent responses and 
therefore immunological memory.4d  Traditionally to circumvent the T-cell independent nature of 
sugars a protein containing T-cell epitopes is covalently linked to the much smaller TACAs 
which allows for an enhanced and long lived IgG antibody responses to occur against these 
antigens.  This fact was elegantly demonstrated in 1929 by Avery, where a Glc-horse globulin 
glycoconjugate was administered to rabbits which in turn produced anti-Glc antibodies.55  The 
induced antibodies caused immunoprecipitation on combination with a different Glc conjugate, 
Glc-egg albumin, further supporting that Glc recognizing antibodies had been produced.  
Additionally, precipitation could be inhibited by first mixing the raised antibodies with Glc before 
exposure to Glc-egg albumin.  Since this initial discovery, various forms of TF-conjugate vaccine 
constructs have been prepared including those based on immunogenic proteins,2a,2d,53f,53h-k 
modified TF antigens,2e,5,34-35,53c gold nanoparticles,2g,53a,53e,53g, TF peptide mimics,53d and 
zwitterionic carbohydrate carriers.53b   
 The protein based constructs, for the most part, rely on conjugation to keyhole limpet 
hemocyanin (KLH), a large highly immunogenic multi-subunit protein isolated from the giant 
keyhole limpet, where it functions as a Cu based oxygen transporter.56  The Tumor associated 
scarbohydrate antigens (TACAs) are generally conjugated to KLH through 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) coupling or by acylation of primary amines with 
sulfosuccinimidyl-4-N-maleimidomethyl cyclohexane-1-carboxylate (sulfo-SMCC) to install thiol 
reactive maleimide groups on the protein surface, the latter of which is commercially available.  
An early report investigated a TF-KLH construct on ovarian cancer patients in a phase I trial.53j  
In this study, 8/10 patients developed cytotoxic antibody responses and 9/10 produced 
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significant IgG and IgM titers against the TF, as determined by enzyme linked immunosorbent 
assays (ELISA) and fluorescence activated cell sorting (FACS).  Another clinical trial involved a 
crotyl linked TF-KLH immunogen that induced antibody responses against synthetic TF.53i  
However, the raised antibodies had little to no affinity for natural TF.  This finding is most likely 
due to significant antibody generation towards the synthetic linker.  A more recent example 
utilizing the carrier protein strategy involved a trivalent TF-KLH glycoconjugate (Fig. 6) in a 
phase I trial on prostate cancer patients with relapsed disease.53f  The clustered format 
approach was believed to better represent the natural presentation of TACAs on cancer cells.  
This vaccine showed promise, being capable of bringing about high IgM and IgG antibody titers 
against the TF antigen with only minor side effects.  In a continuation of this work, α and β-1,3-
Gal C-linked versions of this construct have been prepared in an effort to avoid β-glycosidase 
degradation of TF.53c  The β construct brought about IgG titers against C-linked TF coated 
ELISA plates, while the α construct was ineffective.  Unfortunately the serum was not examined 
for binding capacity against the natural TF antigen.   
 
 
 
 
Fig. 6  Trivalent TF-KLH glycoconjugate.53f  This figure was inspired by Slovin, S. F.; Ragupathi, 
G.; Musselli, C.; Fernandez, C.; Diani, M.; Verbel, D.; Danishefsky, S.; Livingston, P.; Scher, H. 
I. Cancer Immunol. Immunother. 2005, 54, 694-702. 
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 The TF was also one of five TACAs present on a multi-antigen vaccine linked to KLH.2d  
Unfortunately, the presence of different antigens on the same construct resulted in a reduction 
of antibody production against individual TACAs when compared to single antigen 
glycoconjugate vaccines.57  Finally, another TF-KLH conjugate prolonged survival of 1/3 mice 
challenged with TA3-Ha cells (murine breast cancer) and also elicited IgG antibodies against 
the TF.53k  While the above strategies utilize KLH as a carrier, this protein is not the only option.  
A study from 2004 developed a 9-mer peptide (AIIASFAAL) containing TF linked to serine at the 
5-position.53h  This peptide displayed low nM affinity for major histocompatibility complex I and 
when administered to mice produced cytotoxic T-cell lymphocytes capable of lysing lymphoma 
cells in vitro.  
Chemically modified TF has also been investigated with the hope of increasing 
immunogenicity and bioavailability of the disaccharide.  Examples include 3-fluoro, 4-fluoro and 
6,6’-difluoro TF antigens, which were conjugated to the immunogenic proteins tetanus toxoid 
and bovine serum albumin.2e,34-35  In the case of the 4-fluoro derivative, a decrease in the 
enzymatic degradation of the terminal β-1,3-Gal residue was observed, displaying a strong 
resistance to bovine β-galactosidase.35  While the 6,6’ difluoro-TF derivative vaccine was 
capable of obtaining antibodies that could recognize natural TF in ELISA2e and both 4-fluoro and 
6,6’-difluoro constructs induced antiserum that bound to MCF-7 breast cancer cells in FACS 
experiments.  In addition, the 3-fluoro TF peptide conjugate inhibited the binding of TF specific 
antisera to TF-BSA in ELISA, suggesting that this modification could be worth further 
investigation as an inhibitor of galectin-3.34  As discussed in Chapter 1, another chemical 
modification strategy involves the synthesis of an α-aminooxy derivative of the TF antigen, 
replacing the natural Ser/Thr with a nucleophilic handle.5  The aminooxy disaccharide allowed 
for the preparation of tetra TF cyclodecapeptide (RAFT) platforms through oxime bond 
formation with aldehydes present on a cyclic peptide scaffold.  This idea was further extended to 
31 
 
 
 
hexadecavalent constructs simulating the presumed natural clustered arrangement of TACAs 
(Fig. 7).6  The TF-RAFT conjugates have shown promise as galectin-3 inhibitors58 but have not 
yet been studied as a vaccine.  However, the Tn antigen variant coupled to two distinct T-cell 
epitopes and palmitic acid moiety has been evaluated with encouraging results.59   
 
Fig 7  RAFT glycoconjugate design, circles = TACAs.6  This figure was inspired by Bossu, I.; 
Sulc, M.; Krenek, K.; Dufour, E.; Garcia, J.; Berthet, N.; Dumy, P.; Kren, V.; Renaudet, O. 
Organic & Biomolecular Chemistry 2011, 9, 1948-1959. 
 Another unique strategy uses gold nanoparticles as display platforms for delivery of 
TACAs to the immune system.2g  Initial work in this area began with the use of thiopentyl and 
thio-PEG linkers bridging between the TF disaccharides and the thio-gold complex.53g  These 
nanoparticles displayed interesting activity in vivo inhibiting the spread of metastatic breast 
cancer cells to the lungs of mice.  However, when nanoparticle formation was attempted with 
the previously mentioned peptide (AIIAS(TF)FAAL)53hconjugated to a PEG-amino-carboxylate 
linker, the resulting gold particle possessed solubility issues making characterization difficult.  A 
second attempt at preparing TF-peptide nanoparticles proved more successful.53e  This strategy 
used glycosylated MUC-4 peptides with a similar linker but unfortunately no biological data on 
these constructs have been published to date.  A more recent construct relies on a helper B-cell 
epitope and a synthetic mucin peptide fragment containing the TF, both dependent on thio-Au 
complex for nanoparticle formation (Fig. 8, right).2g  This Au-TF based vaccine produced 
statistically significant antibody titers against the TF in the absence of external adjuvant.  In 
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another recent update, TF amino acid (Ser/Thr) nanoparticles (Fig. 8, left) were shown to inhibit 
the growth of galectin-3 positive cells lines much more than galectin-3 negative cells.53a  
Furthermore, the threonine-TF constructs proved more efficient then the serine analogues in 
mediating this biological activity. 
 
Fig. 8  TF gold nanoparticle constructs.2g,53a  This figure was inspired by Brinãs, R. P.; 
Sundgren, A.; Sahoo, P.; Morey, S.; Rittenhouse-Olson, K.; Wilding, G. E.; Deng, W.; Barchi, J. 
J. Bioconjugate Chem. 2012, 23, 1513-1523 and Biswas, S.; Medina, S. H.; Barchi, J. J. 
Carbohydr. Res. 2015, 405, 93-101. 
 Polyamidoamine (PAMAM) glycodendrimers incorporating the TF antigen (Fig. 9, left) 
into multivalent platforms have also been studied as vaccines. While these constructs were not 
immunogenic in vivo, they effectively reduced binding of a monoclonal antibody in ELISA 
experiments suggesting possible galectin-3 inhibition activity.60  Following this work the 
multivalent dendrimer strategy was used with a 15-mer peptide generated from a phage display 
library with selection against two monoclonal anti-TF antibodies.53d  This work produced the TF 
peptide mimic dendrimer in Fig. 9 (right). The construct effectively blocked tumor cell adhesion 
in vitro and surprisingly produced anti-TF antibodies when administered to mice even though no 
carbohydrates were present. 
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Fig 9  (left) PAMAM glycodendrimers, (right) TF mimic dendrimer based on a branched 
tripeptide lysine core.53d,60  This figure was inspired by Heimburg-Molinaro, J.; Almogren, A.; 
Morey, S.; Glinskii, O. V.; Roy, R.; Wilding, G. E.; Cheng, R. P.; Glinsky, V. V.; Rittenhouse-
Olson, K. Neoplasia (Ann Arbor, MI, U. S.) 2009, 11, 780-792 and Roy, R.; Shiao, T. C.; 
Rittenhouse-Olson, K. Braz. J. Pharm. Sci. 2013, 49, 85-108. 
 As an alternative to synthetic methods, natural sources have been investigated for use 
as vaccines.2b,61  In fact the first attempt at a TF based vaccine used neuraminidase treated 
type-O red blood cells in the presence of Salmonella typhi vaccine which also contains the Tn 
and TF antigens.2b,61c  The red blood cell components of this vaccine most likely contain 
significant amounts of asialoglycophorin A.  The loss of sialic acid on this glycoprotein reveals 
the normally masked TF and Tn antigens.2f  Interestingly, this combination was studied on a 
small group of 32 patients after mastectomy or lumpectomy and radio/chemotherapy where all 
of the patients survived >5 years.  In addition, a statistically significant increase in 10 year 
survival rates was observed.  In a continuation of this work, mice where immunized with 
asialoglycophorin A and the passive transfer of these induced antibodies increased survival of 
mice challenged with TF bearing leukemia cells.61a  Also, mice pre-inoculated with this 
glycoprotein conferred increased protection against TF positive leukemia cells when contrasted 
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with control animals.  These recent results coupled with the early trials of the red blood cell/S. 
typhi vaccine warrant further investigation into this strategy.2f 
 A more recent non-synthetic approach was based on the source of natural anti-TF 
antibodies, which are generated in response to a specific gut bacteria in humans.62  These 
researchers isolated a new strain of commensal bacteria, Bacteroides ovatus, which carries TF 
on its capsular polysaccharide coat.61b,62  Mice immunized with this attenuated microbe 
developed IgG and IgM antibody responses against TF in the absence of adjuvant and these 
antibodies were shown to recognize TF present on leukemia cells.  The authors attributed this 
success to natural adjuvanting properties of the bacterium along with the clustered presentation 
of TF.   
 The plethora of vaccine constructs designed to target the TF antigen supports the further 
exploration of this carcinoma biomarker as a suitable focus for cancer immunotherapy.  
However, the popular conjugation of TACAs to immunogenic protein carriers has not seen the 
same success in clinical settings as the conjugation of polysaccharides from infectious 
organisms.2f,54,60  While several clinical trials have been accomplished with TF53f,53i,53j,61c, these 
vaccine constructs have not progressed into viable treatment options and therefore no current 
therapies targeting TF or other TACAs are available in the clinic.2f,53a,60  This outcome is 
highlighted by the failure of Biomira’s Theratope (STn-KLH) vaccine in a phase III clinical trial 
containing over 1000 women from 10 different countries.63  The mean survival rates in this study 
were 23.1 months for treated and 22.3 months for control patients resulting in a failure to meet 
statistical significance.  However, STn expression is limited to about 30% of breast cancers64 
and the patients included in this phase III study were not prescreened for STn positive tumors.2f  
Therefore, a subset of these patients may have shown a statistically significant increase in 
survival.65  This theory was evaluated in a transgenic murine model where the animals were 
pre-inoculated with Theratope and then challenged with murine breast tumor cells (SE3 and 
E3); SE3 was transfected with MUC1 and the sialyl transferase enzyme ST6GalNAc I.65  The 
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results were as expected with the SE3 challenged animals demonstrating increases in survival 
times along with reduction in tumor volumes when contrasted against animals challenged with 
unmodified E3 tumor cells.  This result provides further evidence for the protective effects on 
generation of an immune response against TACAs IF the targeted cells express the required 
antigen. 
 Many factors are thought to play a role in the difficulty of producing TACA based cancer 
vaccines including unwanted antibody responses against carrier/linker components,53i,66 
heterogeneous expression of TACA targets,54 glycosidases reducing bioavailability,52 and the 
difference in carbohydrate antibody binding (µM) vs. protein antibody binding (nM).54  
Carbohydrate antibody affinity relies on hydrogen bonding, electrostatic and hydrophobic 
interactions, in a similar fashion as protein- antibody binding does.  However, it is thought that 
decreases in entropy as a result of limited or reduced bond rotation of the sugars and water 
displacement/reorganization on antibody binding combine to reduce the overall affinity of 
antibodies towards carbohydrates.67  Nature uses multivalency to make up for this decreased 
affinity through the combination of a large amount of weaker interactions.68  Following this 
example, researchers have prepared an ever increasing number of methods aimed to mimic this 
effect.60,69  Nevertheless, as previously stated no current treatments exist that targets TACAs.  
Therefore the search continues for novel carrier formats and immunogenic components that will 
be able to overcome limitations of current methods for carbohydrate based vaccines. 
A4.  The Zwitterionic Polysaccharide A1’s (PS A1) T-cell Dependent Immune Response  
 One such alternative carrier is polysaccharide A1 (PS A1), isolated from the capsular 
polysaccharide (CP) of the commensal microbe Bacteroides fragilis.4d  PS A1 has been 
previously used by our group as an efficient carrier of the Tn antigen, generating IgM and IgG 
antibodies against this TACA.4b  Furthermore, these antibodies were shown to bind Tn 
expressing cancer cells.4c  PS A1 contains a tetrasaccharide repeating unit70 with a molecular 
weight of approximately 130 kDa and is thought to consist of a right handed helical structure 
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with two repeating units per turn.4d,71  This polysaccharide is unique in its ability to elicit a T-cell 
dependent immune response and thus immunological memory, making it an attractive candidate 
for study as a vaccine carrier.4b 
 Traditionally, polysaccharides have been thought to bring about only T-cell independent 
immune responses, generating poor immunogenic memory along with IgM antibodies.72  
Contrary to this belief, the CP of B. fragilis has been shown to elicit a T-cell dependent immune 
response which was demonstrated through extensive experiments in mice and rats.73  Initial 
studies were based on the knowledge that B. fragilis is the major microorganism isolated from 
cultured inter-abdominal abscess tissue.  Therefore, in an attempt to provide protection against 
abscess formation, intraperitoneal (I.P.) injections of CP isolated from B. fragilis were given to 
rats over five weeks.73b  Following this period the animals underwent bacterial challenge and 
after 7 days were euthanized and examined for abscess formation.  The immunized rats were 
found to be overwhelmingly protected against the effects of a B. fragilis infection (abscess 
growth), 0 abscesses in the 5 rats immunized and 5 abscesses in the 5 rats not immunized with 
the CP. 
 The researchers next turned their attention towards gaining insight into the branch of the 
immune system that was responsible for the observed protection.  This question was addressed 
through immunization of athymic nude rats (T-cell knockout) with B. fragilis CP.73b  These 
animals were found to have no protection against abscess formation, while the normal rats did 
not develop abscesses after bacterial challenge.  This result strongly suggests a T-cell 
dependent immune response was being generated by the CP of B. fragilis and was most likely 
responsible for the observed protection of the phenotypically normal animals. 
 Further investigation revealed the two major components of the CP to be a 
tetrasaccharide polymer (PS A1) and a hexasaccharide polymer (PS B, Fig. 10) both containing 
over one hundred repeating units.70,74  Also of note was the finding that PS A1 is an order of 
magnitude more efficient at eliciting abscess formation then either PS B or the complete CP in 
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the presence of adjuvant.  This conclusion is based on the dose required to bring about abscess 
formation in 50% of the population in a rodent model (AD50) PS A1 0.65 µg, PS B 25 µg, and CP 
22 µg.75  In addition, the unusual zwitterionic character of these polysaccharides was found to 
be responsible for the observed immune stimulation.  This was demonstrated through chemical 
modification of the amino and carboxylate functionalities of PS A1 by three different methods: 1) 
reduction of the carboxylate76 2) N-acetylation,75 and 3) deamination (Fig.10).70,75  All of these 
modifications greatly reduced the biological activity observed with native PS A1.75  Similar 
chemical modifications to PS B also resulted in reduced activity with the exception of 
carboxylate reduction, most likely due to the presence of an additional negative charge per 
repeating unit present on this polymer.77  Furthermore, two polysaccharides with zwitterionic 
charge character from Streptococcus pneumonia, C substance which contains three  
  
Fig. 10  (left) Tetrasaccharide repeating unit of PS A1, chemical modification of the amine or 
carboxylate results in loss of biological activity, (right) hexasaccharide repeating unit of PS B. 
 
positive and two negative charges and CP type 1 containing one positive and two negative 
charges, displayed similar behavior as PS A1 with loss of activity on N-acetylation.77  Neutral 
polysaccharides and those with one negative charge were also examined in this study but 
proved to be inactive.  Additionally, PS A1 like responses were manufactured from an inactive 
component of the CP of Salmonella typhi (Fig. 11), which naturally contains only one negatively 
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Could this suggest that a major reason for low saccharide antigenicity is in fact in most 
casecharged carboxylate group.  This polymer is made from α-1,4 linked N-acetyl-2-
aminogalacturonic acids and upon deacetylation a zwitterionic relationship is created.  
Surprisingly this compound displayed similar properties as PS A1, albeit at a 24 fold increase in 
concentration.  This result suggests that while the constituent sugars do play a role in the 
observed biological activity it is the zwitterionic nature of these polymers which is the dominant 
factor. 
 
Fig. 11  Polyuronic acid from Salmonella typhi, removal of the N-acetyl creates zwitterionic 
character and biological properties similar to PS A1. 
 As previously stated, non-zwitterionic carbohydrates require conjugation to T-cell 
dependent carriers, usually in the form of proteins, to elicit immunological memory and the 
production of high affinity IgG antibodies.78  This consequence has been attributed to the carrier 
proteins ability to be endocytosed and processed into glycopeptide fragments by antigen 
presenting cells.  These fragments then bind and are presented by major histocompatibility 
complex class II (MHC II) to receptors on CD4+ T-cells.  The T-cells can then efficiently signal B-
cells through the release of interleukins 2 and 4 (IL-2, IL-4) to stimulate production of IgG 
antibodies and T/B-cell memory, both extremely important for an effective vaccine construct (Fig 
12).72b  Recently, this traditional explanation has been confirmed through confocal microscopy 
using fluorescently labeled Pneumococcal polysaccharide protein conjugates which were 
visualized on the APC surface.79  However later studies have suggested that the majority of 
carbohydrates are T-cell independent due to their inability to bind MHC II and be presented, not 
because of failure to be recognized by T-cell receptors or lack of uptake by APCs.80 
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Fig. 12  B-cell/T-cell interaction required for production of IgG antibodies and immunological 
memory.72b  This figure was inspired by Avci, F. Y.; Li, X.; Tsuji, M.; Kasper, D. L. Semin. 
Immunol. 2013, 25, 146-151. 
 PS A1 has also been shown to activate CD4+ T-cells.  This was demonstrated through 
the proliferation of human CD4+ T-cells in vitro on exposure to this zwitterionic polysaccharide 
(ZPS).81  To further support the importance of zwitterionic character, chemically modified PS A1 
was also studied and as before showed loss of biological activity.  Subsequently, the authors 
prepared a series of lysine-aspartic acid peptides ranging from a monomer to a 25-mer, with the 
15, 20, and 25 unit polymers being able to bring about similar T-cell stimulation as PS A1, 
observed by 3H labeled thymidine incorporation.  Further studies involving the passive transfer 
of T-cells exposed to PS A1 or the zwitterionic peptides resulted in protective effects in rats 
challenged with B. fragilis.  In addition, when the in vitro experiments were repeated in the 
presence of an anti-HLA-DR (a specific subunit of the MHC II complex) monoclonal antibody so 
were the proliferative effects of PS A1, supporting the involvement of MHC II in the observed 
biological activity of PS A1.82 
 Following this work, the role of MHC II and the immune processing of PS A1 were 
determined through confocal microscopy and murine gene knock out experiments.4a  To begin 
the authors successfully observed the presence of fluorescently tagged PS A1 inside as well as 
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on the surface of APCs.  Next, the processing mechanism was examined; PS A1 proved to be 
stable under acidic (pH 5) and reducing conditions but was cleaved after treatment with H2O2.  
This led to rodent NO synthase knockout experiments.  When these knockout animals were 
challenged with B. fragilis or purified PS A1 with adjuvant a marked reduction in abscess 
formation was observed when compared to the wild type animals.  However, when oxidatively 
(O3) cleaved83 PS A1 was used the induction of abscesses was restored suggesting that PS A1 
was processed by a nitric oxide oxidative burst pathway.  Next, MHC II binding was studied in 
vivo using 3H labelled ZPS in wild type and NO knock out mice.  Co-immunoprecipitation of 
spleenocytes from the wild type animals reavealed binding of PS A1 to MHC II (HLA-DR 
subunit) while the NO knock out mice only displayed sparse amounts of ZPS binding.  As 
before, chemically oxidized PS A1 was then studied which showed binding to MHC II in both the 
wild type and the knock out mice, further supporting the NO degragation pathway.  Finally, the 
immune synapse was observed through confocal microscopy by incubating APC/T-cells in the 
presence and absence of ZPS (Fig. 13).  MHC II on APCs surface was stained in red while the 
T-cell receptors were visualized with green.  As can be seen in panel A, in the absence of PS 
A1 no contact is created, but on addition of the polysaccharide a distinctive contact is observed 
as indicated by the yellow region (panel B).  These experiments support the theory that ZPSs 
are endocytosed by APCs, degraded by a NO oxidative burst pathway to smaller fragments <15 
kDa, loaded onto MHC II and presented to CD4+ T-cells (Fig. 13 B) to provide a T-cell 
dependent immune response and immunological memory.  This process mimics the route by 
which foreign protiens are presented with the exception of NO degragation.  The elucidation of 
this mechanism defines the novel biological acitivty of ZPSs and provides further evidence to 
support their use as a carrier of TACAs to the immune system. 
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Fig.13  Confocal microscopy of APC and T-cells incubated without (A) and with PS A1 (B), red 
correlates to MHC II, green correlates to T-cell receptors, yellow represent overlap of these 
regions.4a  This figure was inspired by Cobb, B. A.; Wang, Q.; Tzianabos, A. O.; Kasper, D. L. 
Cell 2004, 117, 677-687. 
 The following studies investigated the role of PS A1’s zwitterionic character in 
endocytosis, NO mediated depolymerization, and interaction with MHC II.84  First, fluorescently 
labeled native and charge modified PS A1 were incubated separately with APC.  Native PS A1 
was visualized in red on the surface in the same area as MHC II outside and inside the cells 
(Fig. 14 A). However, the charge modified polymers remained only inside the APC (Fig. 14 B, 
C).  This suggests that the alternating charge character does not play a role in PS A1 uptake but 
possibly in surface expression.  Next, natural PS A1, chemically altered PS A1, and an anionic 
polysaccharide control were exposed to APC overnight and the endosomal lysates were 
analyzed with size exclusion chromatography.  This experiment resulted in similar elution 
profiles for all of the polysaccharides examined implying that the zwitterionic nature of PS A1 
had no effect on the degradation pathway.  Conversely, on investigation of modified PS A1 
binding to MHC II in an ELISA format a stark contrast was observed, with native PS A1 having 
low µM affinity and the charge modified versions having no interaction at this concentration 
range.  Furthermore, 3H labeled charge modified PS A1 was not observed in co-
immunoprecipitation experiments of APC using an anti-MHC II monoclonal antibody.  Based on 
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these experiments, PS A1’s interaction with the MHC II complex is thought to be largely 
dependent on electrostatic interactions.  This conclusion is further supported by loss of binding 
affinity under conditions of increasing ionic strength and also by the sensitivity of PS A1 - MHC 
II interactions to pH.  These results strengthen the correlation between the zwitterionic character 
and T-cell dependent nature of PS A1 and also aid in the explanation of why anionic/neutral 
polysaccharides fail to induce T-cell dependent responses.   
 
 
Fig. 14  (A) Native PS A1 (red) is seen inside and on the surface of APC, also PS A1 is located 
in the same regions as MHC II (green), (B, C) Charge modified PS A1 is only seen inside APC 
and not on the cell surface.84  This figure was inspired by Cobb, B. A.; Kasper, D. L. 
Glycobiology 2008, 18, 707-718. 
 
A5.  PS A1 Conformation and Function  
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 The size requirements of PS A1 for T-cell activation have also been evaluated.83  To 
explore this prerequisite the ZPS was exposed to O3 at various time intervals, yielding four 
average molecular sizes of 78, 47, 17, and 5 kDa, isolated through size exclusion 
chromatography.  The larger MW polymers were effective at T-cell stimulation and protected 
twice as many rodents from challenge with B. fragilis when compared to animals given the 5 
kDa fragment.  These results demonstrate that PS A1 fragments under 5 kDa lose their 
biological activity presumably as the result of conformational breakdown.  In addition, the 
authors estimate the functional cut off of PS A1 biological activity to be roughly in the 17 kDa 
range or 22 tetrasaccharide repeating units. 
 Extensive NMR experiments and molecular dynamic calculations were conducted on a 
related ZPS also isolated from the CP of B. fragilis, dubbed PS A2.71  These studies found that 
PS A2 consists of a right handed α helix with two repeating units per turn with all charges found 
on the outside edges of the helix.  The positive and negative charges alternate along the 
backbone separated by 10 Å with the helical character creating grooves roughly 10 Å long, 10 Å 
wide, and 5 Å deep (Fig. 15).  The authors proposed that these grooves serve as binding 
domains for proteins and the ZPS α helices were shown to accommodate these spaces quite 
well in docking studies.  Furthermore, the charges located on the edges of the grooves were 
thought to stabilize protein binding through the formation of salt bridges.  In addition, a similar α 
helical character with the accompanied charged grooves has been observed in a ZPS isolated 
from S. pneumoniae.85  Also suggested is that the binding of PS A1 to MHC II could be 
controlled by very similar electrostatic groove interactions as discovered in these studies, again 
highlighting the importance of alternating charge character found in this polymer. 
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Fig. 15  (A) PS A2 stick model of four repeating units, (B) Electrostatic model of PS A2 with 
positive charges in red and negative in blue, arrows showing grooves with the presence of 
charges on all edges.71  This figure was inspired by Wang, Y.; Kalka-Moll, W. M.; Roehrl, M. H.; 
Kasper, D. L. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 13478-13483. 
 The size requirement of PS A1 and α helical character of related ZPSs suggest that the 
biological activity of this polymer is more complex than just the presence of the zwitterionic 
tetrasaccharide; accordingly circular dichroism (CD) experiments have been conducted.86  Initial 
work began with the comparison of α helical rich myoglobin (Fig 16, left), PS A1, and the non-
helical polysaccharide dextran.  The CD spectra of myoglobin was very similar to that of PS A1, 
with both spectral maxima and minima within 10 nm accompanied by similar profiles, while 
dextran’s spectra was basically flat having no similarities to either of the two other materials.  
Enhancements in CD measurements resulting from increased α helical character are commonly 
seen on addition of an organic solvent, due to the strengthening of hydrogen bonding 
interactions.  Consequently, repeating the above measurements in 20% acetonitrile resulted in a 
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~200% increase in signal strength for both myoglobin and PS A1 while no effect was seen in the 
dextran spectra.   
 Next, the researchers turned their attention to studying the α helical character of smaller 
PS A1 fragments.  Towards this effort, native PS A1 was oxidatively cleaved with O3 to various 
MWs.  The CD spectra of the smaller fragments showed gradual loss of maxima/minima with 
the smallest MW PS A1 fraction mimicking the flat dextran spectrum.  This data supports the 
progressive loss of α helical character with reduction of PS A1’s MW (Fig. 16, center).  These 
PS A1 fragments were also examined in vitro using competitive inhibition ELISA experiments 
against a biotinylated peptide antigen for binding HLA-DR (MHC II complex protein) coated 
plates.  The chemically cleaved fragments between 3.0 and 20.0 kDa successfully inhibited the 
labeled protein’s binding, while native PS A1 (grey, Fig 16, right) and fragments below 3.0 kDa 
(orange, Fig. 16, right) were two and seven fold less effective, respectively.  The failure of native 
PS A1 in this assay coincides with the previous observation that the MW of this ZPS must be 
reduced for effective MHC II binding.4a  In addition, these experiments suggest that at least 
partial helical nature is required for binding and subsequent biological activity.   
 Keeping with the previous theme, the effects of charge manipulation on the confirmation 
of PS A1 were studied.  Acetylation of the amine resulted in a drastic change in the CD spectra 
and a similar effect was observed with neutral PS A1 (both amine acetylated and carboxylate 
reduced).  The authors suggested that these modifications create a random coil confirmation of 
PS A1.  The reduction of the carboxylate alone did not have the same drastic consequences but 
this alternation reduced the helical content by an estimated 2-4 fold.  Furthermore, the charge 
altered derivatives lacking an α helical confirmation displayed a stark reduction in MHC II 
binding giving insight into structural causes for the loss of biological activity observed in 
previous work.75  Due to the importance of this confirmation on PS A1’s activity, our group has 
examined the Tn-PS A1 conjugate through CD as well.87  The conjugation of Tn resulted in a 
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partial loss of PS A1 α helical character though not enough to annul the T-cell dependent 
properties of the polymer, with this construct still being able to produce IgG antibodies in mice, 
indicative of a T-cell dependent immune response. 
  
Fig. 16  (left) myoglobin CD spectra, (center) CD spectra of native PS A1 (black) and oxidatively 
cleaved PS A1 exposed to O3 for 15-90 minutes creating fragments ranging from 30-1 kDa, 
(right) Inhibition of peptide binding by various MW PS A1 fragments.86  This figure was inspired 
by Kreisman, L. S. C.; Friedman, J. H.; Neaga, A.; Cobb, B. A. Glycobiology 2007, 17, 46-55. 
B.  Results and Discussion  
B1.  ELISA 
 Inspired by the overwhelming amount of evidence supporting the T-cell dependent 
nature of PS A1 and our group’s previous success with the Tn-PS A1 construct.  We have 
continued the study of TACA-PS A1 constructs by questioning if the TF-PS A1 conjugate can 
generate significant antibody titers against the TF?  Furthermore, if an antibody response is 
generated, will these antibodies have cytotoxic effects against TF expressing human tumor cell 
lines, and finally could this anti-serum slow down the growth of human tumors in severe 
combined immune deficient (SCID) mice?  
 To address the first question we began by administering TF-PS A1 every other week for 
8 weeks with and without (WO) titer max gold® adjuvant to C57BL/6 mice, animals treated with 
PBS were used as negative controls.  The presence of the adjuvant emulsifies the vaccine prior 
to injection effectively increasing the exposure of the construct to the immune system.88  The 
anti-sera was then collected and analyzed for binding against TF-bovine serum albumin (TF-
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BSA) coated ELISA plates using rat anti mouse IgM and IgG secondary antibodies (Fig. 17).  
The isotypes of IgG antibodies produced were examined due to their variable ability to mediate 
antibody dependent cellular cytotoxicity (ADCC), IgG3~IgG2a>IgG2b>IgG1, by human natural 
killer (NK) cells.89  As can be seen in Fig. 17, TF-PS A1 was unable to bring about a significant 
IgG antibody response both with and without adjuvant, only eliciting small amounts of IgG2b.  
The majority of the immune response consisted of pentameric IgM antibodies, while IgG is 
preferred due to the associated immunological memory.  IgM production should not be totally 
discounted because of its ability to activate complement mediated cytotoxicity (CMC), which will 
be discussed later in this chapter.2f 
 The lack of a substantial IgG response to this conjugate can be attributed to several 
possible factors including enzymatic degradation of the terminal Gal residue, blocking IgA or 
IgM antibodies during ELISA, and/or obstruction of the zwitterionic α helical grooves in PS A1 
by the TF, which are required for efficient MHC II binding.86  The loss of Gal from TF would 
produce the Tn-PS A1 construct in vivo and therefore generate antibodies against this antigen 
instead of the TF.  To investigate this possibility we attempted an ELISA experiment using Tn-
BSA coated plates (Fig. 18) with a secondary IgG antibody capable of recognizing all of the 
previously mentioned IgG isotypes.  While we did observe a small amount of binding, these 
titers were too small to confirm this theory, suggesting that bioavailability of the TF was not the 
major problem associated with the lack of IgG immune response.  We next investigated the 
possibility of blocking IgA or IgM antibodies inhibiting binding of the IgGs present in the serum.90  
To address the IgA concern, sera was analyzed for the presence of mucosal IgAs in an ELISA 
format but no significant antibody titer was found (Fig. 19).  Next, we examined for the presence 
of blocking IgMs by removing these pentameric antibodies through a protein G spin column 
protocol.  Protein G is a streptococcal cell surface protein which contains two binding domains 
both having affinity towards the Fc region of human and murine IgG antibodies.91  This protein is 
covalently linked to agarose beads which then bind IgGs, when whole sera is placed on the 
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column, allowing any unbound contents to be washed away effectively separating the IgGs.  
The purified IgGs showed a ~30 fold increase in IgG2b titer along with trace amounts of IgG1 
(Fig. 20, right).  While this does not represent a large IgG response it does confirm the presence 
of IgG antibodies in the whole sera and that the IgMs were partially blocking IgG binding under 
the static conditions of the initial ELISA study (Fig. 17).   
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Fig. 20  (left) Protein G purification of whole sera, (right) antibody titers of IgG purified sera vs. 
TF-BSA. 
 Alternatively, the decrease in immune response as compared to Tn-PS A14b (Fig. 21) 
could be the result of zwitterionic α-helical groove obstruction by the conjugated disaccharide.  If 
the binding domains of PS A1 are not available for significant MHC II interaction this would 
severely limit presentation to CD4+ T-cells resulting in diminished IgG production.  In 
accordance with this analysis, unpublished results from our lab revealed a similar diminished 
IgG response from a trisaccharide PS A1 conjugate.92  Another explanation for Tn-PS A1’s 
increased immunogenicity may involve amplified uptake by APC due to higher affinity for 
terminal GalNAc by  
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carbohydrate receptors.93  These carbohydrate recognition receptors, dubbed C-type lectins, 
have been shown to bind GalNAc and internalize covalently attached proteins and peptides for 
presentation to T-cells.94  A similar mode of action could be occurring with Tn-PS A1 thereby 
increasing its immunogenicity.  In support of these conclusions, a recent study of the murine C-
type lectin MGL2 (macrophage galactose type lectin 2) displayed binding to polyacrylamide-
GalNAc coated ELISA plates with no binding observed in the analogue Gal experiment.93  In 
addition, premixing free GalNAc with MGL2 resulted in loss of binding while Gal had no effect, 
supporting the theory that the carbohydrate recognition domain of this protein does not bind Gal.  
Next, murine bone marrow derived APCs known to express MGL2 were examined for binding 
against polyacrylamide-carbohydrate coated plates.  These APC cells bound both the Tn and 
TF structures, however the binding was 2 fold greater for the Tn antigen (Fig. 22).  These 
results suggest that the presence of Tn may increase internalization of Tn-PS A1 by APCs 
resulting in the more robust antibody responses observed with this construct when compared to 
TF-PS A1.  This data, combined with the known conformational requirement for T-cell 
dependence, suggests that conjugation of the TF disaccharide reduces the biological activity 
resulting in a smaller IgG immune response.  This difference may be the result of blocking 
zwitterionic α-helices on PS A1 by TF causing reduced MHC II binding, lessened uptake by 
APCs when compared to Tn-PS A1, or a combination of both.   
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Fig. 22  % binding of murine bone marrow derived APCs to polyacrylamide-carbohydrate 
coated ELISA plates, α-GalNAc (Tn) displays twice the binding of core 1 (TF).93  This figure was 
inspired by Singh, S. K.; Streng-Ouwehand, I.; Litjens, M.; Weelij, D. R.; García-Vallejo, J. J.; 
van Vliet, S. J.; Saeland, E.; van Kooyk, Y. Molecular Immunology 2009, 46, 1240-1249. 
B2.  Cytotoxicity, FACS, and SCID mice  
 While the diminished antibody response was disappointing, early work involving 
monoclonal antibody mediated cytotoxicity reported loss of function after washing pre-coated 
target cells, however, the cytotoxic action returned when additional antibody was added after 
the washing step.89a  The authors attributed this to weak antibody affinity for the target antigen.  
However, the Fc portion of this antibody was thought to be oriented for efficient effector cell 
binding possessing high affinity for NK-cell receptors resulting in cytotoxic function.  This topic 
has recently been reviewed95 where it was suggested that cancer immunotherapy may not be 
able to be improved by simply creating better binding antibodies but also by creating enhanced 
Fc portions resulting in extremely efficient antibody effector cell interactions.  The authors cite 
examples of enhanced in vitro cytotoxicity on modification of the non-variable regions of several 
monoclonal antibodies.96  Also discussed is the fact that not all high affinity antibodies will 
possess cytotoxic activity.  An example from lymphoma therapy includes CD19 and CD20 cell 
surface protein targets where there exists many high affinity antibodies against both, however 
only anti-CD20 antibodies have shown cytotoxic activity in vivo.  While we are unable to directly 
control the Fc portion of our anti-TF antibodies, we became interested in examining the ability of 
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this sera to function in cytotoxic assays where binding is not the only factor.  Therefore, to 
investigate this possibility we planned to examine the cytotoxicity of our TF-PS A1 raised 
antibodies in 51Cr release experiments using human cancer cell lines known to express the TF 
antigen.   
 The modes of cytotoxicity studied in our 51Cr assays include antibody dependent cellular 
cytotoxicity (ADCC) and complement mediated cytotoxicity (CMC).  In both pathways antibody 
binding recruits non-specific cells or proteins from the immune system, allowing these 
mechanisms to become precise through antibody mediation.  In ADCC natural killer (NK) cell 
receptors recognize the constant region (Fc portion) of bound IgG antibodies on the target cell 
surface, on binding NK-cells release cytotoxic granzymes along with perforin onto the surface of 
the target cell.  The perforin creates an opening in the cell membrane allowing the granzymes to 
enter the cytosol and cleave caspase proteins which leads to cell death by apoptosis, (Fig. 23).  
The release of cytotoxic granules is narrowly focused resulting in minimal damage to 
surrounding cells.  The importance of NK-cell immunity in cancer has been demonstrated 
through NK-cell knockout/depleted murine experiments where these animals were found to be 
2-3 times more susceptible to 3-methylcholanthrene induced tumors.97 
 Alternatively, CMC involves a system of 30 soluble plasma proteins, many of which are 
proteases that cleave and activate the next protein in the CMC cascade.  As a result of this 
mechanism, complement proteins are synthesized as inactive proenzymes which become active 
after cleavage.  In the antibody activated version of CMC, binding of IgG or IgM antibodies to 
the target cell surface reveals recognition domains on the constant region of the bound 
antibody.  The initial protein of the CMC process, the multi-subunit C1q complex, has affinity for 
the newly revealed antibody domains and on binding undergoes a conformational change 
releasing the subunit C1r which cleaves and activates the serine protease C1s beginning the 
proteolytic cascade (Fig. 24).  This pathway effectively labels the targeted cell for attack by the 
terminal protein of CMC, the membrane attack complex.  While both IgGs and IgMs can function 
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in CMC, C1q requires binding two or more Fc portions of antibodies to become activated.  
Therefore IgM antibodies are thought to excel in this pathway due to their pentameric nature 
providing five antibody constant regions on binding and therefore do not require cross linking of 
multiple antibodies, which is a requirement of IgGs.  
 
Fig. 23  ADCC mechanism, this pathway is mediated only by IgG antibodies.  This figure was 
inspired by the book Immunobiology : the immune system in health and disease / Charles A. 
Janeway, Jr, 5th ed., 2001, Garland Publishing, New York. 
 
Fig. 24  (left) multisubunit C1q complex, (right) C1q recognizing bound antibody on target cell 
surface beginning CMC.  This figure was inspired by the book Immunobiology : the immune 
system in health and disease / Charles A. Janeway, Jr, 5th ed., 2001, Garland Publishing, New 
York. 
We began the cytotoxicity study by examining three human breast cancer cell lines SK-
BR-3, MDA-231, and MCF-7 for both ADCC and CMC.  The 51Cr labeled cells were exposed to 
antiserum diluted 1:7 in the presence of NK-cells or complement and then 51Cr release was 
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measured.  The SK-BR-3 cell line showed 4.22% cell death [(experimental – spontaneous) / 
(max – spontaneous) x 100] by the CMC pathway with no significant activity observed in the 
ADCC mechanism, (Fig. 25 and 26).  Serum from PS A1 treated mice served as controls to 
assess for cytotoxicity induced from the carrier alone and for complement or NK-cell toxicity of 
which none of either was found.  The CMC activity observed here is most likely due to the 
presence of IgM antibodies which are known to effectively mediate this pathway.  The MDA-231 
cells unfortunately showed no activity at this antiserum concentration; however the cytotoxicity 
counts for CMC are relatively close to the spontaneous values (668 CMC vs. 821 spontaneous) 
suggesting that higher serum concentrations may show positive results, (Fig. 27).  In addition, 
the PS A1 serum controls for this cell line displayed counts below the spontaneous values.  The 
final tumor cell line examined was MCF-7 and again CMC proved to be active giving a 7.59% 
cell death, also the controls (PS A1 CMC and PS A1 ADCC) proved inactive suggesting that the 
cell death was not the result of carrier induced antibodies or complement/NK-cells acting alone 
(Fig. 29).  This result arose from an approximately two fold difference in 51Cr release over 
spontaneous cell death (CMC 603 vs. 346 spontaneous, Fig. 28), encouraging us to further 
investigate the MCF-7 cell line at higher serum concentrations and to assess antibody binding 
through FACS analysis.   
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 To determine if the data in Fig. 29 was the result of nonspecific interactions we 
examined our antiserum’s binding to the MCF-7 cell line through FACS.  As can be seen in Fig. 
30, TF-PS A1 sera (blue) demonstrated binding to this cell line due to the increase in 
fluorescence intensity (curve shifted to the right) when compared to the cells alone (gray) or 
secondary antibody alone (green).  Also of interest is PS A1 induced antibodies (red) ability to 
bind these cells, suggesting that this polysaccharide is also able to elicit antibodies capable of 
recognizing cancer cells.  Following the confirmation that our serum was indeed recognizing this 
cancer cell line, we turned our attention to further 51Cr release experiments.  In these assays we 
increased the concentration of the antiserum from 1:7 to 1:1 and as before (Fig. 20) purified the 
IgG antibodies away from the rest of the sera.  In addition, the flow through was also analyzed 
in higher concentration CMC experiments due to the presence of the IgMs in this fraction.  On 
exposure of the purified IgG fraction under ADCC conditions we observed 36.80% cell death, 
(Fig. 31 and 32).  This result can be attributed to the increase in concentration and to the 
removal of non IgG serum contents which may have been blocking effective IgG interactions 
under the static conditions of the original experiment (Fig. 28 and 29).  The IgG fraction also 
proved to be functional in CMC giving 31.11% cytotoxicity in the presence of complement.  
Finally, the nonbinding components from the protein G column (flow through) were analyzed 
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under complement mediated conditions.  This serum also demonstrated an increase in 
cytotoxicity as compared to the initial study at the 1:7 serum dilution, most likely as a result of 
the increase in concentration.   
 
Fig. 30  FACS of TF-PS A1 sera (blue), PS A1 sera (red), secondary antibody alone (green) 
and cells alone (gray). 
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 The ELISA and cytotoxicity data suggest that low affinity antibodies have been 
generated by the TF-PS A1 construct that are not observable in a traditional ELISA setting.  
While these antibodies do not have high affinity for TF-BSA coated ELISA plates they have 
been demonstrated to bind MCF-7 cells and to function in ADCC and CMC in vitro.  This data 
underlines the importance of using titers as only the first step in studying possible protective 
effects that could occur from a vaccine induced antibody response.  As an example, the 
Meningococcal polysaccharide vaccine gives high titers in young children but these antibodies 
do not provide substantial bactericidal activity.90,98  In addition, similar results have been found 
on study of the pneumococcal 23 polysaccharide vaccine in the elderly.98-99  While both of these 
examples are found in high risk groups, the fact that high binding antibodies against cell surface 
CD19 are available but are not biologically active against lymphoma in vivo also supports this 
claim.96 
 The in vitro activity encouraged us to examine the antiserum in an in vivo setting.  To 
address this, MCF-7 cells were administered through subcutaneous injection on the left and 
right flanks of 6 female severe combined immunodeficient (SCID) mice which had 2 days prior 
been implanted with a slow release estrogen pellet.  Of these animals 3 control mice received 
PBS injections and 3 experimental mice received anti-TF IgG antibody.  These mice lack both B 
and T cells and therefore are capable of accepting human xenographs.  After 4 days of growth 
the tumors became measurable.  Subsequently the passive transfer of purified IgG antibodies 
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(1:1 dilution, 100 µL) began and continued once a week for 5 weeks with injections given on 
days 4, 11, 18, 25, 32, and 39.  The tumors were measured by calipers three times a week and 
compared vs. animals only receiving PBS injections, Fig. 33.  The mice receiving passive 
transfer of IgG antibodies displayed a 33% (P = 0.040, calculated from Students T-test for two 
independent means) decrease in tumor volume on average when compared to controls after 43 
days of tumor growth.   
 While this is an encouraging result, after day 32 a stark increase in the standard error 
can be observed for the TF-IgG treated mice.  On closer examination the reason for this 
statistical outcome can be attributed to the continued growth of both tumors on the left and right 
tagged animals (blue and green lines respectively, Fig. 34), while the average tumor volume 
from the untagged animal falls off at this point (purple line).  Plotting the individual tumors of 
each mouse (Fig. 35), clearly shows 5 tumors from this group exhibited increased or constant 
volume during the study with only one tumor from the untagged animal falling off (dark blue 
line/No tag tumor 1, Fig. 35).  This effect may be the result of enhanced antibody activity in the 
untagged animal.  However, due to the fact that this was the only tumor to lose volume the data 
collected from this tumor after day 32 could be an outlier and therefore should not be included in 
the calculation of day 43 tumor volume.  When this data point is removed from the average the 
percent change drops to 25% (P = 0.081), alternatively if the percent change is calculated on 
day 32 before the untagged animal tumor drop off the result is again a 25% difference, however, 
with a statistically more relevant (P = 0.0024) reduction in volume.  Although it is useful to 
calculate this value at different points in the experiment the reduced tumor growth trend 
remains, suggesting that the antiserum is capable of slowing tumor growth over the short term 
in these animals most likely through ADCC and/or CMC mechanisms.  Clearly, we would like to 
see a more pronounced reduction in volume in this experiment.  However, this data does 
provide a starting point in the effort to define what our vaccine induced antibodies are capable of 
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in an in vivo setting, allowing us to make a conservative estimate of ~25% tumor reduction vs. 
untreated animals. 
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In conclusion, we have successfully continued the study of TACA-PS A1 conjugates 
through the preparation and biological evaluation of the TF-PS A1 vaccine candidate.  Although 
this construct was unable to produce the same type of ELISA IgG response observed with the 
Tn-PS A1 conjugate.  The elicited antibodies were shown to successfully bind MCF-7 cancer 
cells and participate in 51Cr release cytotoxicity assays with this cell line.  Furthermore a passive 
immunotherapy SCID mice experiment demonstrated that this antiserum is capable of slowing 
the growth of MCF-7 induced tumors over the 5 weeks of the study.  This data should 
encourage further exploration of TACA-PS A1 conjugates in the group.  Specifically an active 
immunotherapy application will be studied using murine tumor cell lines in BALB/c mice.  The 
tumors will be measured as in Fig. 33-35 but the mice will only receive TF-PS A1 construct as 
treatment.   
 
 
 
0
20
40
60
80
100
120
140
160
180
200
0 10 20 30 40 50
V
o
lu
m
e
 i
n
 m
m
3
Days after tumor challenge
Fig. 35  Individual tumor volumes
No tag Tumor 1
No tag tumor 2
Left tag tumor 1
Left tag tumor 2
Right tag tumor 1
Right tumor 2
63 
 
 
 
C.  Experimental 
Mouse injection protocol 
6 week old C57/BL6 mice were purchased from Charles River and allowed to acclimate for 1 
week and then separated into three groups.  The first group contained 12 mice and each 
received 10 µg/50µL Tn-PS A1 with 50µL of titer max gold adjuvant for a total of 100 µL per 
injection.  The second group contained 6 mice and each received 10µg/100µL Tn-PS A1 in PBS 
and the third control group contained 4 mice and each was administered 100 µL of PBS.  The 
first two injections (I.P.) were given on days 1 and 7 with the next three on days 21, 35, and 49. 
10 days after the last injection mice were euthanized with CO2 and the sera was collected by 
cardiac puncture.  The red blood cells were removed with vacutainer tubes and the sera was 
aliquoted into 50 µL portions to avoid multiple freeze thaw cycles and stored at -80oC.   
ELISA 
A 3 µg/mL TF-BSA solution was prepared in pH 9.6 0.10 M NaHCO3 buffer.  This solution was 
then added in 100 µL aliquots to each well of a 96 well plate.  The plate was then incubated at 
37 oC with shaking for 1 hour followed by 24 hours at 4oC.  After incubation the TF-BSA solution 
was expelled and 200 µL of 1% BSA in Tris buffered saline (TBS) blocking solution was added 
and incubated for 1 hr.  Next the plates were washed with TBS pH 7.4 with 0.05% tween 20 and 
0.02% NaN3 3 times.  Following this, 150 µL antisera was added in a 1:100 dilution to the top 
row in the plate and all other wells received 100 µL of TBS.  50 µL of the 1:100 diluted sera was 
then pipetted out of the top row and mixed with the second row, then 50 µL was removed from 
the second row and mixed with the third row. This was repeated until the bottom of the plate 
was reached to give a range of dilutions between 1:100-1:218700.  Following the dilution, the 
plates were incubated for 2 hours at 37oC.  Next, the plates were washed with TBS 3 times.  
Appropriate dilutions of secondary antibodies (IgG1, IgG3, IgG2b, IgM, 1:1000) (general IgG, 
1:5000) were added in triplicate to the wells, with 100 µL per well.  The plates again were 
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incubated for 1 hour, washed 3 times with TBS and then 100 µL of 1.67 mg/mL PNPP solution 
in 1:4 diethanolamine buffer was added.  The plates were allowed to develop at r.t. for 30 
minutes and read on a microtiter plate reader at 405 nm.  For titer analysis OD was plotted 
against the dilution values and a best fit line was obtained.  The equation was then solved to 
give the titer using 0.2 OD as the cut off.   
Protein G spin column  
1 mL of whole serum was diluted to 2 mL with pH 7.2 PBS. This solution was then incubated for 
10 minutes at r.t. with protein G linked agarose beads.  Subsequently, the column was 
centrifuged at 1000g for 1 min, then 2 mL of PBS was added again and the centrifugal washing 
step was repeated. This step was repeated two times for a total of three washes.  These 
fractions represent the non-bound sample components (flow through) containing the IgM 
antibodies.  After removal of the nonbinding components, the IgG antibodies were eluted from 
the column with 1 mL of 0.1 M glycine (pH 2.5) buffer into 100 µL of 1 M Tris (pH 8.5) by 
centrifuging at 1000g for 1 min.  This step was repeated two more times for a total of three 
washes.  Purified IgG Sera used for passive transfer was concentrated with a 30,000 Da 
centrifugal filter to 250 µL and then diluted to 2 mL with PBS giving a 1:1 dilution.  Finally, this 
solution was sterile filtered using a 20 µM filter to afford the antibody solution ready for passive 
transfer to immunocompromised animals.  The flow through fractions were sterile filtered with 
only the first fraction being used for passive transfer.   
Fluorescence-activated cell sorting (FACS) 
1 x 106 MCF-7 cells were fixed with 1% paraformaldehyde centrifuged at 300g at 4 oC for 8 
minutes. The supernatant was then decanted.   100 µL of antisera was added to the cells and 
mixed by pipetting sera in a 1:200 dilution in phosphate buffered saline PBS.  The control cells 
just received PBS during this step.  The antibody was then incubated for 30 minutes at r.t. in the 
dark. Next, the cells again centrifuged at 300g for 8 minutes and the supernatant removed. 1mL 
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of cold PBS was added and the centrifuge step was repeated2 times for a total of three washes.   
100 mL of secondary IgG antibody was added next and this mixture was allowed to incubate for 
30 minutes in the dark.  The cells were then washed with PBS and centrifuged 3 more times 
and finally diluted with 200 µL of PBS.  This solution was then read on the flow cytometer at 488 
nm.   
ADCC and CMC Cytotoxicity  
Target cells of 2 x 104 were plated and allowed to adhere overnight.  The cells were then 
exposed to 51Cr for 4 hours and washed to remove any unabsorbed material.  Subsequently, the 
antisera was added (25 µL or 75 µL) to the cells followed by addition of the NK-cells in a 50:1 
ratio in medium to give of  200 µL/well (for 1:7 dilution) or 150 µL/ well (for 1:1 dilution).  51Cr 
release was measured after 18 hours and % cytotoxicity was calculated by using the following 
formula: (experimental – spontaneous) / (max – spontaneous) x 100.  Spontaneous wells only 
received media.  The CMC experiments were identical except 20 or 15 µL (1:7 and 1:1 
experiments respectively) was added to the medium giving a concentration of 10% complement 
in each well.  All experiments were performed in duplicate.   
Xenograph/SCID mouse studies 
SCID SHO mice were purchased from Charles River and allowed to acclimate for 1 week before 
starting the experiment.  First, a 0.72 mg 60 day release estradiol pellets were implanted 
subcutaneous (SC) in to these animals.  Two days later 5 x 106 MCF-7 cells (100 µL in medium) 
with 100 µL of basement membrane extract (Geltrex), for a total volume of 200 mL per injection, 
was administered SC to the left and right flank of the immunocompromised mice.  After 3 days 
of growth, the tumors became measureable and the passive transfer of purified antibodies was 
begun; IgG and the non-protein G binding contents (flow through) in 1:1 dilution with PBS.  The 
IgG antibodies were administered on day 1, 7, 14, and 21 for a total of 4 injections of 100 µL 
and the flow through was administered on the same interval but in 250 µL portions. Control 
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animals received 100 µL PBS per injection.  The tumor growth was monitored by caliper 
measurement every other day for the 43 days of the study.  Tumor volume was calculated by 
the formula ½(w2 x l), where w is the smaller of the two measurements. 
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CHAPTER 3 - A One-Pot Multicomponent Coupling/Cyclization 
for Natural Herbicide (±)-Thaxtomin A 
 
A. Introduction 
A1.  Thaxtomin A source and biological activity 
 Naturally occurring thaxtomin A (TA, Fig. 1) was first isolated in 1989 from Streptomyces 
scabies, one of the soil bacteria responsible for common scab of potato disease.  This plant 
pathogen effects grade, quality and appearance of root crops (Fig. 1), making it’s study 
economically important in potato producing areas of the world.100  In addition, TA is produced by 
two other phytotoxic Streptomyces bacteria, S. acidiscabies, and S. turgidiscabies, however the 
majority of Streptomyces microbes do not produce TA and therefore are not plant pathogens.  
TA is the most potent and prevalent of the 11 known members of the thaxtomin family; all of the 
thaxtomins contain a DKP core with variations in the presence or absence of amide N-
methylation and the position or deletion of the two hydroxyl groups.101  TA has also been used 
to control weed growth and germination in the presence of grasses and cereals causing no 
toxicity to these crops.102  Since these initial observations, TA has attracted considerable 
attention from industrial102-103 and academic101a communities as the molecule responsible for 
potato scab and additionally as a potent phytotoxin demonstrating activity similar to known 
cellulose biosynthesis inhibitors like dichlobenil and isoxoben.101b  Further study of this molecule 
may provide access to disease resistant strains of crops susceptible to these bacteria.101a  
Interest in TA as a herbicide is highly motivated by the environmentally benign and 
biodegradable properties of the natural product, which contains a cyclic dipeptide or 2,5-
diketopiperazine (DKP) core, composed of a (S)-N-methyl-4-nitrotryptophan and (R)-2-hydroxy-
3-(3-hydroxyphenyl)-N-methylalanine.  The unique 4-nitroindole and the configuration of the 
stereocenters (S-Trp, R-2-hydroxyPhe) have been confirmed as a requirement for the biological 
activity of this natural product through extensive TA derivative studies that clearly shown loss of 
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TA like activity when the nitro substituent is either deleted or moved along the indole nucleus100-
101,104 and on derivatives with the stereochemistry inverted at the hemiaminal center.105   
N
N
O
O
N
NO2
OH
OH
H
                      
Fig. 1  (left) 2,5-diketopiperazine Thaxtomin A, (TA) (center, right) TA causes plant cell necrosis 
seen as raised or pitted lesions.  
 The connection between this secondary metabolite and plant virulence was elegantly 
shown through isolation of TA and application to potato tissue, which reproduced symptoms 
induced by S. scabies.104b,106  This result was later supported by mutant and knockout 
experiments in which removal of TA expression coincided with loss of plant pathogenicity.107  
The exact cellular target of TA is unknown108 but previous reports have suggested that TA alters 
the deposition/composition of plant cell walls and the ability of these cells to undergo efficient 
cytokinesis (plant cell division), greatly affecting the integrity of these structures.109  In addition, 
an Arabidopsis thaliana mutant deficient in a membrane transporter gene displayed resistance 
to TA when compared to the wild type, suggestive of a cell wall/membrane target.110 
 In support of these conclusions, a study from 2005 has suggested a TA induced Ca2+ 
influx mechanism involving nonselective ion channels and proton pumps of the plant cell 
membrane (Fig. 2).111  This model is supported by loss of TA activity on exposure to known 
blockers (La3+, Gd3+) of Ca2+ permeable channels in the plasma membrane and furthermore by 
TA inhibition in the presence of orthovanadate, a known proton pump suppressor.  It is thought 
that TA promoted Ca2+ influx activates the proton pumps in an effort to reestablish the 
membrane potential.  This results in the acidification of the cell wall displacing Ca2+ cross linking 
between the pectin components (poly 1,4 linked α-galacturonic acids),112 thereby weakening the 
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cell wall and allowing entry of S. scabies into the plant tissue.  As previously stated, TA has 
been suspected to act as a cellulose biosynthesis inhibitor causing injury symptoms similar to 
known inhibitors.101b  In agreement with this theory, it has been demonstrated that TA alters the 
genes involved in cellulose synthesis disrupting the movement and the presence of cellulose 
synthases in the plasma membrane.113  These data combine to further support TAs role in the 
disruption of the plant cell wall even though the exact cellular target remains unknown.   
 Also of note is that TA resembles the plant auxin indole acetic acid (IAA) and could be 
competing for binding sites with this hormone.  Keeping this observation in mind, an auxin 
sensitive A. thaliana mutant was studied and shown to be 4-5 times more susceptible to TA then 
the wild type.114  IAA is known to regulate plant growth and it has been observed that TA has an 
amplified effect in actively growing tissues suggesting that more receptors capable of TA 
binding/uptake are present.111  Furthermore, A. thaliana seedlings were protected from TA when 
grown in the presence of IAA or another plant auxin, 2,4-dichlorophenoxyacetic acid (2,4-D).  
The authors suggest direct competition for a binding site or auxin induced symptom reversal as 
possible protective modes of action.114   
 
Fig. 2  (left) Possible model for TA phytotoxic activity, (right) morphological response of TA and 
S. scabies on radish seedlings, (A) broth from culture of S. Scabies, (B) culture supernatant, TA 
at (C) 0, (D) 100, (E) 50, (F) 25, (G) 10 µM concentrations.111,115  This figure was inspired by 
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Tegg, R. S.; Melian, L.; Wilson, C. R.; Shabala, S. Plant Cell Physiol. 2005, 46, 638-648 and 
Leiner, R. H.; Fry, B. A.; Carling, D. E.; Loria, R. Phytopathology 1996, 86, 709-713. 
A2.  TA biosynthesis  
 Due to the aforementioned requirement of the 4-nitro indole moiety for biological activity 
and the uniqueness of this functional group in nature, several studies have been conducted on 
the biosynthesis of TA.116  Early work isolated N-acetyl-4-nitrotyrptophan and N-methyl-4-
nitrotryptophan from S. scabies growth medium, implying that nitration was occurring before 
DKP formation,116g however late stage growth cultures were examined therefore these isolates 
could have been the result of TA degradation.117  The small molecule 5-nitroanthranilic acid (2-
amino-5-nitrobenzoic acid) has also been isolated from growth medium and was initially thought 
to be a precursor to 4-nitroTrp synthesis.116f  However, no increase in TA production was 
observed on addition of this molecule to bacterial cultures and on closer inspection was dubbed 
an unlikely precursor due to the para relationship between the amine and nitro groups.  Further 
study into phytotoxic Streptomyces genomes revealed conserved regions of peptide synthetase 
genes coding for two enzymes, which were then cloned and dubbed Txt A and B.116e  These 
synthetases were found to contain AMPlyation, thiolation, condensation, and N-
methyltransferase domains making these enzymes responsible for N-methyl DKP ring formation 
from the respective amino acid precursors.  The hydroxyl groups of TA were subsequently 
found to be installed through the action of a cytochrome P450 monooxygenase enzyme, Txt C, 
due to the production of didehydroxy TA on mutation of this gene cluster.116d  The authors also 
suggested that the hydroxylations most likely follow DKP formation due to the exclusive 
formation of the didehydroxy derivative in their gene modified bacteria experiments.  In addition, 
it is believed that the α-carbon of the phenylalanine residue is oxidized first, attributable to the 
isolation of mono hydroxyl derivatives of this type.104b  However at this point, the mechanism of 
nitration and location of this enzyme in the biosynthetic pathway was still under investigation.   
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 Examples of nitrated natural products do exist, nevertheless, this functional group is 
generally associated with synthetic molecules and highly energetic compounds.118  It has been 
observed that precursors of these nitrated materials possess an amine or are unsubstituted at 
the respective nitro position, implying that oxidation or a direct nitration mechanism is 
involved.118  In agreement with this theory, it has been suggested that Trp undergoes direct 
nitration before DKP formation in the biosynthesis of TA.116c,116d  Initial study into the nitration 
mechanism involved further investigation of Streptomyces species genomes, which revealed 
conserved genes very similar to mammalian and other bacterial NO synthases (NOS) DNA.119  
In addition, these DNA sequences are located on a pathogenic island capable of transferring TA 
production to nonpathogenic Streptomyces species suggestive of a biosynthetic role.120  
Intrigued by this possibility, the authors deleted the DNA sequences for this NOS enzyme (Txt 
D) in S. turgidiscabies, which resulted in a ~100 fold reduction in TA production when compared 
to the wild type.  As previously observed, the removal of TA expression did not affect the growth 
of the bacteria but coincided with loss of plant pathogenicity.  Furthermore, denitro TA was not 
observed in the medium suggesting that the nitration process is a prerequisite of DKP formation.  
The production of TA was also diminished when S. turgidiscabies was grown in the presence of 
the NOS inhibitor (N-Nitro-L-arginine methyl ester) and NO scavengers, further supporting the 
presumed role of this enzyme.116b  Due to the similarity of Txt D with mammalian NOS and the 
utilization of Arg by these enzymes to generate oxidized nitrogen compounds, 15N labeled Arg 
feeding experiments were conducted.  The extracted TA was found to have incorporated 15N 
exclusively at the nitro position while bacteria fed with 15NH4NO3 produced TA labeled at all four 
nitrogens.  This work provided overwhelming evidence for the involvement of Txt D in the 
biosynthesis of TA and afforded a glimpse into the biosynthetic mechanism of direct nitration.   
 While the nitration was no doubt mediated by the NOS Txt D, the presence of a 4-
nitroTrp precursor was still in question.  The search for this precursor began with the 
observation that the distinctive yellow color of TA containing S. turgidiscabies cultures could be 
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extracted into ethyl acetate.  Alternatively, similar treatment of Txt A gene deleted bacteria 
resulted in the yellow color remaining in the aqueous fraction suggestive of a TA precursor, 
which was determined to be 4-nitroTrp after extensive NMR and MS analysis.117  Furthermore, 
the addition of 4-nitroTrp to mutants lacking NOS/Txt D, which are unable to nitrate Trp 
effectively, restored the production of TA in vivo.  This data substantiates earlier theories that 
envisioned the nitration of Trp occurring prior to DKP core formation.  Subsequent elucidation of 
the 4-nitro installation mechanism demonstrated this process to be based on the action of 
NOS/Txt D and a cytochrome enzyme (Txt E) that catalyzes a direct nitration mechanism using 
NO and O2 as cofactors.116a  As with the other biosynthetic enzymes, knockout experiments 
resulted in loss of bacterial TA production with no observable denitro TA compounds present.  
Additionally restoration of TA expression occurred on feeding purified 4-nitroTrp to the 
respective Txt E deleted cultures.  This suggests that the nitration of Trp is the first step in TA 
biosynthesis and prompted the authors to propose a complete pathway for the synthesis of TA 
(Fig. 3). 
 
Fig. 3  Proposed biosynthetic pathway for the formation of TA.116a  This figure was inspired by 
Barry, S. M.; Kers, J. A.; Johnson, E. G.; Song, L.; Aston, P. R.; Patel, B.; Krasnoff, S. B.; 
Crane, B. R.; Gibson, D. M.; Loria, R.; Challis, G. L. Nat. Chem. Biol. 2012, 8, 814-816. 
 
 
 
SAM 
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A3.  Diketopiperazines and the Ugi reaction  
 2,5-DKPs have been assembled through various strategies.100,105,121  The most popular 
method involves the coupling of a N-protected amino acid with an amino acid ester to provide a 
dipeptide, which after deprotection can be cyclized under acidic or thermal/microwave 
conditions.121a  Examples of alternative approaches include direct condensation of amino 
acids,122 aza-Wittig cyclizations,123 Diels Alder reactions of acylnitroso proline derivatives,124 
chloroacetyl chloride based cyclizations,125 Pd mediated vinyl amidation,126 and enolate 
acylation.127  In addition, the multi component Ugi reaction has also been used extensively for 
the formation of various DKPs.  The multicomponent Ugi reaction between an aldehyde, amine, 
isocyanide, and carboxylic acid begins with imine formation (Scheme 1).  This condensation is 
then followed by isocyanide addition creating a tetrahedral nitrilium intermediate.  The transient 
nitrilium compound then undergoes carboxylic acid addition followed by the irreversible Mumm 
rearrangement to provide a pseudo dipeptide product.  All steps are reversible excluding the 
rate determining Mumm rearrangement.  Finally the reaction continues in the forward path as a 
result of a more stable +4 oxidation state of carbon from its +2 state in the initial isocyanide.128 
 
Scheme 1  Mechanism of the Ugi reaction 
A noteworthy example of the Ugi reaction and DKP formation includes the use of 1-
isocyanocyclohexene.  This isocyanide allows for acid promoted intramolecular cyclization to 
DKPs when Boc protected amino acids are used as the carboxylic acid component.129  The 
methodology proceeds by an Ugi/deBoc/cyclization sequence, with amide activation occurring 
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through formation of an N-acyliminium ion intermediate (Scheme 2).  More recently the starting 
material 1-isocyano-2-(2,2-dimethoxyethyl)benzene has been exploited.  First, the respective 
Ugi adduct is formed and the following acid treatment results in an indolamide intermediate, this 
combined with simultaneous deprotection of N-Boc allows for DKP formation to occur.130  
Additional examples involve solid phase linked isocyanides which were used successfully in Ugi 
based DKP synthesis.  Strategies involving resin free cyclizations and resin cleavage 
cyclizations have also been reported.131  In addition, chloroacetic acid has been utilized for the 
preparation of α-haloacetamides capable of undergoing based induced intramolecular alkylation 
to DKPs.132  Another method involves replacement of the aldehyde component with ethyl 
glyoxaylate which introduces an ester moiety allowing cyclization to occur when the Boc 
protected amino acids are used as the carboxylic acid133 (Scheme 2). 
 
Scheme 2  Ugi reaction and DKP synthesis. 
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A4.  Previous TA synthetic work 
 Early synthetic work focused on the preparation of TA analogues through the 
condensation of tryptophan, phenylalanine and derivatives thereof to provide DKPs lacking the 
hemiaminal functionality, Fig. 4.100,121e  Alternative approaches used aldol disconnections to 
install the aromatic rings directly onto diacetyl-2,5-piperazinedione followed by bromohydrin 
formation for preparation of the hemiaminal center.121f,121g  The drawback to this approach is the 
requirement of a reductive deprotection step which only allows for the preparation of denitro 
derivatives.  A similar aldol based approach has also been used to afford dehydrated TA 
derivatives which displayed similar phytotoxicity against A. thaliana seedlings as TA.121c  Semi 
synthetic alkyl ether derivatives (EtO-, MeO-, and i-PrO-) were also prepared through treatment 
of TA with the respective acidified alcohol under reflux.105  These compounds displayed reduced 
activity with increasing alkyl substituent size and substantial loss of toxicity on inversion of the 
hemiaminal center.  Furthermore, a series of TA derivatives were recently prepared through 
coupling of protected 4-nitroTrp to various amino acid methyl esters which were then cyclized to 
DKP under mild basic conditions yielding TA like compounds lacking the hemiaminal.134  These 
derivatives were prepared to study the effects of altering the hydroxylbenzyl substitution and 
found that m-hydroxyl substitution is favorable for activity.   
 
Fig. 4  Examples of previously prepared TA derivatives. 
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 Pervious synthetic work also includes the synthesis of natural TA which has been 
accomplished using modified glutamic acid as a starting material for the preparation of a 
protected 4-nitroTrp derivative.  This transformation was accomplished under standard Pd-
mediated indole formation with 3-nitro-2-iodoaniline.135  Subsequently, methyl amine and 3-
hydroxyphenyl pyruvic acid were conjugated to the amino acid affording the key pseudo 
dipeptide intermediate.  This intermediate then underwent base induced keto-amide cyclization 
to the hemiaminal DKP TA in a 2.6:1 dr, providing the first synthesis of TA (Scheme 3).   
 
Scheme 3  First synthesis of TA.135b  This figure was inspired by Zhang, H.; Ning, X.; Hang, H.; 
Ru, X.; Li, H.; Li, Y.; Wang, L.; Zhang, X.; Yu, S.; Qiao, Y.; Wang, X.; Wang, P. G. Organic 
Letters 2013, 15, 5670-5673. 
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A5.  Keto-amide cyclization for the preparation of TA 
 As an alternative to these previous reports, we aimed to exploit the Ugi reaction for the 
preparation of TA.  However, our strategy would differ from early DKP Ugi based syntheses due 
to the presence of the hemiaminal center.  Initial analysis began by examining our prior work 
involving intramolecular aza-Michael addition of Ugi adducts providing DKPs, using fumaric acid 
mono ethyl ester to install the required electrophile (Scheme 4).121d  While this exact approach 
does not  
 
Scheme 4  Intramolecular aza-Michael addition of Ugi adducts. 
directly allow for the synthesis of TA, we envisioned a base-induced keto-amide cyclization, 
comparable with the above report (Fig. 2 and Fig. 5).135b  Combined with a multicomponent 
coupling strategy, a keto-amide cyclization would allow access to the desired DKP/TA scaffold 
including the essential hemiaminal.  Although examples of this amide-carbonyl cyclization are 
known,136 the resulting hemiaminals have mainly been used for subsequent elimination, 
reduction,136b,136n or Pictet-Spengler reactions.136d,136g,136k-m 
 
Fig. 5  Keto-amide cyclization from key Ugi precursor 2. 
 The key aspect to this approach is the requirement of a α-keto carboxylic acid (Fig. 6), 
providing the necessary electrophile for the envisioned intramolecular cyclization.  Keto acids 
have been used extensively in the Ugi reaction with initial study involving the preparation of 
lactam derivatives through three component intramolecular transformations (Scheme 5).137  
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More recent applications of these bifunctional substrates are capable of generating an 
impressive array of heterocycles and polycyclic scaffolds.136d,136f-h,138  A current example involves 
the usage of three bifunctional components leading to a reaction cascade ultimately providing 
pyridoquinoxalinediones (Scheme 5).138b  This domino reaction consists of an Ugi, aldol, and 
nucleophilic aromatic substitution sequence with the latter two steps occurring in one pot.  
Despite this previous study there exists only sparse examples involving the utilization of keto-
acids for the preparation of hydroxydiketopiperazines,136f,136o including a single report describing 
control of facial selectivity leading to TA.135b  Previous attempts at Ugi reactions with highly 
enolizable α-keto-acids afforded low yields,136d,136g however, we were eager to investigate the 
tandem Ugi/keto-amide cyclization strategy for the preparation of TA. 
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Scheme 5  (top) Use of keto acids in three component Ugi reactions generating lactams, 
(bottom) Three bifunctional components in the Ugi reaction for the preparation of a polycyclic 
scaffold. 
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B.  Results and Discussion  
B1.  Synthesis of (±)-thaxtomin A 
 Initial work focused on a model system lacking nitro and phenol substituents (Fig. 6).  
This TA derivative can be disconnected to 3-indolylacetaldehyde (4), methylisocyanide (5), 
methyl amine (6), and phenylpyruvic acid (7).  Of these starting materials both methyl amine 
and phenylpyruvic acid are commercially available while the required aldehyde and isocyanide 
can be prepared from literature reports,139 (Scheme 6).  The oxidation of tryptophan took place 
under biphasic conditions in the presence of NaOCl to provide the aldehyde in 25% yield.  While 
this reaction only provided low yields of (4), the reaction could be conducted at a sufficient scale 
to allow further study of this material in the subsequent Ugi reaction.  Next, methyl isocyanide 
was prepared in 60% yield by treating N-methylformamide with tosyl chloride under vacuum 
distillation conditions. 
 
Fig. 6  Ugi based disconnection of acyclic precursor 3. 
 
Scheme 6  Preparation of 3-indolylacetaldehyde (4) and methyl isocyanide (5). 
 With the required starting materials available, the four component reaction was 
conducted in MeOH at r.t.  Unfortunately these conditions provided low yields of the dipeptide 
(3), attributable to possible polymerization of the initially formed imine through an aldol 
process140 or through unwanted indole participation with the nitrilium intermediate.  Thankfully, 
enough of the acyclic precursor (3) was obtained to attempt the DKP cyclization (8), which 
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proceeded in 50% yield using NH3 in MeOH giving the anti diastereomer as the major product 
(Scheme 7).  While this sequence is far from optimized, it provided proof of principle for the 
Ugi/amide ketone cyclization strategy and encouraged us to prepare the required aldehyde (9) 
and acid (10) for the preparation of TA, (Scheme 7).  Keeping in mind that addition of the 
electron withdrawing -NO2 may reduce unwanted indole participation.   
 
Scheme 7  Synthesis of TA derivative 8. 
 Initial work on the aldehyde commenced through treatment of 4-nitroindole with 
bis(dimethylamino)methane.141  This reaction introduced one methylene at the 3-postion of the 
indole system using a Mannich type addition.  Next, dimethyl amine was displaced with KCN 
followed by HCl mediated hydrolysis to the carboxylic acid.  Subsequently, Fischer esterification 
provided the ethyl ester.  The ester was then reduced with diisobutylaluminium hydride 
(DIBALH) to the alcohol which was oxidized to 9 with the 2-iodoxybenzoic acid (IBX),142 
(Scheme 8).   
 The α-keto carboxylic acid (3-hydroxyphenylpyruvic acid, 10) was then prepared as 
described in an earlier report.143  This synthesis began with reaction of 3-hydroxybenzaldehyde, 
N-acetylglycine and acetic anhydride to provide the oxazolone intermediate.  The heterocycle 
then underwent hydrolysis with 3 M HCl to the desired acid 10, (Scheme 8).  The key feature to 
this starting material is the position of the ketone functional group α to the carboxylic acid 
functionality, the presence of which provides the electrophile and the hydroxyl for the all-
important hydroxy DKP cyclization.   
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Scheme 8  Preparation of CHO (9) and acid (10).   
 With all of the starting materials available the four component reaction between methyl 
isocyanide (5), methylamine (6), 4-nitroindolylacetaldehyde (9), and 3-hydroxyphenylpyruvic 
acid (10) gave compound 2 in 37% yield (Scheme 9).144  The acyclic product 2 was then 
subjected to base-mediated keto-amide cyclization using NEt3 in MeOH at r.t. to afford an 
isolated 77% yield of two diastereomeric DKPs in a 10:1 dr ultimately providing anti-1, the 
epimer of TA, as the major product.  While anti-1 is not a natural product, this derivative has 
been demonstrated to possess activity against the tobacco mosaic virus.135b  The combined 
DKPs were then treated with KOH in methanol and heated to 70 oC under microwave irradiation 
for 30 minutes which provided an 85% isolated yield in a 4:1 dr with syn-1 being the major 
product.  In addition, the epimerization of anti-1 was attempted as before except under thermal 
conditions providing a 3:1 syn:anti ratio suggesting that microwave induced bond rotation is 
partial responsible for the increased syn selectivity under microwave conditions.  Alternatively, 2 
could be cyclized and epimerized directly to syn-1 by reaction with KOH in MeOH as noted 
below, to give a 56% yield in a dr of 4:1.   
 Encouraged by the success of our preliminary studies involving the isolation and 
cyclization of the acyclic precursor (2) followed by epimerization of the diastereomer (anti-1) to 
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TA, we explored whether the formation of TA could occur in a sequential one-pot process.  To 
investigate this strategy, the Ugi reaction was attempted as noted earlier with the inclusion of a 
cyclization/epimerization step (KOH, 70 oC) after the multicomponent reaction had occurred.  
This two-step, one-pot sequence successfully provided a highly efficient approach to TA with an 
overall increase in yield, as compared to the stepwise strategies (2→ anti-1→ syn-1) or (2→ 
syn-1), affording TA (syn-1) in 32% isolated yield as well as the minor diastereomer (anti-1) in 
8% yield.  The structures of syn-1 and anti-1 were confirmed by comparison of previously 
reported NMR data104b,135b and unequivocally by the crystal structures (Fig. 7). 
 
Scheme 9  Stepwise and one pot procedures for the preparation of TA, (a) 5 equiv. KOH, 70 oC, 
MW, 30 min, all yields based on combined DKPs with the exception of the one pot preparation. 
                       
Fig. 7  ORTEPs of (±)-thaxtomin A/syn-1 and (±)-anti-1 with hydrogen atoms omitted. 
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B2.  CH-pi interactions  
 During our synthetic studies of TA the syn product proved be the thermodynamically 
favored diastereomer while anti-1 appeared to be kinetically favored which appears to be 
opposite of what would be expected on first glance.  The first clue into the reason for this 
mystery surfaced when we observed significant shielding of the indole methylene protons when 
this DKP was in the natural syn conformation but no such affect with the anti diastereomer, (Fig. 
8).145  While the crystal structure of anti-1 did show a possible phenol-methyl (C21) interaction of 
a similar type.  A closer examination revealed that no distinct CH-pi contact was present due to 
the ~4.0 Å bond distance and lack of 1H NMR shielding, (Fig. 8 and 9).  The shielding effect 
observed in the syn DKP is presumably due to the folded nature of the molecule which places 
these protons directly over the pi cloud of the phenol ring and could be responsible for the 
favoring of syn-1 under our reaction conditions.105  Crystal structures of TA135b,145 and 
hemiaminal ether derivatives105 support this claim (Fig. 9).  Additionally, our structure provides a 
H-phenol distance of 2.60 Å which is very similar to previously reported 2.55 Å and 2.48 Å CH-pi 
distances which also displayed significant proton shielding.1  Furthermore, these data cannot 
simply be discarded as structural packing forces because upfield shifts are observed in solution 
as well.146  Using Gibbs free energy equation for a system at equilibrium  (∆G = -RT ln K) the 
energy of TA’s interaction is 0.94 kcal/mol, a value just below that reported as the lower limit 
(1.5 kcal/mol) of CH-pi bonding by Nishio.147  Also, this DKP ring CH shielding effect has been 
previously observed in aromatic cyclic dipeptides containing phenyl alanine and tyrosine with up 
to 1 ppm shift detected (Fig. 10).148  Moreover when unfolding of the phenyl alanine or tyrosine 
DKPs was attempted in DMSO or formamide (50 oC), in an effort to disrupt dipole-induced-
dipole interactions, the shielding affect remained.  This observation lead the researchers to 
suggest “short range, highly directional effects favoring intramolecular interactions”, which is 
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now believed to be an example of CH-pi bonding having an energy range of ~1.5-2.5 kcal/mol, 
depending on the donor and acceptor.146-147,149 
 
 
 
 
Fig. 8  Proton shielding of syn-1 vs. anti-1. 
 
Hb 
syn 
anti 
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Fig. 9  (left, center) ORTEP diagrams of syn-1 highlighting CH-pi interactions with a CH-phenol 
bond distance of 2.60 Å very similar to previous examples reported by Grossel,1 (right) anti-1 
ORTEP showing no interaction with C21 methyl, bond distances of 4.0 and 4.5 Å to the phenyl 
plane are too far for CH-pi bonding and no shielding is observed in 1H NMR. 
 
Fig. 10  Change in C-H chemical shift in ppm of nonaromatic DKP vs. aromatic DKP. 
 CH-pi bonds occur through the contact of a CH bond with a pi system, e.g. double and 
triple bonds, aromatic rings and heteroaromatics.146  While conventional hydrogen bonds 
generally fall within the 3-7 kcal/mol range, this interaction represents a much weaker force at 
1.5-2.5 kcal/mol.147,149  Alternative to classical hydrogen bonds the electrostatic contribution of 
this interaction is diminished, with the majority of energy coming from dispersion forces, 
determined through ab initio MO calculations.150  It is tempting to simply disregard these 
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interactions as simple van deer Waals forces but it must be remembered that orientation of the 
interaction is important, following the trend that increased linearity results in a stronger bond, 
whereas van deer Waal contacts are independent of approach angle.151  While the electrostatic 
component is diminished, CH-pi interactions are still influenced by the proton donating ability of 
the CH donor and therefore bond strength increases with the presence of greater s-character, 
sp-CH > sp2-CH > sp3-CH.  In addition, the presence of electron withdrawing groups have a 
similar effect on donor function, HCX3 > H2CX2 > H3CX.  The electron density of the pi systems 
is also important and therefore electron donating groups increase the ability of these systems to 
act as a pi-base.147 
 Another interesting quality of CH-pi interactions involves their capacity to function in polar 
protic media such as water and have been observed in peptide and protein structures under 
aqueous conditions.152  While these interactions are weaker than conventional hydrogen bonds 
a large amount of them, found in the protein core, can contribute to overall stability.  
Furthermore, the participating groups are much more rigid and easily desolvated resulting in a 
smaller entropic penalty for the interaction.149  An additional niche involving these CH-pi contacts 
is found in the turn regions of proteins which have a high propensity to contain Pro residues 
preceded or followed by aromatic amino acids.152b,152d  While Pro is capable of providing a stable 
cis-peptide bond itself the presence of aromatic residues enhance the stability of the turn 
through stacking interactions many of which are believed to be CH-pi contacts with the CHα or 
CHδ of the pyrrolidine ring.152e  The presence of aromatic residues preceding cis Pro amide 
bonds have been studied using designer peptides where increased rates of cis-trans 
isomerization and shielding of the pyrrolidine protons has been reported.152f,152g  Furthermore, 
the Pro trans:cis ratio has been altered through careful electronic tuning of tetrapeptide 
sequences, Thr-Xxx-Pro-Asn where Xxx is an aromatic residue para substituted with an electron 
withdrawing or releasing functional group.152a  As the authors predicted the electron rich 
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aromatic systems Xxx = Trp, Tyr(O-), 4-amino-Phe, and 4-thio-Phe had an increased cis 
population providing 1.8:1, 1.7:1, 2.1:1, and 2.2:1 trans:cis ratios respectively while the electron 
poor systems Xxx = 4-(H+)pyridyl-Ala, 4-SO2Me-Phe, 4-nitro-Phe and 4-CF3-Phe strongly 
favored trans 7.6:1, 5.9:1, 5.5:1, and 4.7:1 respectively.  Moreover control peptides Thr-Ala-Pro-
Asn and Thr-Cha-Pro-Asn (Cha = cyclohexyl alanine) favored trans more than any aromatic 
residue studied providing ratios of 10.7:1 and 8.0:1.  Pro-Pro cis amide bonds have also been 
shown to be stabilized by CH-pi bonds, with the tripeptide Ac-Pro-Pro-Phe-NH2 providing a 1:1 
trans:cis ratio while Ac-Pro-Pro-Ala-NH2 gave a 4:1 ratio.152c  It is believed that the CHα of the 
peptide back bone from the first Pro residue interacts with the aromatic side chain across the cis 
peptide bond providing approximately 0.9 kcal/mol stabilization with 1 ppm of shielding in 1H 
NMR.152b,152c  Also of note, is that this interaction energy is very similar to that calculated for TA 
(0.96 kcal/mol), which provides a fourfold increase in cis configuration again analogous to TA’s 
4:1 syn:anti ratio obtained under the KOH/microwave cyclization conditions.   
 These unconventional hydrogen bonds are not only limited to intramolecular contacts 
and have also been observed in the active site of carbohydrate binding proteins where aromatic 
amino acids stack against the axial protons of monosaccharides on the opposite face of axial 
hydroxyls in Gal and Man.153  This stacking contributes to the protein affinity for the sugar along 
with the well-known heteroatom hydrogen bonding.152h,152j,152k,154  In addition, the formation of a 
1:1 Trp-Trp:maltotriose complex in aqueous solution has been reported, the authors suggested 
this complex based on the reduction of self-quenching observed when Trp-Trp was irradiated in 
the presence of the trisaccharide.152i  This lead the researchers to argue that both the α and β 
face axial protons of the sugar were interacting with the aromatic systems thereby separating 
the rings and resulting in the observed increase in fluorescence.  Point mutation experiments 
also support the importance of CH-pi interactions with significant loss of binding on removal of 
Trp from the active site of carbohydrate binding proteins.155  Further residue exchange 
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experiments have demonstrated that an increase in aromatic surface area, studied through 
replacing Trp with naphthylalanine, encourages active site binding of a wheat antimicrobial 
protein which is known to bind chitin polysaccharides.  Alternatively replacing Trp with the 
electron poor 4-fluorophenylalanine was shown to diminish carbohydrate binding in an 
otherwise identical system.154a,156 
 Early evidence for CH-pi interactions came from calorimetric measurements on mixing 
chloroform with substituted benzenes.157  These experiments demonstrated an exothermic 
release on solvent mixing, suggesting that a CH-pi attractive force was responsible.  
Furthermore, addition of methyl substituents onto benzene (toluene, xylenes, and mesitylene) 
was shown to increase the heat of mixing while chloro substitution displayed the opposite effect.  
This theory was later substantiated through 1H NMR experiments of chloroform and aromatic 
solvents, which displayed significant upfield shifts when compared to spectra of pure 
chloroform.158   
 In addition, conformational studies have shown that altering the electronic properties of 
aromatic acceptors or CH donors manipulated the folded nature of molecules thought to be 
dependent on CH-pi interactions.156,159  A noteworthy example involves the study of 
conformational isomerism on the hinged molecule found in Fig. 11.159b  This compound has a 
distinct CH-pi contact in its folded form which is lacking in the extended conformation creating a 
useful tool to study aryl-CH interactions.  In addition, the ratio between the two confirmations 
can be directly observed due to the shielding of the meta aromatic proton in the folded state.  
The authors found that cyano and nitro substitution at Y created the highest folded:extended 
ratios of 75:25, with methyl, methoxy, and H giving a 60:40 ratio.  This result can be attributed to 
an increase in CH donor capacity in the presence of EWGs as discussed above.  A tert-butyl 
ester was also examined and displayed the highest ratio (80:20, folded:extended) of the 
compounds examined, demonstrating that this interaction is not limited to aryl-aryl contacts.  
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The authors did not provide an explanation for the tert-butyl effect, however, a more favorable 
CH-phenyl bond distance and/or an increase in linearity of the interaction may be responsible.  
Finally, the folded ratios were examined under various solvent conditions, CDCI3, CD3-NO2, d6-
DMSO, C6D6, and CCl4 but were found to be insensitive to solvent alterations.  Another example 
involves the conformational analysis of Diels-Alder adducts found in Fig. 12.159a  The authors 
studied the ability of the benzylic methyl protons to interact with the phenyl system, here the aryl 
CH protons do not compete because of the distance to the aromatic system.  Again, an 
increasing CH donor capacity coincided with the presence of electron withdrawing substituents 
with syn:anti ratios ranging from 43:57 for X=NMe2 to 70:30 for X=NO2 in DMSO. 
 
Fig. 11  Hinged dibenzodiazocine for the study of intramolecular CH-pi interactions, folded on 
left, extended on right, Y = NO2 or CN ratio 75:25, Y = H, CH3, or OCH3 ratio 60:40, tert-butyl 
ester in the place of the aryl ester provides a ratio of 80:20, folded:extended.159b  This figure was 
inspired by Paliwal, S.; Geib, S.; Wilcox, C. S. Journal of the American Chemical Society 1994, 
116, 4497-4498 
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Fig. 12  Syn:anti ratios of substituted Diels-Alder imides.159a  This figure was inspired by 
Kishikawa, K.; Yoshizaki, K.; Kohmoto, S.; Yamamoto, M.; Yamaguchi, K.; Yamada, K. Journal 
of the Chemical Society, Perkin Transactions 1 1997, 1233-1240. 
B3.  Isoskeletal TA derivatives  
 These previous examples, combined with the observation that TA favors the syn 
configuration under thermodynamic conditions, encouraged us to examine electronically 
modified derivatives in an attempt to influence the 80:20 syn:anti ratio.  The DKPs were 
prepared using the Ugi keto-amide cyclization sequence with the phenylpyruvic acids (7, 10) 
and indole acetaldehydes (9, 11, Table 1).  The indole acetaldehydes lacking -NO2 substitution 
required protection to obtain useful yields due to unwanted indole participation.  To begin, we 
removed the phenyl -OH (12) and then equilibrated at 70 oC in the presence of KOH, which 
gave a reduced syn:anti ratio of 67:33 presumably because of the decrease in electron density 
on the aryl substituent.147  The removal of -NO2 (13) also resulted in loss of syn preference 
reducing the ratio to 60:40.  This result is similar to work mentioned above (Fig. 12) in which 
electron withdrawing groups were shown to increase benzylic hydrogen’s bonding capacity 
whereas electron donating groups had the opposite outcome.159  Finally, both -OH and -NO2 
substitution was removed (8) resulting in the lowest syn:anti ratio of 57:43, most likely due to the 
combination of effects noted above.  These results suggest that the electronic nature of the 
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indole and phenyl rings do indeed play a role in the observed syn:anti ratio and may very well 
be influencing the CH-pi interface when MeOH is used as the solvent.   
Table 1  Preparation of electronically modified TA derivatives  
 
entry cmpd X Y Z syn:antia %yieldb 
1 1 NO2 H OH 80:20 21% 
2 12 NO2 H H 67:33 23% 
3 13 H Bzc OH 60:40 26% 
4 8 H Bzc H 57:43 27% 
aRatio determined using 1H NMR integration. bCalculated over 2 steps. cBenzoyl protection required for 8 and 13 to limit indole 
participation due to the absence of the nitro group.   
 In conclusion, we have utilized methylamine, methyl isocyanide, 3-hydroxyphenyl 
pyruvic acid, and 4-nitroindolylacetaldehyde in a two-step one-pot Ugi/DKP cyclization 
procedure for the preparation of racemic TA.  While this approach is innately restricted by the 
Ugi reaction in that only racemic TA is attained, it undoubtedly validates the power of 
multicomponent reactions to produce biologically confirmed scaffolds, including those rooted in 
natural products, in a highly convergent fashion.  TA also demonstrates an interesting folded 
nature which can readily be observed in significant proton shielding effects.  Through further 
investigation of this phenomenon we have shown that the diastereomeric ratio of isoskeletal TA 
derivatives can be altered at equilibrium through manipulation of electronics, Table 1.  We 
believe this effect to be the result of diminishing CH-pi donor and/or acceptor capacity causing 
reduced syn preference when compared to TA.  Here in we have provided further evidence to 
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support the folded environment of aromatic DKPs and have highlighted the importance that a 
relatively weak intramolecular interaction can have on a diastereomeric ratio at equilibrium.  
Future work on this project will involve investigating the scope of the Ugi keto-amide cyclization 
process, examining simple TA derivatives for improved or diminished activity against 
Arabidopsis thaliana, and continuing the effort to locate the exact cellular target of TA. 
C. Experimental, data for compounds 9, 10, 2, syn-1 and anti-1 reproduced from, Bourgault, J. 
P.; Maddirala, A. R.; Andreana, P. R. “A one-pot multicomponent coupling/cyclization for natural 
product herbicide (±)-thaxtomin A” Organic & Biomolecular Chemistry 2014, 12, 8125-8127. 
General procedure 1, Ugi reaction 
0.036 g (0.137 mmol) of the respective RCHO was dissolved in 0.28 mL of methanol. This 
solution was then cooled to 4 oC and 0.012 mL (0.137 mmol) of methyl amine solution was 
added (40% in H2O).  After 5 minutes, keeping the temperature at 4 oC, 0.007 mL (0.137 mmol) 
of methyl isocyanide and 0.025 g (0.137 mmol) of phenyl pyruvic acid were added sequentially 
and the mixture was allowed to stir for 22 hours while warming to room temperature.  Next, the 
reaction was concentrated and purified by flash column chromatography or prep TLC using 20:1 
DCM:MeOH as the eluent to provide either the acyclic Ugi product or the anti-DKP directly, 
depending on the starting materials used. 
General procedure 2, Cyclization of acyclic Ugi starting materials/DKP epimerization/N-
benzoyl deprotection  
0.034 g (0.683 mmol) acyclic Ugi or DKP was dissolved in 1.2 mL of MeOH, then 0.34 mL of a 
1.0 M KOH (0.34 mmol) in MeOH solution was added.  Next, the reaction mixture was heated to 
70 oC for 30 minutes in the microwave.  The mixture was allowed to cool to r.t., followed by 
addition of 0.022 mL (0.38 mmol) of AcOH to neutralize the remaining KOH.  The reaction was 
concentrated and purified by flash column chromatography or prep TLC using 20:1 DCM:MeOH 
to provide the diastereomers. 
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2-(4-Nitro-1H-indol-3-yl)acetaldehyde (9).  Procedure modified from Revelant, G.; Dunand, S.; 
Hesse, S. P.; Kirsch, G., Synthesis 2011, 2935-2940. 9.40 mL of a 1M DIBAL-H (9.40 mmol) 
solution in THF was added slowly to 0.528 g (2.12 mmol) ethyl 2-(4-nitro-1H-indol-3-yl)acetate 
dissolved in 14 mL of anhydrous DCM at 4 oC.  The reaction was allowed to warm to room 
temperature over 1 hour and then quenched with 4 mL methanol added dropwise.  After gas 
evolution had stopped, 30 mL of 20% sodium potassium tartrate was added and the resulting 
slurry was filtered through a pad of celite.  The celite was then washed several times with 10:1 
DCM:MeOH; subsequently the filtrate was washed with saturated NaHCO3 and brine solution to 
provide the crude alcohol which was taken to the next step without further purification.  To the 
crude alcohol was added 35 mL of acetonitrile and 1.79 g (6.40 mmol) of IBX and the 
suspension was heated at 100 oC for 1 hour.  After the reaction had cooled to room temperature 
it was filtered through a pad of celite and then dried.  The crude was then purified by flash 
column chromatography using DCM:MeOH to provide 9 ( 0.301 g, 70%) as a dark yellow solid, 
m.p. 116-118oC.  Data for 9.  1H NMR (600 MHz, CD3CN):  9.92 (bs, 1H), 9.76 (s, 1H), 7.87 (d, J 
= 7.8 Hz, 1H), 7.81 (d, J = 7.8 Hz, 1H), 7.42 (s, 1H), 7.26 (t, J = 7.8 Hz, 1H), 4.02 (s, 2H); 13C 
NMR (150 MHz, CD3CN): δ 201.5, 143.4, 140.5, 131.1, 121.4, 120.3, 119.4, 118.5, 107.3, 43.1; 
ESI HRMS: [M+Na]+ calcd for C10H8N2NaO3 227.0433, found 227.0424. 
3-Hydroxyphenylpyruvic acid (10).  Procedure from Wong, H. N. C.; Xu, Z. L.; Chang, H. M.; 
Lee, C. M., Synthesis 1992, 793-797 with modified purification as described below.  3.00 g (24.6 
mmol) 3-hydroxybenzaldehyde, 3.45 g (29.5 mmol) of N-acetyl glycine, 2.62 g (31.8 mmol) 
sodium acetate, and 11.6 mL of acetic anhydride were combined and heated at 120 oC for 5 
hours.  After the reaction had cooled to room temperature 12 mL of ice water was added.  The 
resulting precipitate was filtered and washed with 50% aqueous EtOH (4 x 5 mL) then 
recrystallized from acetone.  The orange solid (4.18 g) and 102 mL of 3M HCl were combined 
and heated at 100 oC for 3 hours and 40 minutes.  The reaction was allowed to cool, the 
precipitate filtered off and the filtrate extracted with (3 x 35 mL) ethyl acetate.  The combined 
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organic layers were then concentrated and subsequently dissolved in a minimal amount of 
diethyl ether.  The remaining dark brown solid was filtered off and the solvent was removed 
under reduced pressure to provide 10 (36% over two steps, 1.60 g) as a yellow solid, m.p. 160-
162 oC.  1H NMR (600 MHz, CD3OD): δ 7.34 (s, 1H), 7.15 (m, 2H), 6.67 (m, 1H), 6.41 (s, 1H); 
13C NMR (150 MHz, CD3OD): δ 168.4, 158.3, 142.2, 137.6, 130.1, 122.5, 117.2, 115.6, 111.6; 
ESI LRMS: [M-H] - found 179.2.  
(±)-Acyclic Ugi precursor (2).  To 0.010 g (0.049 mmol) 2-(4-nitro-1H-indol-3-yl)acetaldehyde 
was added 0.10 mL of MeOH followed by 4.2 µL of methyl amine solution (40% in water).  The 
imine formation was allowed to take place over 5 minutes at room temperature.  Then 2.6 µL 
(0.049 mmol) of methyl isocyanide and 0.0088 g (0.049 mmol) of 3-hydroxyphenylpyruvic acid 
were added sequentially and the reaction was left to stir overnight.  The reaction was then 
concentrated under reduced pressure to an oil and purified by preparative TLC with 20:1 
DCM:MeOH (3 times) to provide 2 (0.0080 g, 37%) as a yellow-orange solid, m.p. 101-103 oC.  
Data for 2, as a mixture of two rotamers.  1H NMR (600 MHz, CD3OD): δ 7.94 (d, J = 7.8 Hz, 
1H), 7.88 (d, J = 7.9 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H), 
7.32 (s, 1H), 7.26 (t, J = 8.0 Hz, 1H), 7.22 (t, J = 8.0 Hz, 1H), 7.10 (t, J = 7.8 Hz, 1H), 6.95 (t, J = 
7.8 Hz, 1H), 6.71 (m, 2H), 6.58 (m, 3H), 6.31 (m, 1H), 6.15 (m, 1H), 5.09 (dd, J1 = 5.9 Hz, J2 = 
9.6 Hz, 1H), 4.73 (dd, , J1 = 4.6 Hz, J2 = 9.7 Hz, 1H), 3.79 (d, J = 17.4 Hz, 1H), 3.74 (d, J = 15.3 
Hz, 1H), 3.62 (d, J = 15.3 Hz, 1H), 3.58 (dd, , J1 = 4.6 Hz, J2 = 14.9 Hz, 1H), 3.51 (dd, J1 = 5.9 
Hz, J2 = 14.9 Hz, 1H), 3.23 (dd, J1 = 9.6 Hz, J2 = 14.9 Hz, 1H), 3.13 (dd, J1 = 9.7 Hz, J2 = 14.9 
Hz, 1H), 3.01 (s, 3H), 2.75 (s, 3H), 2.70 (s, 6H), 2.57 (d, J = 17.3 Hz, 1H); 13C NMR (150 MHz, 
CD3OD): δ 199.0, 198.5, 171.8, 171.6, 169.31, 169.28, 158.9, 158.4, 144.0, 143.8, 141.18, 
141.15, 134.9, 134.2, 131.4, 130.9, 130.7, 130.2, 122.1, 121.8, 121.6, 121.2, 120.2, 119.9, 
119.6, 119.1, 119.0, 118.6, 117.8, 117.7, 115.5, 115.0, 110.5, 110.3, 63.4, 58.8, 47.4, 46.2, 
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31.9, 29.7, 27.5, 27.1, 26.6, 26.4; ESI HRMS: [M+Na]+ calcd for C22H22N4NaO6 461.1437, found 
461.1440. 
(±)-Anti-1.  To 0.022 g (0.050 mmol) of acyclic Ugi (2) was added 0.50 mL of MeOH, then 0.070 
mL (0.50 mmol) triethylamine and the mixture was allowed to stir for 30 minutes at room 
temperature.  The reaction was then concentrated to dryness and purified by preparative TLC 
using a solvent system of 20:1 DCM:MeOH (3 times) to provide anti-1 and syn-1 (0.017 g, 77%, 
dr 10:1).  Pure anti-1 is a yellow solid with a m.p. of 207-208 oC.  This purification procedure is 
sufficient for the separation of the diastereomers, if desired, however this material was utilized 
for the preparation of (±)-thaxtomin A and therefore anti-1 and syn-1 were combined.  Data for 
anti-1.  1H NMR (600 MHz, CD3OD): δ 7.75 (d, J = 7.8 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.16 
(m, 2H), 7.04 (t, J = 7.6 Hz, 1H), 6.67 (m, 1H), 6.43 (m, 2H), 3.56 (dd, J1 = 3.7 Hz, J2 = 15.3 Hz, 
1H), 3.31 (m, 2H, overlapping with solvent residual peak), 3.13 (d, J = 13.4 Hz, 1H), 3.00 (d, J = 
13.4 Hz, 1H), 2.80 (s, 3H), 2,79 (s, 3H); 13C NMR (150 MHz, CD3OD): δ 168.4, 167.7, 158.6, 
144.3, 140.8, 136.7, 130.4, 130.1, 121.7, 121.0, 120.2, 118.7, 118.3, 117.4, 115.5, 108.8, 87.50, 
63.0, 44.9, 32.9, 30.4, 28.1; ESI HRMS: [M+Na]+ calcd for C22H22N4NaO6 461.1437, found 
461.1455. 
(±)-Thaxtomin A (syn-1), from anti-1.  To 0.017 g (0.039 mmol) of the diastereomeric mixture 
was added 1.6 mL MeOH and 0.19 mL of 1M KOH (0.20 mmol) in MeOH.  The reaction mixture 
was subsequently heated to 70 oC for 30 minutes (5 minute ramp) with a CEM Discover 
microwave.  After the reaction had cooled, 12 µL (0.21 mmol) of acetic acid was added and the 
reaction was concentrated. The crude material was purified by preparative TLC using a solvent 
system of 20:1 DCM:MeOH (3 times) to provide syn-1 and anti-1 (0.014 g, 85%, dr 4:1).  Pure 
syn-1 is an orange solid, m.p. 205-206 oC.  Data for thaxtomin A, syn-1.  1H NMR (600 MHz, 
CD3OD): δ 7.84 (dd, J = 7.9 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.23 (t, J = 8.1 Hz, 1H), 7.18 (t, J 
= 8.0 Hz, 1H), 6.95 (s, 1H), 6.75 (m, 1H), 6.70 (m, 2H), 3.86 (dd, J1 = 6.4 Hz, J2 = 8.8 Hz, 1H), 
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3.31 (overlapping with solvent residual peak, 1H), 3.13 (d, J = 13.5 Hz, 1H), 3.03 (s, 3H), 2.82 
(s, 3H), 2.60 (dd, J1 = 6.3 Hz, J2 = 14.1 Hz, 1H), 1.61 (dd, J1 = 8.9 Hz, J2 = 14.1 Hz, 1H); 13C 
NMR (150 MHz, CD3OD): δ 168.3, 166.8, 159.1, 143.6, 141.1, 137.4, 132.5, 131.2, 122.7, 
121.0, 119.8, 119.3, 118.6, 118.4, 115.9, 110.5, 88.0, 64.6, 43.5, 34.2, 33.5, 28.5; ESI HRMS: 
[M+Na]+ calcd for C22H22N4NaO6 461.1437, found 461.1460. 
(±)-Thaxtomin A (syn-1), from acyclic starting material.  To 0.016 g (0.036 mmol) of the Ugi 
precursor was added 1.6 mL MeOH and 0.18 mL of 1M KOH (0.18 mmol) in MeOH.  The 
reaction mixture was subsequently heated to 70 oC for 30 minutes (5 minute ramp) with a CEM 
Discover microwave.  After the reaction had cooled, 11 µL (0.19 mmol) of acetic acid was added 
and the reaction was concentrated. The crude material was purified by preparative TLC using a 
solvent system of 20:1 DCM:MeOH (3 times) to provide syn-1 and anti-1 (0.009 g, 56%, dr 4:1. 
Alternatively, the crude material could be recrystallized using 20:1 DCM:MeOH and hexanes.  
Data matched that of thaxtomin A prepared from the diastereomer as described above. 
(±)-Thaxtomin A (syn-1), one pot procedure.  To 0.010 g (0.049 mmol) 2-(4-nitro-1H-indol-3-
yl)acetaldehyde was added 0.10 mL of MeOH followed by 4.2 µL (0.049 mmol) of methyl amine 
solution (40% in water).  The imine formation was then allowed to take place over 5 minutes at 
room temperature.  Then, 2.6 µL (0.049 mmol) of methylisocyanide and 0.0088 g (0.049 mmol) 
of 3-hydroxyphenylpyruvic acid were added sequentially and the reaction was left to stir for 20 
hours.  The reaction was then diluted with 0.80 mL of MeOH and 0.13 mL of 1M KOH (0.13 
mmol) in MeOH.  Following this addition, the reaction mixture was heated to 70 oC in a 
microwave reactor for 30 minutes (5 minute ramp time).  After the reaction had cooled to 
ambient temperature, the base was neutralized with 0.008 mL (0.14 mmol) of AcOH.  The 
solvent was then removed under vacuum and the crude material purified by preparative TLC 
with a solvent system of 20:1 DCM:MeOH (4 times) to provide syn-1 (0.0068 g, 32%) and anti-1 
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(0.0017, 8%).  The yield for anti-1 was calculated by 1H NMR because of the presence of an 
inseparable impurity.  Data for syn-1 and anti-1 matched that as reported above.   
Procedure for NaOCl oxidation of tryptophan modified from R. A. Gray, Arch. Biochem. Biophys. 
1959, 81, 480-488.  To 2.00 g (9.79 mmol) of tryptophan was added 66 mL H20 and 10 mL of 10 
% NaOH.  The solution was stirred until all of the tryptophan had dissolved.  Next, 4M HCl was 
slowly added until crystals of tryptophan just started to form near pH 8- patience is needed with 
this step.  This solution was then diluted with 800 mL of H2O, then 500 mL of toluene was added 
to form a biphasic reaction mixture which was stirred vigorously throughout the reaction 
process.  Next, 135 mL of 0.52 % NaOCl (Chlorox diluted 1:9) was added dropwise.  After this 
addition, the reaction mixture was heated at 50 oC for 30 minutes in a hot water bath.  
Subsequently, the solution was transferred to a separatory funnel and the organic layer was 
separated while still warm.  The aqueous layer was washed with toluene 2 times and the 
combined organic layers were then dried over MgSO4 and filtered to provide the crude 
aldehyde.  Next, the toluene solution was concentrated to approximately 10 mL and diluted with 
90 mL ACN. This was followed by addition of 1.41 mL (19.6 mmol) 1,3-propanediol and 75 mg 
(0.436 mmol) PTSA.  After the reaction was judged to be complete by TLC, 0.070 mL (0.479 
mmol) of NEt3 was added.  The crude residue was then dissolved in EA, washed with water, 
dried over MgSO4, filtered, and concentrated.  The remaining oil was purified by dissolving in a 
minimal amount of DCM followed by addition of Hexanes until a dark brown impurity oiled out.  
The solution was then decanted, filtered, and concentrated to give 1 g (47%) of the 1,3-dioxane 
derivative as a dark red oil.  Next, 0.500 g of 1,3-dioxane, 3 mL of 50% NaOH, 3.5 mL of THF, 1 
mL H2O, and 0.076 g TBAB (0.23 mmol) were combined and stirred for 30 minutes.  Then, 0.30 
mL of benzyl chloride was added dropwise as a solution in 1 mL THF.  After 30 minutes, 
saturated NaHCO3 was added and the aqueous layer was extracted 3 times with EA.  The 
combined organic layers were then dried over MgSO4, filtered, and concentrated.  The crude 
material was purified by flash column chromatography using 1:4 EA:Hex as the eluent to 
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provide the N-benzoyl-1,3-dioxane (0.300 g, 41%) as a yellow oil.  To 0.250 g (0.780 mmol) of 
N-benzoyl-1,3-dioxane was added 4 mL of water followed by dropwise addition of 8 mL of TFA.  
The reaction mixture was then heated at 60 oC for 15 minutes.  The solution was allowed to cool 
to r.t.  The acid was then neutralized with saturated NaHCO3 and extracted 3 times with EA.  
The organic layer was dried over MgSO4, filtered and concentrated.  The crude was purified by 
flash column chromatography using 1:5 EA:Hex as the eluent to provide 11 (0.052 g, 25%) as a 
yellow oil.  Data for 11.  1H NMR (600 MHz, acetone-d6): δ 9.78 (t, J = 1.8 Hz, 1H), 8.38 (d, J = 
8.4 Hz, 1H), 7.81 (d, J = 7.8 Hz, 2H), 7.70 (t, J = 7.2 Hz, 1H), 7.61 (m, 3H), 7.47 (s, 1H), 7.42 (t, 
J = 7.8 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 3.89 (s, 2H); 13C NMR (150 MHz, (acetone-d6): δ 199.8, 
169.8, 137.9, 136.5, 133.5, 132.6, 130.7, 130.3, 128.4, 126.6, 125.4, 120.8, 117.9, 114.8, 40.9; 
ESI-LRMS found 286.4 [M + Na].   
Prepared as described in general procedures 1 and 2 to provide syn-12 (0.032 g, 23%, two 
steps) and anti-12 (0.0015 g, 25 %) as oils, dr 2:1.  Data for syn-12.  1H NMR (600 MHz, 
CD3OD): δ 7.83 (d, J = 7.9 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.32 (t, J = 
7.4 Hz, 1H), 7.21 (m, 3H), 6.83 (s, 1H), 3.88 (dd, J1 = 5.9 Hz, J2 = 8.6 Hz, 1H), 3.29 (d, J = 13.7 
Hz, 1H), 3.15 (d, J = 13.6 Hz, 1H), 3.00 (s, 3H), 2.83 (s, 3H), 2.63 (dd, J1 = 5.9 Hz, J2 = 14.3 Hz, 
1H), 1.63 (dd, J1 = 8.6 Hz, J2 = 14.3 Hz, 1H); 13C NMR (150 MHz, CD3OD): δ 168.3, 166.9, 
143.7, 141.0, 136.1, 132.1, 131.8, 130.1, 129.9, 129.2, 128.9, 121.1, 119.8, 119.3, 118.5, 110.4, 
87.9, 64.6, 43.8, 34.1, 33.2, 28.6; ESI-LRMS found 445.7 [M + Na].  Data for anti-12.  1H NMR 
(600 MHz, CD3OD): δ 7.74 (d, J = 7.8 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.23 (m, 3H), 7.17 (m, 
2H), 6.97 (m, 2H), 3.54 (dd, J1 = 3.4 Hz, J2 = 15.2, 1H), 3.24 (m, 2H), 3.21 (d, J = 13.5 Hz, 1H), 
3.07 (d, J = 13.5 Hz, 1H), 2.80 (s, 3H), 2.73 (s, 3H); 13C NMR (150 MHz, CD3OD): δ 168.3, 
167.7, 144.3, 140.8, 135.4, 130.1, 129.9, 129.2, 128.6, 121.0, 120.2, 118.7, 118.3, 108.8, 87.6, 
63.0, 45.0, 32.8, 30.5, 28.1; ESI-LRMS found 445.6 [M + Na].   
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Prepared as described in general procedures 1 and 2 to provide syn-13 (0.008 g, 26%, two 
steps) and anti-13 (0.006 g, 22%) as oils, dr 1.5:1.  Data for syn-13.  1H NMR (600 MHz, 
CD3OD) : δ 7.55 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.13 (t, J = 7.8 Hz, 1H), 7.10 (t, J = 
7.2 Hz, 1H), 7.03 (t, J = 7.2 Hz, 1H), 6.92 (s, 1H), 6.71 (dd, J1 = 1.8 Hz, J2 = 8.4 Hz, 1H), 6.61 
(s, 1H), 6.39 (d, J = 7.8, 1H), 4.22 (dd, J1 = 4.2 Hz, J2 = 8.4 Hz, 1H), 2.99 (s, 3H), 2.95 (d, J = 
13.8 Hz, 1H), 2.82 (m, 2H), 2.57 (s, 3H), 1.71, (dd, J1 = 8.4 Hz, J2 = 15.0 Hz, 1H); 13C NMR (150 
MHz, CD3OD) : δ 168.4, 168.1, 158.9, 138.2, 137.2, 131.0, 128.2, 125.2, 122.9, 122.7, 120.1, 
119.4, 118.7, 115.6, 112.5, 111.6, 87.4, 64.1, 44.2, 34.6, 32.1, 28.9; ESI-LRMS found 416.4 [M 
+ Na].  Data for anti-13.  1H NMR (600 MHz, CD3OD) : δ 7.45 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 
8.2 Hz, 1H), 7.06 (t, J = 7.9 Hz, 2H), 6.98 (t, J = 7.9 Hz, 1H), 6.91 (s, 1H), 6.68 (m, 1H), 6.45 (m, 
2H), 3.38 (dd, J1 = 3.1 Hz, J2 = 15.2 Hz, 1H), 3.32 (m, 1H, overlapping with solvent residual 
peek), 3.23 (dd, J1 = 4.5 Hz, J2 = 15.2 Hz, 1H), 3.05 (d, J = 13.4 Hz, 1H), 2.98 (d, J = 13.4 Hz, 
1H), 2.87 (s, 3H), 2.83 (s, 3H); 13C NMR (150 MHz, CD3OD) : δ 168.3, 168.2, 158.6, 137.6, 
136.7, 130.4, 128.8, 124.9, 122.5, 121.8, 119.8, 119.6, 117.5, 115.5, 112.3, 108.6, 87.5, 62.6, 
45.0, 32.9, 28.4, 28.3; ESI-LRMS found 416.5, [M + Na].   
Prepared as described in general procedures 1 and 2 to provide syn-8 (0.0037 g, 27%, two 
steps) and anti-8 (0.0028 g, 23%) as oils, dr 1.3:1.  Data for syn-8.  1H NMR (600 MHz, CD3OD) 
: δ 7.55 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.23 (m, 3H), 7.13 (t, J = 7.0 Hz, 1H), 7.06 
(t, J = 7.0 Hz, 1H), 6.91 (s, 1H), 6.74 (m, 2H), 4.25 (dd, J1 = 4.1 Hz, J2 = 6.3 Hz, 1H), 2.95 (dd, 
J1 = 3.5 Hz, J2 = 15.1 Hz, 1H), 2.79 (s, 3H), 2.75 (s, 4H, overlapping with benzylic CH), 2.31 (d, 
J = 13.4 Hz, 1H), (dd, J1 = 6.4 Hz, J2 = 15.1 Hz, 1H); 13C NMR (150 MHz, CD3OD) : δ 168.7, 
168.0, 138.1, 136.0, 132.0, 129.4, 128.5, 128.3, 125.2, 122.8, 120.2, 119.6, 112.7, 110.8, 86.9, 
64.2, 45.0, 34.0, 30.5, 29.3; ESI-LRMS found 400.5 [M + Na].  Data for anti-8.  1H NMR (600 
MHz, CD3OD) : δ 7.44 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 7.26 (m, 3H), 7.06 (t, J = 7.0, 
1H), 6.98 (m, 3H), 6.91 (s, 1H), 3.34 (m, 2H), 3.21 (dd, J1 = 4.6 Hz, J2 = 18.5 Hz, 1H), 3.13 (d, J 
100 
 
 
 
= 13.4 Hz, 1H), 3.06 (d, J = 13.5, 1H), 2.88 (s, 3H), 2.79 (s, 3H); 13C NMR (150 MHz, CD3OD) : 
δ 168.18, 168.13, 137.6, 135.4, 130.8, 129.4, 128.8, 128.7, 124.9, 122.5, 119.8, 119.6, 112.3, 
108.5, 87.5, 62.6, 45.0, 32.9, 28.4, 28.3; ESI-LRMS found 400.5 [M + Na]. 
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Appendix A,  1H and 13C NMR for Chapter 1 
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JPB2-98-C-CDCL3-2
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JPB2-101-C-CDCL3-2.esp
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JPB2-134-H-CDCL3-5.25.11.esp
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JPB2-134-C-CDCL3-5
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JPB2-134BETA-H-CDCL3-5
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JPB2-134BETA-C-CDCL3-5.25.11.esp
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JPB2-137-H-CDCL3-6.21.11.esp
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JPB2-137-C-CDCL3-6.21.11.esp
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JPB2-116-H-CDCL3-3
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JPB2-116-C-CDCL3-3.30.11.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
-0.05
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
o
rm
a
liz
e
d
 I
n
te
n
si
ty
2
0
.4
7
2
0
.6
6
2
5
.3
5
5
7
.9
4
6
1
.4
6
6
5
.1
6
6
6
.9
5
6
8
.4
9
7
0
.9
7
7
5
.1
4
7
5
.3
2
7
6
.6
8
7
7
.0
0
7
7
.3
2
1
0
0
.5
4
1
0
2
.9
1
1
2
6
.0
0
1
2
8
.1
1
1
2
8
.9
2
1
3
7
.4
3
1
6
9
.3
4
1
7
0
.0
2
1
7
0
.2
1
1
7
0
.8
3
 
  
121 
 
 
 
COSY 
 
JPB2-116COSY-CDCL3-4.6.11.esp
5.5 5.0 4.5 4.0
F2 Chemical Shift (ppm)
3.5
4.0
4.5
5.0
5.5
6.0
F
1
 C
h
e
m
ic
a
l S
h
ift
 (
p
p
m
)
 
  
122 
 
 
 
HMQC 
 
123 
 
 
 
 
JPB2-122-H-CDCL3-4.19.11.esp
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JPB2-122-C-CDCL3-4.19.11.esp
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JPB2-122-C-CDCL3-4
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3-51-H-12.6.12.esp
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Expansion 13C NMR 
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COSY 
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PS A1 1H NMR at 60 oC 
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Expansion of isolated PS A1 (15), HDO referenced to 4.35, for comparison with 
literature data see pg. 135 
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1H NMR of PS A1 (15) from, Tzianabos, A. O.; Pantosti, A.; Baumann, H.; Brisson, J. 
R.; Jennings, H. J.; Kasper, D. L., J. Biol. Chem. 1992, 267, 18230-18235. 
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1H NMR expansion 4.3-5.5 ppm of PS A1 (15) at 60 oC 
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1H NMR of TF-PS A1 (16) at room temperature  
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Expansion of TF-PS A1 oxime signal 1H NMR 
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Expansion of TF-PS A1 1H NMR at 60 oC 
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1D TOCSY TF-PSA1 (16) of doublet at 5.46, at r.t. with 120 ms mixing time 
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1D TOCSY TF-PSA1 (16) of doublet at 4.61, at r.t. with 120 ms mixing time 
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Appendix B,  1H and 13C NMR Spectra for Chapter 3 
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Expansion 1H NMR 6 - 8 ppm 
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Expansion 1H NMR 4.5 -5.2 ppm 
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Expansion 1H NMR 2.5 - 4 ppm 
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(±)-2 as a mixture of rotamers  
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Expansion 13C NMR 24 -66 ppm 
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Expansion 13C NMR 106 -146 ppm 
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Expansion 13C NMR 169 -172 ppm 
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1H NMR expansion 
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1H NMR expansion  
 
(±)-syn-13 
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Appendix C  Crystal structure data for (±)-syn-1 and (±)-anti-1 
Crystallography Information for (±)-thaxtomin A, (±)-syn-1 
Crystals of x-ray crystallographic quality were obtained by slow evaporation from MeOH at 3 oC 
yielding orange crystals. 
A yellow needle-like specimen of C22H22N4O6, approximate dimensions 0.015 mm x 0.018 mm 
x 0.172 mm, was used for the X-ray crystallographic analysis. The X-ray intensity data were 
measured. 
The total exposure time was 92.23 hours. The frames were integrated with the Bruker SAINT 
software package using a narrow-frame algorithm. The integration of the data using 
a triclinic unit cell yielded a total of 9047reflections to a maximum θ angle of 68.67° (0.83 Å 
resolution), of which 3726 were independent (average redundancy 2.428, completeness 
= 90.9%, Rint = 2.25%, Rsig = 2.60%) and 3185 (85.48%) were greater than 2σ(F2). The final cell 
constants of a = 8.1838(6) Å, b = 8.4093(6) Å, c = 18.4956(15) Å, α = 83.381(7)°, β 
= 77.526(4)°, γ = 63.273(5)°, volume = 1109.80(14) Å3, are based upon the refinement of the 
XYZ-centroids of 3662 reflections above 20 σ(I) with 11.78° < 2θ < 136.2°. Data were corrected 
for absorption effects using the multi-scan method (SADABS). The ratio of minimum to 
maximum apparent transmission was 0.897. The calculated minimum and maximum 
transmission coefficients (based on crystal size) are 0.6750 and 0.7530.  
 
The structure was solved and refined using the Bruker SHELXTL Software Package, using the 
space group P -1, with Z = 2 for the formula unit, C22H22N4O6. The final anisotropic full-matrix 
least-squares refinement on F2 with 398 variables converged at R1 = 4.06%, for the observed 
data and wR2 = 10.97% for all data. The goodness-of-fit was 1.041. The largest peak in the final 
difference electron density synthesis was 0.566 e-/Å3and the largest hole was -0.476 e-/Å3 with 
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an RMS deviation of 0.042 e-/Å3. On the basis of the final model, the calculated density 
was 1.408 g/cm3 and F(000), 496 e-. 
 
CCDC #                               1000681 
Chemical formula C22H22N4O6 
Formula weight 438.43 
Temperature 160(2) K 
Wavelength 1.54178 Å 
Crystal size 0.015 x 0.018 x 0.172 mm 
Crystal habit yellow needle 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 8.1838(6) Å α = 83.381(7)° 
 
b = 8.4093(6) Å β = 77.526(4)° 
 
c = 18.4956(15) Å γ = 63.273(5)° 
Volume 1109.80(14) Å3 
 
Z 2 
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Density (calculated) 1.408 Mg/cm3 
Absorption coefficient 0.884 mm-1 
F(000) 496 
 
Theta range for data 
collection 
2.45 to 68.67° 
Index ranges -9<=h<=9, -9<=k<=9, -22<=l<=21 
Reflections collected 9047 
Independent reflections 3726 [R(int) = 0.0225] 
Coverage of independent 
reflections 
90.9% 
Absorption correction multi-scan 
Max. and min. transmission 0.7530 and 0.6750 
Structure solution technique direct methods 
Structure solution program SHELXS-97 (Sheldrick, 2008) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-97 (Sheldrick, 2008) 
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Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 
3726 / 0 / 398 
Goodness-of-fit on F2 1.041 
Δ/σmax 0.001 
Final R indices 
3185 data; 
I>2σ(I) 
R1 = 0.0406, wR2 = 
0.1042 
 
all data 
R1 = 0.0482, wR2 = 
0.1097 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0513P)2+0.6481P] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.566 and -0.476 eÅ-3 
R.M.S. deviation from    mean      0.042 eÅ-3 
 
  
182 
 
 
 
ORTEP diagram of (±)-thaxtomin A (syn-1) with hydrogen atoms omitted 
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Crystallography Information for (±)-anti-1 
A specimen of C22.20H22.80N4O6.20, approximate dimensions 0.050 mm x 0.136 mm x 0.137 mm, 
was used for the X-ray crystallographic analysis. The X-ray intensity data were measured. 
The total exposure time was 28.67 hours. The frames were integrated with the Bruker SAINT 
software package using a narrow-frame algorithm. The integration of the data using a 
monoclinic unit cell yielded a total of 21585 reflections to a maximum θ angle of 59.84° (0.89 Å 
resolution), of which 3100 were independent (average redundancy 6.963, completeness = 
100.0%, Rint = 2.45%, Rsig = 1.29%) and 2963 (95.58%) were greater than 2σ(F2). The final cell 
constants of a = 13.4151(3) Å, b = 11.3424(3) Å, c = 14.8403(3) Å, β = 111.2467(10)°, volume = 
2104.61(9) Å3, are based upon the refinement of the XYZ-centroids of 9986 reflections above 
20 σ(I) with 7.621° < 2θ < 119.5°. Data were corrected for absorption effects using the multi-
scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.907. 
The calculated minimum and maximum transmission coefficients (based on crystal size) are 
0.6820 and 0.7520.  
 
The structure was solved with direct methods and subsequent Difference Fourier Syntheses 
and refinements. Non-hydrogen atoms were refined with anisotropic atomic displacement 
parameters, disordered non-hydrogen atoms were refined with isotropic atomic displacement 
parameters.  H-atoms with occupancy of 0.8 or 1 were located from Difference Fourier 
Syntheses and refined with isotropic atomic displacement parameters.  Hydrogen atoms with 
occupancy of 0.5 were calculated and Hydrogen atoms with occupancies less than 0.5 were 
ignored.  
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The hydroxyphenyl-group is disordered over several positions. Three different conformations 
were deconvoluted. Conformation "B" can be found in the crystal with a 50% probablility having 
the OH-group located on the same side of the molecule as the NO2 group. The aromatic rings 
of two conformers "A1 and A2" overlap and are refined with an occupancy of 0.5, while the OH-
groups of these conformers are disordered over two positions with occupancies of 0.3 (A1) and 
0.2 (A2). Stabilization of these conformers results from the different possibilities of H-bonding. 
The OH-groups  of conformer B and A1 form a H-bond to the keto - O5, while conformer A2 is in 
close contact to the free solvent molecule methanol. 
 
The methanol molecules are disordered over an inversion center and were refined with a  
scattering factor simulating 50% C and 50% O occupancy. 
H-atoms with occupancy of less than 0.5 were not included in the refinement. 
 
The final anisotropic full-matrix least-squares refinement on F2 with 366 variables converged at 
R1 = 4.17%, for the observed data and wR2 = 11.06% for all data. The goodness-of-fit was 
1.075. The largest peak in the final difference electron density synthesis was 0.531 e-/Å3 and the 
largest hole was -0.373 e-/Å3 with an RMS deviation of 0.050 e-/Å3. On the basis of the final 
model, the calculated density was 1.404 g/cm3 and F(000), 934 e-.  
Chemical formula C22.20H22.80N4O6.20 
Formula weight 444.84 g/mol 
Temperature 100(2) K 
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Wavelength 1.54178 Å 
Crystal size 0.050 x 0.136 x 0.137 mm 
Crystal system monoclinic 
Space group P 1 21/n 1 
Unit cell dimensions a = 13.4151(3) Å α = 90° 
 
b = 11.3424(3) Å β = 111.2467(10)° 
 
c = 14.8403(3) Å γ = 90° 
Volume 2104.61(9) Å3 
 
Z 4 
Density (calculated) 1.404 g/cm3 
Absorption coefficient 0.872 mm-1 
F(000) 934 
  
Theta range for data collection 3.81 to 59.84° 
Index ranges -15<=h<=15, -11<=k<=12, -16<=l<=16 
Reflections collected 21585 
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Independent reflections 3100 [R(int) = 0.0245] 
Coverage of independent reflections 100.0% 
Absorption correction multi-scan 
Max. and min. transmission 0.7520 and 0.6820 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2014 (Sheldrick, 2014) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3100 / 0 / 366 
Goodness-of-fit on F2 1.075 
Final R indices 
2963 data; 
I>2σ(I) 
R1 = 0.0417, wR2 = 0.1095 
 
all data R1 = 0.0431, wR2 = 0.1106 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0523P)2+2.1110P] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.531 and -0.373 eÅ-3 
R.M.S. deviation from mean 0.050 eÅ-3 
 
ORTEP diagram of (±)-anti-1 with hydrogen atoms omitted 
187 
 
 
 
 
  
188 
 
 
 
REFERENCES 
(1) Grossel, M. C.; Cheetham, A. K.; Hope, D. A. O.; Weston, S. C. J. Org. Chem. 1993, 58, 
6654-6661. 
(2) (a) Kuduk, S. D.; Schwarz, J. B.; Chen, X.-T.; Glunz, P. W.; Sames, D.; Ragupathi, G.; 
Livingston, P. O.; Danishefsky, S. J. J. Am. Chem. Soc. 1998, 120, 12474-12485. (b) Springer, 
G. F.; Desai, P. R.; Spencer, B. D.; Tegtmeyer, H.; Carlstedt, S. C.; Scanlon, E. F. Cancer 
Detect. Prev. 1995, 19, 374-80. (c) Sabbatini, P. J.; Ragupathi, G.; Hood, C.; Aghajanian, C. A.; 
Juretzka, M.; Iasonos, A.; Hensley, M. L.; Spassova, M. K.; Ouerfelli, O.; Spriggs, D. R.; Tew, 
W. P.; Konner, J.; Clausen, H.; Abu Rustum, N.; Dansihefsky, S. J.; Livingston, P. O. Clin. 
Cancer Res. 2007, 13, 4170-4177. (d) Zhu, J.; Wan, Q.; Lee, D.; Yang, G.; Spassova, M. K.; 
Ouerfelli, O.; Ragupathi, G.; Damani, P.; Livingston, P. O.; Danishefsky, S. J. J. Am. Chem. 
Soc. 2009, 131, 9298-9303. (e) Hoffmann-Röder, A.; Kaiser, A.; Wagner, S.; Gaidzik, N.; 
Kowalczyk, D.; Westerlind, U.; Gerlitzki, B.; Schmitt, E.; Kunz, H. Angew. Chem. Int. Ed. 2010, 
49, 8498-8503. (f) Heimburg-Molinaro, J.; Lum, M.; Vijay, G.; Jain, M.; Almogren, A.; 
Rittenhouse-Olson, K. Vaccine 2011, 29, 8802-8826. (g) Brinãs, R. P.; Sundgren, A.; Sahoo, P.; 
Morey, S.; Rittenhouse-Olson, K.; Wilding, G. E.; Deng, W.; Barchi, J. J. Bioconjugate Chem. 
2012, 23, 1513-1523. 
(3) (a) Glinsky, V. V.; Glinsky, G. V.; Rittenhouse-Olson, K.; Huflejt, M. E.; Glinskii, O. V.; 
Deutscher, S. L.; Quinn, T. P. Cancer Res. 2001, 61, 4851-4857. (b) Heimburg, J.; Yan, J.; 
Morey, S.; Glinskii, O.; Huxley, V.; Wild, L.; Klick, R.; Roy, R.; Glinsky, V.; Rittenhouse-Olson, K. 
Neoplasia 2006, 8, 939 - 948. (c) Yu, L.-G.; Andrews, N.; Zhao, Q.; McKean, D.; Williams, J. F.; 
Connor, L. J.; Gerasimenko, O. V.; Hilkens, J.; Hirabayashi, J.; Kasai, K.; Rhodes, J. M. J. Biol. 
Chem. 2007, 282, 773-781. (d) Rhodes, J. M.; Campbell, B. J.; Yu, L.-G. Biochem. Soc. Trans. 
2008, 36, 1482-1486. 
189 
 
 
 
(4) (a) Cobb, B. A.; Wang, Q.; Tzianabos, A. O.; Kasper, D. L. Cell 2004, 117, 677-687. (b) De 
Silva, R. A.; Wang, Q.; Chidley, T.; Appulage, D. K.; Andreana, P. R. J. Am. Chem. Soc. 2009, 
131, 9622-9623. (c) Silva, R.; Appulage, D.; Pietraszkiewicz, H.; Bobbitt, K.; Media, J.; Shaw, J.; 
Valeriote, F.; Andreana, P. Cancer Immunol. Immunother. 2012, 61, 581-585. (d) Surana, N. K.; 
Kasper, D. L. Immunol. Rev. 2012, 245, 13-26. 
(5) Renaudet, O.; Dumy, P. Tetrahedron Lett. 2004, 45, 65-68. 
(6) Bossu, I.; Sulc, M.; Krenek, K.; Dufour, E.; Garcia, J.; Berthet, N.; Dumy, P.; Kren, V.; 
Renaudet, O. Organic & Biomolecular Chemistry 2011, 9, 1948-1959. 
(7) (a) Jiaang, W.-T.; Chang, M.-Y.; Tseng, P.-H.; Chen, S.-T. Tetrahedron Lett. 2000, 41, 3127-
3130. (b) Keding, S. J.; Endo, A.; Danishefsky, S. J. Tetrahedron 2003, 59, 7023-7031. (c) 
Svarovsky, S. A.; Barchi Jr, J. J. Carbohydr. Res. 2003, 338, 1925-1935. (d) Cato, D.; Buskas, 
T.; Boons, G. J. J. Carbohydr. Chem. 2005, 24, 503-516. 
(8) Gibson, M. S.; Bradshaw, R. W. Angew. Chem. Int. Ed. 1968, 7, 919-930. 
(9) Ing, H. R.; Manske, R. H. F. J. Chem. Soc. 1926, 129, 2348-2351. 
(10) Cao, S.; Tropper, F. D.; Roy, R. Tetrahedron 1995, 51, 6679-6686. 
(11) Renaudet, O.; Dumy, P. Tetrahedron Lett. 2001, 42, 7575-7578. 
(12) Marcaurelle, L. A.; Shin, Y.; Goon, S.; Bertozzi, C. R. Org. Lett. 2001, 3, 3691-3694. 
(13) Hosokawa, S.; Ogura, T.; Togashi, H.; Tatsuta, K. Tetrahedron Lett. 2005, 46, 333-337. 
(14) Hudak, J. E.; Yu, H. H.; Bertozzi, C. R. J. Am. Chem. Soc. 2011, 133, 16127-16135. 
(15) Andersson, M.; Oscarson, S. Glycoconjugate J. 1992, 9, 122-5. 
(16) (a) Rodriguez, E. C.; Marcaurelle, L. A.; Bertozzi, C. R. J. Org. Chem. 1998, 63, 7134-
7135. (b) Liu, H.; Wang, L.; Brock, A.; Wong, C.-H.; Schultz, P. G. J. Am. Chem. Soc. 2003, 
125, 1702-1703. 
(17) Kalia, J.; Raines, R. T. Angew. Chem. Int. Ed. 2008, 47, 7523-7526. 
190 
 
 
 
(18) (a) Cervigni, S. E.; Dumy, P.; Mutter, M. Angew. Chem. Int. Ed. 1996, 35, 1230-1232. (b) 
Kubler-Kielb, J.; Vinogradov, E.; Ben-Menachem, G.; Pozsgay, V.; Robbins, J. B.; Schneerson, 
R. Vaccine 2008, 26, 3587-3593. 
(19) (a) Canne, L. E.; Ferre- D'Amare, A. R.; Burley, S. K.; Kent, S. B. H. J. Am. Chem. Soc. 
1995, 117, 2998-3007. (b) Rose, K.; Zeng, W.; Regamey, P.-O.; Chernushevich, I. V.; Standing, 
K. G.; Gaertner, H. F. Bioconjugate Chem. 1996, 7, 552-556. 
(20) Goddard-Borger, E. D.; Stick, R. V. Org. Lett. 2007, 9, 3797-3800. 
(21) Crich, D.; de la Mora, M.; Vinod, A. U. J. Org. Chem. 2003, 68, 8142-8148. 
(22) Smith, A. B.; Ott, G. R. J. Am. Chem. Soc. 1996, 118, 13095-13096. 
(23) The excess TBDPSCl was hydrolyzed to TBDPSOH, regrettably TBDPSOH and 9 had the 
same rf ethyl acetate/hexanes, requiring the usage of toluene for the seperation 
(24) Lin, C.-C.; Lin, N.-P.; Sahabuddin, L. S.; Reddy, V. R.; Huang, L.-D.; Hwang, K. C.; Lin, C.-
C. J. Org. Chem. 2010, 75, 4921-4928. 
(25) The yield of this reaction was not calculated b/c of the presence of an inseperable impurity 
(26) Wong, C.-H.; Ye, X.-S.; Zhang, Z. J. Am. Chem. Soc. 1998, 120, 7137-7138. 
(27) Lefeber, D. J.; Kamerling, J. P.; Vliegenthart, J. F. G. Org. Lett. 2000, 2, 701-703. 
(28) Schmidt, R. R.; Michel, J. Angew. Chem. Int. Ed. 1980, 19, 731-732. 
(29) Dziadek, S.; Brocke, C.; Kunz, H. Chem. Eur. J. 2004, 10, 4150-4162. 
(30) Tanaka, H.; Adachi, M.; Takahashi, T. Chem. Eur. J. 2005, 11, 849-862. 
(31) See supporting info Carbon NMR data for 16 
(32) Hermanson, G. T., Bioconjugate Techniques. Academic Press: San Diego, 1996. 
(33) Odom, O. W.; Robbins, D. J.; Lynch, J.; Dottavio-Martin, D.; Kramer, G.; Hardesty, B. 
Biochemistry 1980, 19, 5947-5954. 
(34) Hoffmann-Roeder, A.; Johannes, M. Chem. Commun. (Cambridge, U. K.) 2011, 47, 9903-
9905. 
191 
 
 
 
(35) Johannes, M.; Reindl, M.; Gerlitzki, B.; Schmitt, E.; Hoffmann-Röder, A. Beilstein Journal of 
Organic Chemistry 2015, 11, 155-161. 
(36) (a) Friedenreich, V., The Thomsen hemagglutination phenomenon. Copenhagen, Denmark, 
1930. (b) Thomsen, O. Z Immunitaèts Forsch 1927, 52, 85-90. 
(37) Kurtenkov, O.; Klaamas, K.; Mensdorff-Pouilly, S.; Miljukhina, L.; Shljapnikova, L.; 
Chužmarov, V. Acta Oncologica 2007, 46, 316-323. 
(38) Ju, T.; Otto, V. I.; Cummings, R. D. Angew. Chem. Int. Ed. 2011, 50, 1770-1791. 
(39) Yu, L.-G. Glycoconjugate J. 2007, 24, 411-420. 
(40) Santos-Silva, F.; Fonseca, A.; Caffrey, T.; Carvalho, F.; Mesquita, P.; Reis, C.; Almeida, R.; 
David, L.; Hollingsworth, M. A. Glycobiology 2005, 15, 511-517. 
(41) (a) Fortuna-Costa, A.; Gomes, A. M.; Kozlowski, E. O.; Stelling, M. P.; Pavão, M. S. G. 
Frontiers in Oncology 2014, 4, 138. (b) Zhao, Q.; Barclay, M.; Hilkens, J.; Guo, X.; Barrow, H.; 
Rhodes, J.; Yu, L.-G. Molecular Cancer 2010, 9, 154. (c) Khaldoyanidi, S.; Glinsky, V.; Sikora, 
L.; Glinskii, A.; Mossine, V.; Quinn, T.; Glinsky, G.; Sriramarao, P. J. Biol. Chem. 2003, 278, 
4127 - 4134. 
(42) Glinskii, O. V.; Li, F.; Wilson, L. S.; Barnes, S.; Rittenhouse-Olson, K.; Barchi, J. J., Jr.; 
Pienta, K. J.; Glinsky, V. V. Oncotarget 2014, 5, 1382-9. 
(43) Frisch, S.; Francis, H. The Journal of Cell Biology 1994, 124, 619-626. 
(44) Iurisci, I.; Tinari, N.; Natoli, C.; Angelucci, D.; Cianchetti, E.; Iacobelli, S. Clin. Cancer Res. 
2000, 6, 1389-1393. 
(45) (a) Guha, P.; Kaptan, E.; Bandyopadhyaya, G.; Kaczanowska, S.; Davila, E.; Thompson, 
K.; Martin, S. S.; Kalvakolanu, D. V.; Vasta, G. R.; Ahmed, H. Proc. Natl. Acad. Sci. U. S. A. 
2013, 110, 5052-5057, S5052/1-S5052/10. (b) Gao, X.; Zhi, Y.; Sun, L.; Peng, X.; Zhang, T.; 
Xue, H.; Tai, G.; Zhou, Y. J. Biol. Chem. 2013, 288, 33953-33965,S33953/1-S33953/4. (c) 
Glinskii, O. V.; Sud, S.; Mossine, V. V.; Mawhinney, T. P.; Anthony, D. C.; Glinsky, G. V.; 
Pienta, K. J.; Glinsky, V. V. Neoplasia (Ann Arbor, MI, U. S.) 2012, 14, 65-73. (d) Glinsky, V. V.; 
192 
 
 
 
Kiriakova, G.; Glinskii, O. V.; Mossine, V. V.; Mawhinney, T. P.; Turk, J. R.; Glinskii, A. B.; 
Huxley, V. H.; Price, J. E.; Glinsky, G. V. Neoplasia (Ann Arbor, MI, U. S.) 2009, 11, 901-909. 
(e) Cumpstey, I.; Sundin, A.; Leffler, H.; Nilsson, U. J. Angew. Chem., Int. Ed. 2005, 44, 5110-
5112. (f) Glinsky, V. V.; Glinsky, G. V.; Glinskii, O. V.; Huxley, V. H.; Turk, J. R.; Mossine, V. V.; 
Deutscher, S. L.; Pienta, K. J.; Quinn, T. P. Cancer Res. 2003, 63, 3805-3811. (g) Khaldoyanidi, 
S. K.; Glinsky, V. V.; Sikora, L.; Glinskii, A. B.; Mossine, V. V.; Quinn, T. P.; Glinsky, G. V.; 
Sriramarao, P. J. Biol. Chem. 2003, 278, 4127-34. (h) Nangia-Makker, P.; Hogan, V.; Honjo, Y.; 
Baccarini, S.; Tait, L.; Bresalier, R.; Raz, A. Journal of the National Cancer Institute 2002, 94, 
1854-1862. (i) Glinsky, V. V.; Huflejt, M. E.; Glinsky, G. V.; Deutscher, S. L.; Quinn, T. P. 
Cancer Res. 2000, 60, 2584-2588. 
(46) Glinsky, G.; Mossine, V.; Price, J.; Bielenberg, D.; Glinsky, V.; Ananthaswamy, H.; Feather, 
M. Clin Exp Metastasis 1996, 14, 253-267. 
(47) Peletskaya, E. N.; Glinksy, G.; Deutscher, S. L.; Quinn, T. P. Mol. Diversity 1996, 2, 13-18. 
(48) (a) Soerme, P.; Arnoux, P.; Kahl-Knutsson, B.; Leffler, H.; Rini, J. M.; Nilsson, U. J. J. Am. 
Chem. Soc. 2005, 127, 1737-1743. (b) Oeberg, C. T.; Leffler, H.; Nilsson, U. J. J. Med. Chem. 
2008, 51, 2297-2301. 
(49) Tellez-Sanz, R.; Garcia-Fuentes, L.; Vargas-Berenguel, A. Curr. Med. Chem. 2013, 20, 
2979-2990. 
(50) Salameh, B. A.; Cumpstey, I.; Sundin, A.; Leffler, H.; Nilsson, U. J. Bioorg. Med. Chem. 
2010, 18, 5367-5378. 
(51) (a) Jiménez-Barbero, J.; Dragoni, E.; Venturi, C.; Nannucci, F.; Ardá, A.; Fontanella, M.; 
André, S.; Cañada, F. J.; Gabius, H.-J.; Nativi, C. Chem. Eur. J. 2009, 15, 10423-10431. (b) 
Venturi, F.; Venturi, C.; Liguori, F.; Cacciarini, M.; Montalbano, M.; Nativi, C. J. Org. Chem. 
2004, 69, 6153-6155. 
(52) Richichi, B.; Thomas, B.; Fiore, M.; Bosco, R.; Qureshi, H.; Nativi, C.; Renaudet, O.; Ben 
Mohamed, L. Angew. Chem., Int. Ed. 2014, 53, 11917-11920. 
193 
 
 
 
(53) (a) Biswas, S.; Medina, S. H.; Barchi, J. J. Carbohydr. Res. 2014, Ahead of Print. (b) 
Bourgault, J. P.; Trabbic, K. R.; Shi, M.; Andreana, P. R. Organic & Biomolecular Chemistry 
2014, 12, 1699-1702. (c) Awad, L.; Madani, R.; Gillig, A.; Kolympadi, M.; Philgren, M.; Muhs, A.; 
Gerard, C.; Vogel, P. Chem. - Eur. J. 2012, 18, 8578-8582, S8578/1-S8578/59. (d) Heimburg-
Molinaro, J.; Almogren, A.; Morey, S.; Glinskii, O. V.; Roy, R.; Wilding, G. E.; Cheng, R. P.; 
Glinsky, V. V.; Rittenhouse-Olson, K. Neoplasia (Ann Arbor, MI, U. S.) 2009, 11, 780-792. (e) 
Sundgren, A.; Barchi Jr, J. J. Carbohydr. Res. 2008, 343, 1594-1604. (f) Slovin, S. F.; 
Ragupathi, G.; Musselli, C.; Fernandez, C.; Diani, M.; Verbel, D.; Danishefsky, S.; Livingston, 
P.; Scher, H. I. Cancer Immunol. Immunother. 2005, 54, 694-702. (g) Svarovsky, S. A.; Szekely, 
Z.; Barchi, J. J. Tetrahedron: Asymmetry 2005, 16, 587-598. (h) Xu, Y.; Gendler, S. J.; Franco, 
A. The Journal of Experimental Medicine 2004, 199, 707-716. (i) Adluri, S.; Helling, F.; Ogata, 
S.; Zhang, S.; Itzkowitz, S. H.; Lloyd, K. O.; Livingston, P. O. Cancer Immunol. Immunother. 
1995, 41, 185-92. (j) MacLean, G. D.; Bowen-Yacyshyn, M. B.; Samuel, J.; Meikle, A.; Stuart, 
G.; Nation, J.; Poppema, S.; Jerry, M.; Koganty, R.; Wong, T. J Immunother (1991) 1992, 11, 
292-305. (k) Fung, P. Y. S.; Madej, M.; Koganty, R. R.; Longenecker, B. M. Cancer Res. 1990, 
50, 4308-4314. 
(54) Astronomo, R. D.; Burton, D. R. Nat. Rev. Drug Discovery 2010, 9, 308-324. 
(55) (a) Avery, O. T.; Goebel, W. F. The Journal of Experimental Medicine 1929, 50, 533-550. 
(b) Goebel, W. F.; Avery, O. T. The Journal of Experimental Medicine 1929, 50, 521-531. 
(56) (a) Gatsogiannis, C.; Markl, J. J. Mol. Biol. 2009, 385, 963-983. (b) Harris, J. R.; Markl, J. 
Micron 1999, 30, 597-623. 
(57) Slovin, S.; Ragupathi, G.; Fernandez, C.; Diani, M.; Jefferson, M.; Wilton, A.; Kelly, W. K.; 
Morris, M.; Solit, D.; Clausen, H.; Livingston, P.; Scher, H. Cancer Immunol. Immunother. 2007, 
56, 1921-1930. 
(58) André, S.; Renaudet, O.; Bossu, I.; Dumy, P.; Gabius, H.-J. J. Pept. Sci. 2011, 17, 427-437. 
194 
 
 
 
(59) (a) Bettahi, I.; Dasgupta, G.; Renaudet, O.; Chentoufi, A. A.; Zhang, X.; Carpenter, D.; 
Yoon, S.; Dumy, P.; BenMohamed, L. Cancer Immunol. Immunother. 2009, 58, 187-200. (b) 
Grigalevicius, S.; Chierici, S.; Renaudet, O.; Lo-Man, R.; Deriaud, E.; Leclerc, C.; Dumy, P. 
Bioconjugate Chem. 2005, 16, 1149-1159. 
(60) Roy, R.; Shiao, T. C.; Rittenhouse-Olson, K. Braz. J. Pharm. Sci. 2013, 49, 85-108. 
(61) (a) Yi, B.; Zhang, Z.; Zhang, M.; Schwartz-Albiez, R.; Cao, Y. Oncol. Rep. 2013, 30, 1841-
1847. (b) Ulsemer, P.; Henderson, G.; Toutounian, K.; Loeffler, A.; Schmidt, J.; Karsten, U.; 
Blaut, M.; Goletz, S. Cancer Immunol. Immunother. 2013, 62, 875-887. (c) Springer, G. F. J. 
Mol. Med. (Berlin) 1997, 75, 594-602. 
(62) Henderson, G.; Ulsemer, P.; Schoeber, U.; Loeffler, A.; Alpert, C.-A.; Zimmermann-
Kordmann, M.; Reutter, W.; Karsten, U.; Goletz, S.; Blaut, M. Glycobiology 2011, 21, 1277-
1289. 
(63) (a) Zeichner, S. B. JAOA: Journal of the American Osteopathic Association 2012, 112, 482-
483. (b) Miles, D.; Roché, H.; Martin, M.; Perren, T. J.; Cameron, D. A.; Glaspy, J.; Dodwell, D.; 
Parker, J.; Mayordomo, J.; Tres, A.; Murray, J. L.; Ibrahim, N. K.; Group, t. T. S. The Oncologist 
2011, 16, 1092-1100. 
(64) (a) Julien, S.; Delannoy, P. Recent Res. Dev. Cancer 2003, 5, 185-199. (b) Miles, D.; 
Papazisis, K. Clinical Breast Cancer 3, S134-S138. 
(65) Julien, S.; Picco, G.; Sewell, R.; Vercoutter-Edouart, A. S.; Tarp, M.; Miles, D.; Clausen, H.; 
Taylor-Papadimitriou, J.; Burchell, J. M. Br J Cancer 2009, 100, 1746-1754. 
(66) (a) Jegerlehner, A.; Wiesel, M.; Dietmeier, K.; Zabel, F.; Gatto, D.; Saudan, P.; Bachmann, 
M. F. Vaccine 2010, 28, 5503-5512. (b) Buskas, T.; Li, Y.; Boons, G.-J. Chem. - Eur. J. 2004, 
10, 3517-3524. (c) Renjifo, X.; Wolf, S.; Pastoret, P.-P.; Bazin, H.; Urbain, J.; Leo, O.; Moser, M. 
J. Immunol. 1998, 161, 702-706. 
(67) Bundle, D. R.; Young, N. M. Curr. Opin. Struct. Biol. 1992, 2, 666-73. 
(68) Mammen, M.; Chio, S.-K.; Whitesides, G. M. Angew. Chem., Int. Ed. 1998, 37, 2755-2794. 
195 
 
 
 
(69) Galan, M. C.; Dumy, P.; Renaudet, O. Chem. Soc. Rev. 2013, 42, 4599-612. 
(70) Baumann, H.; Tzianabos, A. O.; Brisson, J. R.; Kasper, D. L.; Jennings, H. J. Biochemistry 
1992, 31, 4081-4089. 
(71) Wang, Y.; Kalka-Moll, W. M.; Roehrl, M. H.; Kasper, D. L. Proc. Natl. Acad. Sci. U. S. A. 
2000, 97, 13478-13483. 
(72) (a) Avci, F. Y.; Kasper, D. L. Annual Review of Immunology 2010, 28, 107-130. (b) Avci, F. 
Y.; Li, X.; Tsuji, M.; Kasper, D. L. Semin. Immunol. 2013, 25, 146-151. 
(73) (a) Shapiro, M. E.; Onderdonk, A. B.; Kasper, D. L.; Finberg, R. W. The Journal of 
Experimental Medicine 1982, 155, 1188-1197. (b) Onderdonk, A. B.; Markham, R. B.; Zaleznik, 
D. F.; Cisneros, R. L.; Kasper, D. L. The Journal of Clinical Investigation 1982, 69, 9-16. (c) 
Kasper, D. L.; Onderdonk, A. B.; Crabb, J.; Bartlett, J. G. Journal of Infectious Diseases 1979, 
140, 724-731. 
(74) Tzianabos, A. O.; Pantosti, A.; Baumann, H.; Brisson, J. R.; Jennings, H. J.; Kasper, D. L. 
J. Biol. Chem. 1992, 267, 18230-18235. 
(75) Tzianabos, A.; Onderdonk, A.; Rosner, B.; Cisneros, R.; Kasper, D. Science 1993, 262, 
416-419. 
(76) Taylor, R. L.; Conrad, H. E. Biochemistry 1972, 11, 1383-1388. 
(77) Tzianabos, A. O.; Onderdonk, A. B.; Smith, R. S.; Kasper, D. L. Infection and Immunity 
1994, 62, 3590-3593. 
(78) Guttormsen, H. K.; Sharpe, A. H.; Chandraker, A. K.; Brigtsen, A. K.; Sayegh, M. H.; 
Kasper, D. L. Infection and Immunity 1999, 67, 6375-6384. 
(79) Lai, Z.; Schreiber, J. R. Vaccine 2009, 27, 3137-3144. 
(80) Avci, F. Y.; Li, X.; Tsuji, M.; Kasper, D. L. Nat. Med. (N. Y., NY, U. S.) 2011, 17, 1602-1609. 
(81) Tzianabos, A. O.; Finberg, R. W.; Wang, Y.; Chan, M.; Onderdonk, A. B.; Jennings, H. J.; 
Kasper, D. L. J. Biol. Chem. 2000, 275, 6733-6740. 
196 
 
 
 
(82) Kalka-Moll, W. M.; Tzianabos, A. O.; Bryant, P. W.; Niemeyer, M.; Ploegh, H. L.; Kasper, D. 
L. J. Immunol. 2002, 169, 6149-6153. 
(83) Kalka-Moll, W. M.; Tzianabos, A. O.; Wang, Y.; Carey, V. J.; Finberg, R. W.; Onderdonk, A. 
B.; Kasper, D. L. J. Immunol. 2000, 164, 719-724. 
(84) Cobb, B. A.; Kasper, D. L. Glycobiology 2008, 18, 707-718. 
(85) Choi, Y.-H.; Roehrl, M. H.; Kasper, D. L.; Wang, J. Y. Biochemistry 2002, 41, 15144-15151. 
(86) Kreisman, L. S. C.; Friedman, J. H.; Neaga, A.; Cobb, B. A. Glycobiology 2007, 17, 46-55. 
(87) Trabbic, K. R.; De Silva, R. A.; Andreana, P. R. MedChemComm 2014, 5, 1143-1149. 
(88) Guy, B. In Adjuvants for protein- and carbohydrate-based vaccines, John Wiley & Sons, 
Inc.: 2009; pp 89-115. 
(89) (a) Christiaansen, J. E.; Sears, D. W. Cancer Res. 1984, 44, 3712-3718. (b) Anasetti, C.; 
Martin, P. J.; Morishita, Y.; Badger, C. C.; Bernstein, I. D.; Hansen, J. A. The Journal of 
Immunology 1987, 138, 2979-81. 
(90) Maslanka, S. E.; Tappero, J. W.; Plikaytis, B. D.; Brumberg, R. S.; Dykes, J. K.; Gheesling, 
L. L.; Donaldson, K. B. J.; Schuchat, A.; Pullman, J.; Jones, M.; Bushmaker, J.; Carlone, G. M. 
Infection and Immunity 1998, 66, 2453-2459. 
(91) (a) Björck, L.; Kronvall, G. The Journal of Immunology 1984, 133, 969-74. (b) Sjöbring, U.; 
Björck, L.; Kastern, W. J. Biol. Chem. 1991, 266, 399-405. 
(92) Ghosh, S.; Andreana, P. R. J. Carbohydr. Chem. 2014, 33, 381-394. 
(93) Singh, S. K.; Streng-Ouwehand, I.; Litjens, M.; Weelij, D. R.; García-Vallejo, J. J.; van Vliet, 
S. J.; Saeland, E.; van Kooyk, Y. Molecular Immunology 2009, 46, 1240-1249. 
(94) van Vliet, S. J.; Aarnoudse, C. A.; Broks-van den Berg, V. C. M.; Boks, M.; Geijtenbeek, T. 
B. H.; van Kooyk, Y. Eur. J. Immunol. 2007, 37, 2075-2081. 
(95) Nimmerjahn, F.; Ravetch, J. V. Cancer Immun 2012, 12, 13. 
197 
 
 
 
(96) Lazar, G. A.; Dang, W.; Karki, S.; Vafa, O.; Peng, J. S.; Hyun, L.; Chan, C.; Chung, H. S.; 
Eivazi, A.; Yoder, S. C.; Vielmetter, J.; Carmichael, D. F.; Hayes, R. J.; Dahiyat, B. I. Proc. Natl. 
Acad. Sci. U. S. A. 2006, 103, 4005-4010. 
(97) Cullen, S. P.; Brunet, M.; Martin, S. J. Cell Death Differ 2010, 17, 616-623. 
(98) Plotkin, S. A.; Plotkin, S. A. Clinical Infectious Diseases 2008, 47, 401-409. 
(99) Romero-Steiner, S.; Musher, D. M.; Cetron, M. S.; Pais, L. B.; Groover, J. E.; Fiore, A. E.; 
Plikaytis, B. D.; Carlone, G. M. Clin Infect Dis 1999, 29, 281-8. 
(100) King, R. R.; Lawrence, C. H.; Clark, M. C.; Calhoun, L. A. Journal of the Chemical Society, 
Chemical Communications 1989, 849-850. 
(101) (a) King, R. R.; Calhoun, L. A. Phytochemistry (Elsevier) 2009, 70, 833-841. (b) King, R. 
R.; Lawrence, C. H.; Gray, J. A. Journal of Agricultural and Food Chemistry 2001, 49, 2298-
2301. 
(102) Koivunen, M.; Marrone, P.; Boddy, L. Uses of thaxtomin and thaxtomin compositions as 
herbicides. WO2014013343A2, 2014. 
(103) (a) Inman, S.; Semones, S. Methods of controlling weeds with thaxtomin and thaxtomin 
compositions in combination with a beneficial herbicide. WO2013066894A2, 2013. (b) Leep, D.; 
Doricchi, L.; Perez Baz, M. J.; Millan, F. R.; Fernandez Chimeno, R. I. Use of thaxtomin for 
selective control of rice and aquatic based weeds. WO2010121079A2, 2010. 
(104) (a) King, R. R.; Calhoun, L. A. Magn. Reson. Chem. 2009, 47, 273-276. (b) King, R. R.; 
Lawrence, C. H.; Calhoun, L. A. Journal of Agricultural and Food Chemistry 1992, 40, 834-837. 
(105) Krasnoff, S. B.; Lobkovsky, E. B.; Wach, M. J.; Loria, R.; Gibson, D. M. Journal of 
Agricultural and Food Chemistry 2005, 53, 9446-9451. 
(106) King, R. R.; Lawrence, C. H.; Clark, M. C. Am. Potato J. 1991, 68, 675-80. 
(107) Joshi, M. V.; Bignell, D. R. D.; Johnson, E. G.; Sparks, J. P.; Gibson, D. M.; Loria, R. Mol. 
Microbiol. 2007, 66, 633-642. 
198 
 
 
 
(108) Tegg, R. S.; Shabala, S. N.; Cuin, T. A.; Davies, N. W.; Wilson, C. R. BMC Plant Biol. 
2013, 13, 76. 
(109) Fry, B. A.; Loria, R. Physiol. Mol. Plant Pathol. 2002, 60, 1-8. 
(110) Scheible, W.-R.; Fry, B.; Kochevenko, A.; Schindelasch, D.; Zimmerli, L.; Somerville, S.; 
Loria, R.; Somerville, C. R. The Plant Cell Online 2003, 15, 1781-1794. 
(111) Tegg, R. S.; Melian, L.; Wilson, C. R.; Shabala, S. Plant Cell Physiol. 2005, 46, 638-648. 
(112) Hepler, P. K.; Winship, L. J. Journal of Integrative Plant Biology 2010, 52, 147-160. 
(113) Bischoff, V.; Cookson, S. J.; Wu, S.; Scheible, W.-R. J. Exp. Bot. 2009, 60, 955-965. 
(114) Tegg, R. S.; Gill, W. M.; Thompson, H. K.; Davies, N. W.; Ross, J. J.; Wilson, C. R. Plant 
Dis. 2008, 92, 1321-1328. 
(115) Leiner, R. H.; Fry, B. A.; Carling, D. E.; Loria, R. Phytopathology 1996, 86, 709-713. 
(116) (a) Barry, S. M.; Kers, J. A.; Johnson, E. G.; Song, L.; Aston, P. R.; Patel, B.; Krasnoff, S. 
B.; Crane, B. R.; Gibson, D. M.; Loria, R.; Challis, G. L. Nat. Chem. Biol. 2012, 8, 814-816. (b) 
Wach, M. J.; Kers, J. A.; Krasnoff, S. B.; Loria, R.; Gibson, D. M. Nitric Oxide 2005, 12, 46-53. 
(c) King, R. R.; Lawrence, C. H.; Embleton, J.; Calhoun, L. A. Phytochemistry (Elsevier) 2003, 
64, 1091-1096. (d) Healy, F. G.; Krasnoff, S. B.; Wach, M.; Gibson, D. M.; Loria, R. J. Bacteriol. 
2002, 184, 2019-2029. (e) Healy, F. G.; Wach, M.; Krasnoff, S. B.; Gibson, D. M.; Loria, R. Mol. 
Microbiol. 2000, 38, 794-804. (f) King, R. R.; Lawrence, C. H.; Calhoun, L. A. Phytochemistry 
1998, 49, 1265-1267. (g) King, R. R.; Lawrence, C. H. Phytochemistry 1995, 40, 41-3. 
(117) Johnson, E. G.; Krasnoff, S. B.; Bignell, D. R. D.; Chung, W.-C.; Tao, T.; Parry, R. J.; 
Loria, R.; Gibson, D. M. Mol. Microbiol. 2009, 73, 409-418. 
(118) Winkler, R.; Hertweck, C. ChemBioChem 2007, 8, 973-977. 
(119) Kers, J. A.; Wach, M. J.; Krasnoff, S. B.; Widom, J.; Cameron, K. D.; Bukhalid, R. A.; 
Gibson, D. M.; Crane, B. R.; Loria, R. Nature (London, U. K.) 2004, 429, 79-82. 
(120) Kers, J. A.; Cameron, K. D.; Joshi, M. V.; Bukhalid, R. A.; Morello, J. E.; Wach, M. J.; 
Gibson, D. M.; Loria, R. Mol. Microbiol. 2005, 55, 1025-1033. 
199 
 
 
 
(121) (a) Borthwick, A. D. Chem. Rev. 2012, 112, 3641-3716. (b) Ivachtchenko, A. V.; 
Ivanenkov, Y. A.; Kysil, V. M.; Krasavin, M. Y.; Ilyin, A. P. Russ. Chem. Rev. 2010, 79, 787-817. 
(c) Molesworth, P. P.; Gardiner, M. G.; Jones, R. C.; Smith, J. A.; Tegg, R. S.; Wilson, C. 
Australian Journal of Chemistry 2010, 63, 813. (d) Santra, S.; Andreana, P. R. Org. Lett. 2007, 
9, 5035-5038. (e) King, R. R. Canadian Journal of Chemistry 1997, 75, 1172. (f) Moyroud, J.; 
Gelin, J.; Chêne, A.; Mortier, J. Tetrahedron 1996, 52, 8525-8534. (g) Gelin, J.; Mortier, J.; 
Moyroud, J.; Chene, A. The Journal of Organic Chemistry 1993, 58, 3473-3475. 
(122) (a) Santagada, V.; Fiorino, F.; Perissutti, E.; Severino, B.; Terracciano, S.; Cirino, G.; 
Caliendo, G. Tetrahedron Lett. 2003, 44, 1145-1148. (b) Falorni, M.; Giacomelli, G.; Porcheddu, 
A.; Taddei, M. Eur. J. Org. Chem. 2000, 1669-1675. 
(123) Majumdar, K. C.; Ray, K.; Ganai, S. Synlett 2010, 2010, 2122-2124. 
(124) Sheradsky, T.; Silcoff, E. Molecules 1998, 3, 80-87. 
(125) (a) Cho, S.-D.; Song, S.-Y.; Kim, K.-H.; Zhao, B.-X.; Ahn, C.; Joo, W.-H.; Yoon, Y.-J.; 
Falck, J. R.; Shin, D.-S. Bull. Korean Chem. Soc. 2004, 25, 415-416. (b) Orena, M.; Porzi, G.; 
Sandri, S. J. Org. Chem. 1992, 57, 6532-6536. 
(126) Richard, D. J.; Schiavi, B.; Joullié, M. M. Proceedings of the National Academy of 
Sciences of the United States of America 2004, 101, 11971-11976. 
(127) Peng, J.; Clive, D. L. J. J. Org. Chem. 2009, 74, 513-519. 
(128) De Silva, R. A.; Santra, S.; Andreana, P. R. Organic Letters 2008, 10, 4541-4544. 
(129) Hulme, C.; Morrissette, M. M.; Volz, F. A.; Burns, C. J. Tetrahedron Lett. 1998, 39, 1113-
1116. 
(130) Rhoden, C. R. B.; Rivera, D. G.; Kreye, O.; Bauer, A. K.; Westermann, B.; Wessjohann, L. 
A. J. Comb. Chem. 2009, 11, 1078-1082. 
(131) (a) Chen, J. J.; Golebiowski, A.; Klopfenstein, S. R.; West, L. Tetrahedron Lett. 2002, 43, 
4083-4085. (b) Hulme, C.; Peng, J.; Morton, G.; Salvino, J. M.; Herpin, T.; Labaudiniere, R. 
Tetrahedron Lett. 1998, 39, 7227-7230. 
200 
 
 
 
(132) Marcaccini, S.; Pepino, R.; Pozo, M. C. Tetrahedron Lett. 2001, 42, 2727-2728. 
(133) Hulme, C.; Cherrier, M. P. Tetrahedron Lett. 1999, 40, 5295-5299. 
(134) Zhang, H.; Wang, Q.; Ning, X.; Hang, H.; Ma, J.; Yang, X.; Lu, X.; Zhang, J.; Li, Y.; Niu, 
C.; Song, H.; Wang, X.; Wang, P. G. Journal of Agricultural and Food Chemistry 2015, 63, 
3734-3741. 
(135) (a) Huang, H.; Xue, Z.; Zhang, H.; Yan, D. Total synthesis of thaxtomin a analogues and 
their intermediates. WO2014149171A1, 2014. (b) Zhang, H.; Ning, X.; Hang, H.; Ru, X.; Li, H.; 
Li, Y.; Wang, L.; Zhang, X.; Yu, S.; Qiao, Y.; Wang, X.; Wang, P. G. Organic Letters 2013, 15, 
5670-5673. 
(136) (a) Nishimura, T.; Unni, A. K.; Yokoshima, S.; Fukuyama, T. J. Am. Chem. Soc. 2013, 
135, 3243-3247. (b) Yamaguchi, T.; Blázquez, B.; Hesek, D.; Lee, M.; Llarrull, L. I.; Boggess, B.; 
Oliver, A. G.; Fisher, J. F.; Mobashery, S. ACS Medicinal Chemistry Letters 2012, 3, 238-242. 
(c) Frebault, F. C.; Simpkins, N. S. Tetrahedron 2010, 66, 6585-6596. (d) Znabet, A.; 
Zonneveld, J.; Janssen, E.; De Kanter, F. J. J.; Helliwell, M.; Turner, N. J.; Ruijter, E.; Orru, R. 
V. A. Chem. Commun. (Cambridge, U. K.) 2010, 46, 7706-7708. (e) Yamazaki, Y.; Mori, Y.; 
Oda, A.; Okuno, Y.; Kiso, Y.; Hayashi, Y. Tetrahedron 2009, 65, 3688-3694. (f) Faggi, C.; Neo, 
A. G.; Marcaccini, S.; Menchi, G.; Revuelta, J. Tetrahedron Lett. 2008, 49, 2099-2102. (g) El 
Kaim, L.; Gageat, M.; Gaultier, L.; Grimaud, L. Synlett 2007, 2007, 0500-0502. (h) Sañudo, M.; 
Marcaccini, S.; Basurto, S.; Torroba, T. J. Org. Chem. 2006, 71, 4578-4584. (i) Li, X.; Song, L.; 
Xing, C.; Zhao, J.; Zhu, S. Tetrahedron 2006, 62, 2255-2263. (j) Herzon, S. B.; Myers, A. G. J. 
Am. Chem. Soc. 2005, 127, 5342-5344. (k) Siwicka, A.; Wojtasiewicz, K.; Rosiek, B.; Leniewski, 
A.; Maurin, J. K.; Czarnocki, Z. Tetrahedron: Asymmetry 2005, 16, 975-993. (l) Zawadzka, A.; 
Leniewski, A.; Maurin, J.; Wojtasiewicz, K.; Siwicka, A.; Blachut, D.; Czarnocki, Z. Eur. J. Org. 
Chem. 2003, 2003, 2443-2453. (m) Zawadzka, A.; Leniewski, A.; Maurin, J. K.; Wojtasiewicz, 
K.; Czarnocki, Z. Org. Lett. 2001, 3, 997-999. (n) Overkleeft, H. S.; van, W. J.; Pandit, U. K. 
201 
 
 
 
Tetrahedron 1994, 50, 4215-24. (o) Gross, H.; Gloede, J.; Keitel, I.; Kunath, D. J. Prakt. Chem. 
1968, 37, 192-9. 
(137) (a) Pirrung, M. C.; Sarma, K. D. Synlett 2004, 2004, 1425-1427. (b) Harriman, G. C. B. 
Tetrahedron Lett. 1997, 38, 5591-5594. (c) Short, K. M.; Mjalli, A. M. M. Tetrahedron Lett. 1997, 
38, 359-362. 
(138) (a) Ayaz, M.; Xu, Z.; Hulme, C. Tetrahedron Lett. 2014, 55, 3406-3409. (b) Xu, Z.; De 
Moliner, F.; Cappelli, A. P.; Hulme, C. Org. Lett. 2013, 15, 2738-2741. (c) Xu, Z.; De Moliner, F.; 
Cappelli, A. P.; Hulme, C. Angew. Chem., Int. Ed. 2012, 51, 8037-8040, S8037/1-S8037/102. 
(d) Xu, Z.; Ayaz, M.; Cappelli, A. A.; Hulme, C. ACS Comb. Sci. 2012, 14, 460-464. (e) Mehta, 
V. P.; Modha, S. G.; Ruijter, E.; Van Hecke, K.; Van Meervelt, L.; Pannecouque, C.; Balzarini, 
J.; Orru, R. V. A.; Van der Eycken, E. J. Org. Chem. 2011, 76, 2828-2839. (f) Jida, M.; 
Malaquin, S.; Deprez-Poulain, R.; Laconde, G.; Deprez, B. Tetrahedron Lett. 2010, 51, 5109-
5111. (g) Marcaccini, S.; Neo, A. G.; Marcos, C. F. J. Org. Chem. 2009, 74, 6888-6890. 
(139) (a) Schuster, R. E. S., J. E.; Casanova, J. Organic Syntheses 1966, 46, 75. (b) Gray, R. 
A. Arch. Biochem. Biophys. 1959, 81, 480-488. 
(140) Layer, R. W. Chem. Rev. 1963, 63, 489-510. 
(141) Bell, I. M.; Fraley, M.; Biftu, T.; Zhu, C.; Nair, A. Preparation of spirolactam CGRP 
receptor antagonists. WO2013169567A1, 2013. 
(142) Revelant, G.; Dunand, S.; Hesse, S. p.; Kirsch, G. Synthesis 2011, 2011, 2935-2940. 
(143) Wong, H. N. C.; Xu, Z. L.; Chang, H. M.; Lee, C. M. Synthesis 1992, 1992, 793-797. 
(144) Based on isolated yield, equillibrium between the hemiaminal and the keto-amide forms 
may be complicating the purification 
(145) Bourgault, J. P.; Maddirala, A. R.; Andreana, P. R. Organic & Biomolecular Chemistry 
2014, 12, 8125-8127. 
(146) Nishio, M. CrystEngComm 2004, 6, 130-158. 
(147) Nishio, M. Phys. Chem. Chem. Phys. 2011, 13, 13873-13900. 
202 
 
 
 
(148) Kopple, K. D.; Marr, D. H. Journal of the American Chemical Society 1967, 89, 6193-
6200. 
(149) Nishio, M.; Umezawa, Y.; Fantini, J.; Weiss, M. S.; Chakrabarti, P. Physical Chemistry 
Chemical Physics 2014, 16, 12648-12683. 
(150) Sakaki, S.; Kato, K.; Miyazaki, T.; Musashi, Y.; Ohkubo, K.; Ihara, H.; Hirayama, C. J. 
Chem. Soc., Faraday Trans. 1993, 89, 659-64. 
(151) (a) Takahashi, O.; Kohno, Y.; Iwasaki, S.; Saito, K.; Iwaoka, M.; Tomoda, S.; Umezawa, 
Y.; Tsuboyama, S.; Nishio, M. Bull. Chem. Soc. Jpn. 2001, 74, 2421-2430. (b) Steiner, T.; 
Desiraju, G. R. Chem. Commun. (Cambridge) 1998, 891-892. 
(152) (a) Zondlo, N. J. Acc. Chem. Res. 2013, 46, 1039-1049. (b) Ganguly, H. K.; Majumder, B.; 
Chattopadhyay, S.; Chakrabarti, P.; Basu, G. J. Am. Chem. Soc. 2012, 134, 4661-4669. (c) 
Dasgupta, B.; Chakrabarti, P.; Basu, G. FEBS Lett. 2007, 581, 4529-4532. (d) Saha, R. P.; 
Bahadur, R. P.; Chakrabarti, P. Journal of Proteome Research 2005, 4, 1600-1609. (e) 
Bhattacharyya, R.; Chakrabarti, P. J. Mol. Biol. 2003, 331, 925-940. (f) Wu, W.-J.; Raleigh, D. P. 
Biopolymers 1998, 45, 381-394. (g) Reimer, U.; Scherer, G.; Drewello, M.; Kruber, S.; 
Schutkowski, M.; Fischer, G. J. Mol. Biol. 1998, 279, 449-460. (h) Nishio, M.; Umezawa, Y.; 
Hirota, M.; Takeuchi, Y. Tetrahedron 1995, 51, 8665-8701. (i) Otsuki, J.-i.; Kobayashi, K.; Toi, 
H.; Aoyama, Y. Tetrahedron Lett. 1993, 34, 1945-1948. (j) Vyas, N.; Vyas, M.; Quiocho, F. 
Science 1988, 242, 1290-1295. (k) Quiocho, F. A.; Vyas, N. K. Nature 1984, 310, 381-386. 
(153) (a) Fernández-Alonso, M. d. C.; Cañada, F. J.; Jiménez-Barbero, J.; Cuevas, G. J. Am. 
Chem. Soc. 2005, 127, 7379-7386. (b) Vandenbussche, S.; Díaz, D.; Fernández-Alonso, M. C.; 
Pan, W.; Vincent, S. P.; Cuevas, G.; Cañada, F. J.; Jiménez-Barbero, J.; Bartik, K. Chem. Eur. 
J. 2008, 14, 7570-7578. 
(154) (a) Asensio, J. L.; Ardá, A.; Cañada, F. J.; Jiménez-Barbero, J. Acc. Chem. Res. 2012, 
46, 946-954. (b) Phillips, D. C. Proceedings of the National Academy of Sciences of the United 
States of America 1967, 57, 483-495. 
203 
 
 
 
(155) Flint, J.; Bolam, D. N.; Nurizzo, D.; Taylor, E. J.; Williamson, M. P.; Walters, C.; Davies, G. 
J.; Gilbert, H. J. J. Biol. Chem. 2005, 280, 23718-23726. 
(156) Chávez, M. I.; Andreu, C.; Vidal, P.; Aboitiz, N.; Freire, F.; Groves, P.; Asensio, J. L.; 
Asensio, G.; Muraki, M.; Cañada, F. J.; Jiménez-Barbero, J. Chemistry – A European Journal 
2005, 11, 7060-7074. 
(157) Tamres, M. J. Am. Chem. Soc. 1952, 74, 3375-3378. 
(158) Reeves, L. W.; Schneider, W. G. Can. J. Chem. 1957, 35, 251-261. 
(159) (a) Kishikawa, K.; Yoshizaki, K.; Kohmoto, S.; Yamamoto, M.; Yamaguchi, K.; Yamada, K. 
Journal of the Chemical Society, Perkin Transactions 1 1997, 1233-1240. (b) Paliwal, S.; Geib, 
S.; Wilcox, C. S. Journal of the American Chemical Society 1994, 116, 4497-4498. 
 
  
204 
 
 
 
ABSTRACT 
BIOLOGICAL EVALUATION OF THE VACCINE CANDIDATE TF-PS A1 AND A ONE-POT 
MULTICOMPONENT COUPLING/CYCLIZATION FOR NATURAL PRODUCT HERBICIDE (±)-
THAXTOMIN A 
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The α-aminooxy derivative of the Thomsen–Friedenreich tumor associated carbohydrate 
antigen has been synthesized in 11 steps utilizing a D-GalN3 acceptor carrying a pre-installed α-
N-hydroxysuccinimidyl moiety.  The natural α linkage was prepared in high selectivity employing 
a suitably protected D-GalN3-thioglycoside donor with N-hydroxysuccinimide.  With access to α-
TF-ONH2, the preparation of the TF-PS A1 vaccine candidate ensued smoothly through oxime 
bond formation.  This construct was then administered to C57/BL6 mice in the presence of titer 
max gold adjuvant.  The induced antibodies were then examined through ELISA, 51Cr cytotoxic 
assays and a SCID mouse study involving MCF-7 induced tumors.  While the induced antibody 
titers were not substantial these antibodies were shown to have ~30% cytotoxicity in ADCC and 
CMC based assays against the breast cancer cell line MCF-7.  In addition passive transfer of 
the IgG antibody fraction reduced the tumor of volume (20%) of SCID mice challenged with the 
MCF-7 cell line when compared to PBS treated controls.  These antibodies were also shown to 
bind the colon cancer cell line HCT-116 and MCF-7 through FACS analysis.   
Herbicide (±)-thaxtomin A has been prepared in a one-pot procedure with a 32% isolated 
yield.  The Ugi reaction was utilized with 4-nitroindolylacetaldehyde, methylamine, 3-
hydroxyphenylpyruvic acid, and methyl isocyanide to prepare in situ a dipeptide intermediate 
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which then underwent an alkaline mediated keto-amide cyclization to provide TA and it’s anti 
diastereomer.  Modification of diastereoselectivity to favor the syn confirmation (TA) was 
realized using microwave-induced irradiation in the presence of KOH.  In addition a series of 
electronically modified derivatives have been prepared to study the interesting CH-pi interaction 
found in TA.  These derivatives when cyclized have provided further evidence for the CH-pi 
influence on the formation of the syn DKP due to the increase of the anti product when the nitro 
and phenol substituents were removed.  With this evidence we believe the CH-pi contact is 
influencing the diastereomeric ratio creating the observed syn preference of TA under 
thermodynamic conditions.   
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